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Abstract 
The molecular events responsible for the activation and growth of gonadotropin-
independent stages of follicles are not well understood. This study is interested on the 
role  of  TGFβ  signalling  based  on  preliminary  findings  from  our  laboratory  suggesting  
that this pathway is important in this context. Specifically, nuclear expression of the 
TGFβ  signalling  mediators  and  transcription  factor  Smad2/3  were more evident in the 
granulosa cells of primordial follicles but appeared to be excluded from nuclei in cells 
of early growing follicles. The overall aim of this thesis was to identify factors that have 
the potential to inhibit the Smad2/3 pathway and potentially determine their impact on 
early follicle development in the mouse ovary. Therefore, the first part of the study 
evaluated the expression of a selected of candidate genes (known to inhibit Smad 
signalling) during early follicle development. 
Many Smad inhibitors were detectable, although serine-threonine kinase receptor 
associated protein Strap was further evaluated as its protein expression in granulosa 
cells of small follicles coincided with Smad2/3 staining. Neonatal mouse ovary 
fragments and preantral follicle culture models were employed to evaluate the function 
of Strap. Inhibition of Strap caused a significant reduction in the proportion of 
primordial follicles, leading to an increase in the proportion and size of growing 
follicles, while Strap supplementation promoted the growth of preantral follicles. 
Therefore, it is indicated that Strap can regulate the early follicle development in a 
stage-dependent manner and its function can be employed to expand our knowledge 
regarding several reproductive disorders, such as premature ovarian failure. 
The expression of another Smad inhibitor, Tmepai, was also assessed and was found to 
be specifically localised in small preantral follicles that had just initiated growth. Since 
this coincided with the aforementioned reduction in nuclear Smad2/3, attempts were 
then made  to  determine  whether  TGFβ  signalling  regulated  its  expression.  Inhibition  of  
TGFβRI   in   cultured   preantral   follicles   caused   a   significant decrease in Tmepai 
expression level. Thus, it is suggested that Tmepai can regulate TGFβ  signalling  in  a  
negative feedback mechanism and consequently a relevant role in follicle growth. 
Finally,  considering  that  TGFβ  requires processing for their activity, and considering 
the  evidence  in  this  thesis  and  elsewhere  that  TGFβ  signalling  is  important  throughout  
the early stages  of  follicle  development,  we  looked  at  the  expression  of  the  latent  TGFβ  
binding proteins (Ltbp) in mouse ovaries. 
 xix 
Transcripts of Ltbp1-4 were expressed in the immature and adult ovaries. Ltbp1 protein 
appeared to be more evident in the ovary surface, while Ltbp4 mainly detected in blood 
vessels. These distinct expression patterns might indicate that each Ltbp member 
functions in a diverse way. 
In conclusion, this thesis presents a series of studies that show the essential role of 
TGFβ/Smad2/3  signalling  in  the  regulation  of  early  follicle  development  in  the  mouse  
ovary. The expression of many Smad2/3 inhibitors indicates that Smad pathway is 
regulated by a complex mechanism. Strap can regulate early follicle growth in a stage-
specific manner. Tmepai is detectable in follicles with specific growth stages and 
regulated   through   TGFβRI   receptor.   The extracellular modulator of TGFβ   ligands 
(Ltbp1-4) are expressed in the ovary, where their relative proteins localised in distinct 
compartments of the ovary. 
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Chapter 1 
Introduction 
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1.1. Background 
The fundamental role of the ovary is not only the secretion of steroid hormones, which are 
necessary for sexual maturation, the establishment of pregnancy and metabolism, but also to 
provide fully-grown oocytes for permitting the successful propagation of the species (Knight 
and Glister, 2003). It is proposed that the population of primordial follicles, small quiescent 
structures, present at birth reflects the entire number of follicles that are accessible to females 
throughout their reproductive lifespan (Bristol-Gould et al., 2006; Kezele et al., 2002). The 
percentage of these follicles is decreasing with age due to the continuous process of activation 
and atresia (Hansen et al., 2008); for example, in mouse ovaries, the percentage of primordial 
follicles decreases from 84% on day4 after birth to 51% at the age of 42 days, and these data 
varies depending on strain (Canning et al., 2003).  
Over the past decades, details regarding factors that potentially activate some of the primordial 
follicles to grow have been described (Broekmans et al., 2009; Pangas, 2012). Prior to that, the 
focus of many investigations was in relation to the regulation of follicle growth by endocrine 
signalling pathways of the hypothalamic–pituitary–ovarian axis (Findlay et al., 2000; McGee 
and Hsueh, 2000). However, more recently, advances in molecular and genetic protocols have 
revealed that molecular processes are involved in the earliest stages of follicle development 
(Pangas et al., 2008; Wang et al., 2013). Thus, it has been suggested that the early stages of 
follicle growth or maintenance are regulated by interactions of locally secreted factors (Kim, 
2012; Komatsu et al., 2015). Data from numerous laboratories have highlighted the role of the 
TGFβ superfamily members and their canonical Smad pathway as one of these essential intra-
ovarian factors (Ding et al., 2010; Fenwick et al., 2013; Li, 2015; Tomic et al., 2004). TGFβ 
superfamily proteins are extracellular ligands which are widely expressed in the body tissues 
and are implicated in multiple cell activities including proliferation, differentiation, migration, 
and degeneration during both prenatal and postnatal life (Rahimi and Leof, 2007). Three types 
of functionally different TGFβ   signalling   components,   called  Smads, have been described. 
These include the receptor-regulated Smads (R-Smad; Smad1/2/3/5/8), common Smad (Co-
Smad; Smad4), and the inhibitory Smads (I-Smad; Smad6/7), reviewed by (Lonn et al., 2009; 
Shi and Massague, 2003). 
TGFβ signalling is initiating by the interaction between a particular activated TGFβ ligand with 
its specific transmembrane receptors (type I and II serine/ threonine kinase receptors) for 
activation by phosphorylation (Groppe et al., 2008). Following this, the R-Smads are recruited 
to interact with the TGFβ ligand/receptors complex for phosphorylation, which then allows 
complex formation with a Co-Smad (Inman et al., 2002).  
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Translocation of the R-Smad/Co-Smad complex into the nucleus is essential for regulation the 
expression of the target gene through interaction with various coactivator/repressor 
transcription factors (Ross and Hill, 2008; Schmierer and Hill, 2007). TGFβ signalling can also 
be inhibited by the I-Smads, where Smad6 can inhibit Bmp and Amh signalling (Bai et al., 
2000), while Smad7 can inhibit TGFβ, activin, Gdf9 and with less affinity for the Bmp pathway 
(Chen et al., 2009). In the ovary, different TGFβ ligands that signal via Smad2/3 are shown to 
be involved with follicle development including the TGFβ isoforms (TGFβ 1-3), Activin, and 
Gdf9, while, others such as Bmp and Amh signal through the Smad1/5/8 pathway (Kaivo-oja 
et al., 2006; Li et al., 2008b). Importantly, this implicates the Smad family as regional 
modulators of different stages of follicle growth (Li et al., 2008b; Tian et al., 2010). In the 
ovary, TGFβ can also exert its biological effects through non-Smad pathways, such as MAPK, 
PI3K/AKT, Rho (Hough et al., 2012; Mu et al., 2012).  
TGFβ/Smad signalling is regulated at different cell levels including extracellular regulation by 
the latent TGFβ binding proteins Ltbps (Su et al., 2015) and intracellularly (in addition to the 
I-Smads) by various Smad inhibitors such as Strap (Reiner and Datta, 2011) and Tmepai (Bai 
et al., 2014). Dysregulation of TGFβ/Smad signalling is associated with many pathological and 
reproductive disorders such as cancer (Fink et al., 2003), polycystic ovary syndrome 
(Hatzirodos et al., 2011) and ovarian failure (Pangas et al., 2006). In other tissues, additional 
TGFβ signalling inhibitors and suppressors have been recognised to implicate the cell 
physiology and pathology, such as Ski/ SnoN (Deheuninck and Luo, 2009), Ppm1a (Dai et al., 
2011) and Smurf1/ Smurf2 (Inoue and Imamura, 2008). Although TGFβ/ Smad signalling is 
active in the ovary, the expression and effect of such inhibitors on follicle development have 
not been defined yet. Therefore, initially, it is important to determine whether such factors are 
detectable in the ovary and then to further investigate their functional impact on follicle growth. 
Understanding molecular events that regulate the TGFβ signalling in follicles might be helpful 
to understand initial activation of primordial follicles or mechanisms that operate to maintain 
the quiescent state. Clinically, these regulators might be applicable for treatment of several 
causes of female infertility. For example, in vitro activation of primordial follicles, prevention 
of early follicle depletion, or to maintain the quiescent state of primordial follicles during 
treatments of cancer. This chapter provides information on mechanisms and factors that are 
implicating in the early follicle development. Particular attention is focussed on the 
TGFβ/Smad signalling compartments, its extracellular and intracellular regulators. 
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1.2. Mouse models for studying the ovarian function 
In women, exposure to various factors, such as anti-cancer treatments, some medicines, and 
environmental pollutants can negatively affect the function of the ovary and can promote 
exhaustion of the follicle reserve leading to a decrease in fertility (Tilly, 2003). The mouse has 
been widely used to understand both the physiological or pathological factors that affect follicle 
and ovary development in women. For example, genetically modified mice were generated to 
study ovarian cancer in women (Fong and Kakar, 2009), also female mice were utilised to 
determine how dietary intakes can affect both the ovary function and reproductive lifespan 
(Nehra et al., 2012). Unlike ovaries from larger mammals, the small size of rodent ovaries has 
been widely exploited for the purposes of whole organ culture (Drummond et al., 2003; Eppig 
and O'Brien, 1996). In addition, postnatal mouse ovaries have been considered as a valuable 
system to investigate the role of different factors that implicated in the regulation of the 
primordial follicle development since the majority of follicles at this time are non-growing (Jin 
et al., 2010). It has been shown that ovary culture conserves the physiological interactions not 
only among follicles of different stages of development but also between follicles (Abdi et al., 
2013). Over the last two decades, genetically modified mouse/ovary models have been 
extensively used to understand an essential information on the molecular mechanisms 
regulating primordial follicle growth (Reddy et al., 2008; Zheng et al., 2012).  
Likewise, preantral follicle cultures have been developed where encapsulation of cultured 
follicle with materials such as alginate hydrogel and fibrin-alginate gel provides support of 
follicle growth by maintaining the crosstalk between oocytes and the surrounding cells (Jin et 
al., 2010; Pangas et al., 2003). In addition, whole ovary culture and co-culture systems have 
been described (Morgan et al., 2015). More recently, ovary fragments culture model have been 
used to identify the effect of exogenous treatments on early follicle development (Komatsu et 
al., 2015). Studies have also highlighted the usefulness of an in vivo ovary transplantation 
model to study follicle growth where mouse ovaries are maintained under the kidney capsule 
to recapitulate normal environmental conditions of follicle growth compared to in vitro culture 
models (Wang et al., 2013). 
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1.3. Follicle formation  
Follicle formation requires three essential steps, firstly, formation and migration of primordial 
germ cell during embryogenesis, secondly, the formation of oogonia clusters in the ovary, and 
thirdly, the formation of individual primordial follicles (Pepling, 2006) . In the mouse ovary 
(Figure 1.1), the ovarian primordial germ cells (PGCs) originate around 6.5-7.5 days post coitus 
(dpc) of embryonic life in the extraembryonic mesoderm (Lawson and Hage, 1994; Saitou and 
Yamaji, 2012). PGCs migrate between 10-11 dpc to the genital ridge where they continue to 
multiply by mitosis to produce oogonial clusters (germ cell cysts) (McLaren, 2000). Then, 
oogonia embark on the early stages of meiosis, at approximately 13.5 dpc, to form oocytes 
(Pesce et al., 2002). From 17.5dpc to the 5th day after birth (continued arrested until ovulation), 
most oocytes become arrested at the diplotene phase of meiotic prophase I. From this stage, 
cyst breakdown occurs and oocytes become enclosed by a number of flattened precursor 
granulosa cells to generate primordial follicles (Hirshfield, 1991; McGee and Hsueh, 2000; 
Pepling and Spradling, 2001).  
Kit ligand (Stem Cell Factor, SCF) is detectable in prenatal mouse ovaries from 16.5dpc and it 
is proposed that Kit signalling has an essential impact on the rate of cyst breakdown by 
preventing apoptosis of oocytes during the assembly of primordial follicles (Jones and Pepling, 
2013). Culturing neonatal rodent ovaries with Kit protein supplemented media promotes 
primordial follicle formation, whereas immunoneutralisation by Kit antibody reduces the 
number of follicle formations (Wang and Roy, 2004). 
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Figure 1.1. Overview of primordial follicle formation in the mouse ovary. The generation of germ line 
cyst occurs when the primordial germ cells (circle shapes) reaches the genital ridge after 10.5 days post-
coitus (dpc). Some germ cells inside the germ cyst initiate meiosis at 13.5 dpc; then, at 17.5 dpc, a 
portion of oocytes become arrested at the diplotene stage. Breakdown of germ cysts and invasion of 
pre-granulosa cells (blue shapes) occurs shortly after birth, thus, each individual oocyte forms a 
primordial follicle; however, a substantial of oocytes loss occurs around this time, adapted from 
(Pepling, 2006). 
An additional group of growth factors called neurotrophins are also essential for primordial 
follicle formation. For example, mutation of neurotrophic tyrosine kinase receptor type 1 
(NTRK1) in mouse ovaries revealed a reduction in the number of primordial follicles with a 
high proportion of oocytes still enclosed in germ cell cysts (Dissen et al., 2001; Kerr et al., 
2009). Other examples of growth factors that signal through NTRK2 receptors are brain- 
derived neurotrophic factor (BDNF) and neurotrophin 4 (NT4). Inhibiting the function of either 
BDNF or NT4 in cultured mouse ovaries causes an increase in the percentage of degenerative 
oocytes (Spears et al., 2003). Interestingly, a mutation in the signalling receptor (NTRK2) led 
to a decrease in the number of oocytes accompanied by a reduction in primordial follicle 
formation (Kerr et al., 2009).  
TGFβ superfamily members are also involved in primordial follicle formation; for instance, in 
mice, deletion of bone morphogenetic protein 15 (Bmp15) or growth differentiation factor 9 
(Gdf9) caused incomplete cyst breakdown manifested by substantial increases in the population 
of follicles containing more than one oocyte (Yan et al., 2001). Similarly, overexpression of 
inhibinα,  an  activin  antagonist,  also  leads  to  increased  numbers  of  the  primordial follicle with 
multiple oocytes, suggesting the importance of activin in follicle formation (McMullen et al., 
2001).  In  the  rat  ovary,  incubation  of  immature  ovaries  with  TGFβ1  led to a reduction in the 
formation of primordial follicles; however, populations were increased in ovaries treated with 
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either  connective   tissue  growth   factor  CTGF,  or  with  a  combination  of  TGFβ1  and  CTGF.  
These outcomes indicated the essential role of CTGF in both primordial follicle formation and 
the size of primordial follicle pool (Schindler et al., 2010). In endothelial cells, CTGF is 
identified as an extracellular protein that can directly associate with signalling molecules 
cooperates in various functions such as tissue healing and extracellular matrix formation 
(Brigstock, 2002). In vitro and in vivo studies showed that steroidal hormones, such as 
oestrogen and progesterone can impair both cyst breakdown and oocytes degeneration 
indicating the importance of maternal endocrinal system in primordial follicle formation (Chen 
et al., 2007; Kezele and Skinner, 2003).  
Before the formation of individual follicles, a high proportion of oocytes undergo apoptosis 
(Hirshfield, 1991; Kim, 2012). Apoptosis of primordial germ cells or oocytes is characterised 
by morphological changes including nuclear condensation, loss outer membrane integrity, 
shrinking, and subsequently cellular death (Pesce and De Felici, 1994). It is suggested that 
genetic abnormalities or unsuccessful generation of some cellular compartments of the germ 
cell, such as the mitochondria, might explain oocyte death during cyst breakdown (Hunt and 
Hassold, 2002). It has also been proposed that oocyte degeneration not only acts as a nursing 
resource for the remaining oocytes (Lei and Spradling, 2016), but also, to provide space for 
somatic precursor granulosa cells to enclose each individual oocyte (Pepling and Spradling, 
2001). In addition, others have proposed the importance of the programmed cell death as a 
mechanism to eliminate inadequately formed cells, which might affect the well-formed cells 
(Tingen et al., 2009). Primordial germ cells and oocytes can degenerate either before or after 
being enclosed by somatic cells (pre-granulosa cells). Degeneration of either structure prior to 
primordial follicle formation is called attrition; however, the term atresia is generally referred 
to the degeneration of the completely formed follicle (Hsueh et al., 1994).  
In mice, the primordial follicles initially form in the ovarian medulla from 17.5 dpc; however, 
according to the mouse strain, the process of primordial follicle formation in the ovarian cortex 
might be delayed until the postpartum period between 5th to 8th dpc (Pepling, 2012). In humans, 
the period of primordial follicle formation is initiated from the 4th month of gestation and ends 
by the time of parturition, where a portion of primordial follicles start to grow while the 
majority remain quiescent (Gougeon, 1996). In humans, a constant reduction in the population 
of small follicles from approximately 500,000 at birth to less than 1,000 follicles at menopause 
(Hansen et al., 2008). In mice, it has indicated that ovaries at 6dpp contain more than 10,000 
primordial follicles and this number declines to less than 3,000 at the age of 45 days (Bristol-
Gould et al., 2006).  
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Another study on four different mouse strains aged between d4 and d42, revealed significant 
difference between groups in the population of primordial follicles and also the rate of follicle 
loss at both time points, suggesting that the number of primordial follicles in the ovary and rate 
of follicle atresia are largely dependent on the strain (Canning et al., 2003). 
1.4. Regeneration of oocytes 
It is generally accepted that the population of primordial follicles at birth is the only source of 
follicles for the entire reproductive lifespan and new oocytes/follicles cannot be generated after 
this time (Kezele et al., 2002; Kezele and Skinner, 2003; McGee and Hsueh, 2000). In mice 
ovary, attempts were applied to extend the reproductive lifespan by increasing the population 
of primordial follicles; however, it has found that even in this context, the ovary was able to 
minimise the size of the artificially increased ovarian reserve (Flaws et al., 2001; Tingen et al., 
2009). However, within the last decade, several reproductive biologists have challenged this 
concept and indicated the possibility of oocyte generation from stem cells that can develop into 
primordial follicles, reviewed by (Oktay and Oktem, 2007; Zhang et al., 2013). Initially, a study 
has proposed that mouse primordial follicles can develop (77 follicles/ovary each day) in 
postnatal ovaries from oogonial stem cells; the study stated that these cells are located in the 
ovary epithelium and are positive for Ddx4, a marker of germline cells and oocytes (Johnson 
et al., 2004). The authors later altered their assumptions about the positive staining of oogonial 
stem cells for Ddx4, stating that these cells were originally derived from the blood and bone 
marrow rather than ovary (Johnson et al., 2005). 
More recently, female germline stem cells (FGCs) were obtained from postnatal mouse ovaries 
(5dpp) processed by a long series of cultivation, purification, and isolation. Then, FGCs were 
transplanted into ovaries of infertile adult female mice where these cells underwent oogenesis 
and offspring were successfully obtained (Zou et al., 2009). Similar outcomes were presented 
after isolating oogonial stem cells OSCs obtained from adult mouse ovarian cortical tissue from 
women, where oocytes of 35-50μm  were  generated  (White et al., 2012). 
Despite these findings, other have tried to confirm the possibility of postnatal oogenesis after 
exposure to radiotherapy; however, both adult and postnatal ovaries from the treated mice 
failed to show any signs of follicle renewal (Kerr et al., 2012). The concept of neo-oogenesis 
would be tremendously significant, since nowadays, infertility due to the ovarian ageing is 
more prevalent among women. The main reasons for this are related to social aspects such as 
development of careers and increased education level. In addition, increased patient survival 
after anti-cancer treatments, or due to pathological, physiological, and genetics causes, which 
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promotes premature ovarian failure (Jeruss and Woodruff, 2009) means that the primordial 
population of these women would be further compromised. 
1.5. Follicle classification  
Follicles can generally be categorised into three sections (Figure 1.2). Firstly, gonadotropin 
(Gn)-independent, lasts from the generation of primordial follicles to the secondary phase in 
which follicle growth is modulated via various intra-ovarian growth factors (Edson et al., 2009; 
Orisaka et al., 2009). Secondly, ‘gonadotrophin- responsive’ ranges from the secondary to the 
small antral, where the follicles will react to the hormonal effects, but do not depend on them 
for development (Picton et al., 2003; Scaramuzzi et al., 2011). Thirdly, during the 
gonadotrophin- dependent stage, follicle growth (from small antral to large antral) is supported 
by FSH and the LH surge and the interaction between somatic cells and oocyte (Eppig, 2001; 
Orisaka et al., 2009). 
 
Figure 1.2. Stages of mammalian follicle development. Throughout the gonadotrophin-independent 
stage, primordial follicles originate from primordial germ cells surrounded by pre-granulosa cells. 
Development of primordial follicles into the primary stage is thought to be regulated by growth factors, 
manifested by increased oocyte size, morphological changes of flattened pre-granulosa cells into 
cuboidal and granulosa cell proliferation. The progression of primary follicles to secondary follicles 
includes further growth of the oocyte, proliferation of the granulosa cells to form a second layer, and 
development of the theca cells. Development of the later stages is largely dependent on gonadotrophin 
including follicle stimulating hormone FSH and luteinizing hormone LH where follicle are recognised 
by a larger size, more granulosa cell layers, and the development of antrum, after which, follicles either 
ovulate or undergo atresia, adapted from (Edson et al., 2009). 
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1.6. Primordial follicle activation 
Activation of the primordial follicle to initiate the growth process is an essential step of follicle 
development. Even though many studies focused on this process, the mechanisms or factors 
that regulating follicle activation are still not well understood (Edson et al., 2009; Kim, 2012). 
Activation of primordial follicles is thought to be continuous and irreversible, and follicles that 
initiate growth either continue growing towards ovulation or degenerate by atresia (Edson et 
al., 2009; Scaramuzzi et al., 2011). The transition from primordial to primary growth stage is 
characterised by an increase in oocyte size, morphological change of granulosa cells from 
flattened to cuboidal and increases the number of granulosa cells.  
Before puberty, a portion of the primordial follicles are activated to grow; however, these 
follicles later undergo atresia because of insufficient levels of pituitary gonadotropins 
(Hirshfield, 1992). In mouse ovaries, the majority of non-growing primordial follicles are 
distributed in the marginal region underneath the ovarian surface, while growing follicle are 
mainly localised in the medulla of the ovary (Byskov et al., 1997; Da Silva-Buttkus et al., 2009) 
(Figure 1.3). 
 
Figure 1.3. Distribution and types of follicles in pre-pubertal and adult mouse ovaries. The majority of 
follicles in the day 4 ovary are primordial follicles (1) with several transitional follicles (2) that have 
initiated growth. By day 16, more primordial follicles are activated to grow to the primary (3) and 
secondary (4) stages, mostly located in the medulla, while the peripheral region of the ovary is still 
dense with primordial follicles. In the adult ovary, due to the advances in follicle growth, other ovary 
structures can recognise including small (5) and large (6) antral follicles, corpora lutea (7) and atretic 
follicles (8) are evident, while the population of primordial follicles is noticeably reduced.  
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Many hypotheses and mechanisms have been proposed to explain why particular primordial 
follicles are activated to grow while others remain in a dormant state; for example, it has been 
proposed that primordial follicles located close to growing follicles are more likely to be 
activated than others situated among a group of non-growing follicles. This statement indicates 
a significant growth inhibitory effect of primordial follicles on each other (Da Silva-Buttkus et 
al., 2009). Others suggested that oocytes of growing follicles might produce growth factors that 
stimulate or enhance the growth of the adjacent primordial follicle, such as Gdf9 (Pangas, 
2012), and bone morphogenetic proteins Bmp15 (Gdf9b) (Knight and Glister, 2006). In 
contrast, some of the TGFβ superfamily members were suggested to have an inhibitory impact 
on the activation of primordial follicles preventing them from growing, such as Anti-Mullerian 
Hormone (Amh), which is secreted from granulosa cells of growing preantral follicles 
(Durlinger et al., 2002). Despite this evidence, it should also be noted that in cultured neonatal 
mouse ovaries, where the source of Amh secretion is absent, a portion of primordial follicles 
still remain dormant (Jin et al., 2010). In humans, treatment of ovary fragments with human 
recombinant Activin A protein (50ng/ml) demonstrated a considerable decrease in the 
proportion of the activated primordial follicle relative to untreated control, with no impact on 
follicle atresia (Ding et al., 2010). 
Other TGFβ superfamily members have also been directly implicated in primordial follicle 
activation; for example, treatment of immature (2dpp) mouse ovaries with rhBmp7 protein 
revealed an increased transition rate of primordial follicles into primary staged follicles 
accompanied with upregulation of Fshr expression supporting further follicle growth (Lee et 
al., 2004). Similarly, in postnatal rat ovaries, treatment with Bmp4 protein resulted in increased 
primordial to primary transition with a corresponding increase in ovary size. In contrast, 
massive oocyte degeneration, decreased primordial to primary transition and small ovary size 
after immunoneutralisation of Bmp4 (Nilsson and Skinner, 2003). 
The bi-directional interaction between the granulosa cells and the oocyte is essential for the 
process of primordial follicle activation (Eppig, 2001; Kezele et al., 2002). For example, in 
vitro studies revealed that kit ligand (KL) and its receptor c-kit, has a key role in primordial 
follicle activation; treatment of cultured neonatal rodent ovaries by KL antibody caused 
inhibition of primordial follicle activation (Reynaud et al., 2001; Wang and Roy, 2004). It has 
been identified that granulosa cells are responsible for the production of KL, which can 
promote oocyte growth (Kezele and Skinner, 2003). KL increases the expression of androgens 
by stimulating the growth of both stromal and theca cells (Parrott and Skinner, 2000). 
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KL also activates the cell proliferative kinase pathways, such as PI3K/AKT, which are 
important component regulators of oocyte growth by inactivation of Foxo3a (Accili and Arden, 
2004). Foxo3a is a member of forkhead box (Fox) subfamily that has a critical role in female 
fertility. During primordial follicle assembly, Foxo3 is expressed in the nucleus of the oocyte; 
however, as the follicle starts to grow, Foxo3 translocate into the cytoplasm, indicating that the 
nucleocytoplasmic translocation of Foxo3 is associated with follicle growth (John et al., 2008).  
Mice lacking Foxo3a in their oocytes exhibited loss of their reproductive efficiency followed 
by infertility manifested by enlarged ovaries due to the increased number of activated follicles 
accompanied with early depletion of primordial follicles from the ovary (Castrillon et al., 
2003). Interestingly, during the process of primordial to primary follicle transition, pre-
granulosa cells change their morphology from a flattened or squamous to cuboidal shape 
(Hirshfield, 1991).  
Forkhead box protein L2 (Foxl2) is mainly expressed in pre-granulosa cells of primordial 
follicles being significantly decreased in granulosa cells of growing follicle (Uda et al., 2004). 
This transcription factor also belongs to the Fox family and is not only essential for granulosa 
cell differentiation and proliferation, but also in the determination of female gender (Uhlenhaut 
and Treier, 2011). Foxl2 null mice exhibits primordial follicles with a normal morphology; 
however, as these follicles start to grow their pre-granulosa cells fail to cuboidalise while 
oocytes continue to grow prematurely and become surrounded by several undeveloped 
granulosa cells indicating that Foxl2 is a regulator of granulosa cell growth (Schmidt et al., 
2004). The role of PI3K pathway on primordial follicle development and apoptosis was 
determined using genetically modified ovary models; for example, the basic level of PI3K is 
essential to keep the quiescent state of primordial follicles (Zheng et al., 2012).  
In mouse ovaries, stimulation of PI3K pathway by blocking the inhibitory effect of PTEN, a 
PI3K pathway inhibitor, leads to premature activation of a high proportion of primordial 
follicles followed by early ovarian failure, indicating that PTEN is a negative regulator of 
primordial follicle activation (Reddy et al., 2008). However, suppression or inhibition of the 
PI3K pathway causes pathological conditions manifested by a high apoptosis rate in primordial 
follicles, suggesting that the PI3K pathway participates in cell survival and disruption of this 
pathway might cause premature ovarian failure and infertility (Reddy et al., 2009) (Figure 1.4). 
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Figure 1.4. Effect of modulated PI3K pathway on primordial follicle growth and survival. In the ovary, 
the optimal level of PI3K signalling is required to maintain the majority of primordial follicles (PFs) in 
an inactive state. Inhibition of PI3K signalling causes substantial death among primordial follicles. In 
contrast, activation of PI3K signalling causes massive activation of primordial follicle growth and 
depletion of the primordial follicle pool. Adapted from (Reddy et al., 2009).  
In rat ovaries, basic fibroblast growth factor (bFGF) has been localised in the oocytes of 
growing follicles (Ergin et al., 2008) and in granulosa and theca cells of growing follicles in 
human ovaries (Yamamoto et al., 1997). Throughout the process of primordial to primary 
follicle transition, bFGF function in the activation of stromal, granulosa and theca cell 
development. Supplementation of bFGF to cultured neonatal rat ovaries led to decreases in the 
number of primordial follicles accompanied with a significant increase in the population of 
growing follicles (Nilsson et al., 2001b). In the immature rat ovary culture, leukaemia 
inhibitory factor (LIF) was also found to cause a considerable increase in the percentage of 
growing follicles and a decline in the percentage of primordial follicles, particularly in the 
presence of insulin. By contrast, immunoneutralisation using anti-LIF antibodies revealed a 
moderate reduction in follicle activation (Nilsson et al., 2002). However, in mice, a recent study 
indicated that treatment of the cultured ovary fragments with anti-LIF antibodies enhanced 
follicle growth, while supplementation of rLIF protein caused inhibition the growth of growing 
follicles (Komatsu et al., 2015). Keratinocyte growth factor (KGF), also called fibroblast 
growth factor 7 (FGF7), is expressed in oocytes of primordial follicles, granulosa cells, and 
stroma cells in human ovaries (Abir et al., 2009). FGF7 exerts positive growth effects on the 
adjacent pre-granulosa and granulosa cells and therefore enhances the process of primordial to 
primary follicle transition (Nilsson and Skinner, 2003) (Figure 1.5). 
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Figure 1.5. Several factors influencing primordial follicle activation and transition. Primordial follicle 
(PF) activation and transition to the primary stage are regulated by the cooperative interaction of various 
growth factors produced either by the oocyte (bFGF, GDF9 and Bmp15), the surrounding pre/granulosa 
cells (LIF, KL and AMH), stroma cells (KGF) or from circulation (Insulin). Neighbouring primordial 
follicles influence activation of the primordial follicle. Several pathways function to enhance cell 
proliferation such as PI3K, AKT and ERK resulting in increased primordial follicle activation. Adapted 
from (Knight and Glister, 2006). 
1.7. Overview of the transforming growth factor TGFβ  superfamily 
TGFβ superfamily proteins are extracellular ligands extensively expressed throughout the body 
and are implicated in many physiological activities including proliferation, differentiation, 
migration, and cell degeneration during both pre-and postnatal life (Rahimi and Leof, 2007). 
TGFβ superfamily members are structurally related and consist of more than 40  members 
including TGFβ (β1,  β2  β3),  Activin  (A,  B  and  AB), Inhibin (A and B), Growth differentiation 
factor (Gdf9), Bone Morphogenetic Proteins (Bmps1-15), Anti-Müllerian Hormone (Amh), 
Nodal and Lefty (Drummond et al., 2003; Pangas, 2012). Briefly, all of the TGFβ ligands can 
signal through a heteromeric serine/threonine kinase receptor complex, which in turn activates 
the cytoplasmic Smad mediators by phosphorylation (Shi and Massague, 2003; ten Dijke and 
Hill, 2004). Activated Smads interact with another type of Smad (Smad4) to enhance their 
translocation to the nucleus where target gene transcription occurs (Brown et al., 2007; 
Moustakas and Heldin, 2008). The third type of Smad (I-Smads) can attenuate or inhibit the 
signalling pathway at different levels (Goto et al., 2007; Yan and Chen, 2011).  
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In the ovary, modulation of TGFβ signalling is associated with activation of primordial follicles 
(Ding et al., 2010), impaired follicle growth (Li, 2015) or the development of pathological 
phenotypes (Pangas et al., 2008). 
1.7.1. Functional role of the TGFβ  superfamily in the ovary 
Over the last two decades, many studies have investigated the role of the TGFβ superfamily in 
the regulation of follicle growth (Knight and Glister, 2006; Pangas, 2012). In mice, knockout 
of  TGFβ1  delayed  sexual  maturity  and  disruption  ovarian  function  (Ingman et al., 2006). In 
cows, TGFβ1-3 proteins are expressed in oocytes of primordial and growing follicles, TGFβ2 
and   β3   in   granulosa   cells   of   all   developmental   follicle   stages,  while TGFβ1 is exclusively 
localised in the granulosa cells of primordial to early antral follicles (Nilsson et al., 2003). 
Bmp proteins, such as Bmp4 and Bmp7 are thought to be essential for the primordial to the 
primary follicle transition in rodents (Ding et al., 2013; Shimasaki et al., 2004). 
Immunostaining of juvenile rat ovaries indicated that Bmp4 is detectable in precursor theca 
cells (Nilsson and Skinner, 2003). Passive immunisation of mice with anti-Bmp4  (50μg)  for 7 
days revealed a significant reduction in primordial to primary follicle transition accompanied 
with reduced ovary size (Tanwar et al., 2008). In neonatal rat ovaries, in vitro treatment with 
anti-Bmp4 IgG demonstrated similar outcomes with less activation of primordial follicles and 
a significant increase in oocyte apoptosis. Conversely, treatment with exogenous Bmp4 protein 
caused a significant increase in the population of growing follicles with a concomitant decrease 
in the proportion of primordial follicles (Nilsson and Skinner, 2003). 
Treatment of neonatal mouse ovaries with rhBmp7 also promoted activation and transition of 
quiescent primordial follicles to the primary stage (Lee et al., 2004). By comparison, Bmp6 is 
detectable in the oocyte and granulosa cells of growing follicles and has been shown to 
influence FSH–induced steroidogenesis, but the effect of this protein on early follicle 
development has not been investigated (Otsuka et al., 2001). In both neonatal and mature 
ovaries, Bmp15 (Gdf9b) and Gdf9 proteins are detectable in oocytes of all follicle stages that 
have initiated growth (McGrath et al., 1995).  
Deletion of Gdf9 from mouse ovaries exhibited inadequate granulosa cell proliferation, 
insufficient oocyte development, and failure of theca cell formation (Elvin et al., 1999). More 
recently, natural homozygous mutations of Bmp15 and Gdf9 in ewes revealed loss of fertility 
manifested by defective follicle development and anovulation. Surprisingly, ewes carrying 
heterozygous mutations (i.e. one copy) exhibited increased ovulation rate (Hanrahan et al., 
2004). 
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In immature female rats, the effect of in vivo treatment with exogenous Gdf9 protein caused an 
increase in the number of primary and small preantral (i.e. growing) follicles with a significant 
reduction in the population of primordial follicles indicating that Gdf9 is essential for the 
transition of primordial to primary follicle stage (Vitt et al., 2000).  
Anti-Müllerian hormone (Amh) is believed to inhibit the transition of primordial follicles. 
Treatment of neonatal mouse ovaries with exogenous Amh protein prevented the majority of 
primordial follicles from growing (Durlinger et al., 2002). However, this statement has been 
challenged by incubation of postnatal mouse ovaries, which is free from the source of Amh as 
the majority of follicles are primordial, at the end of culture, different stages of follicle growth 
were determined including primordial follicles (Jin et al., 2010).  
Activin is expressed in granulosa cells of growing follicles and is formed by a combination of 
two  β  subunits  (either  βA  or  βB).  Thus,  three  isoforms of activin have been identified included 
activin  A  (βA- βA),  B  (βB- βB),  or  AB  (βA  -βB)  (Knight and Glister, 2001). Generally, activin 
has a role in the progression of oocyte growth, granulosa cell proliferation in preantral follicles 
and enhancement of antrum formation in late stage pre-antral follicles (Zhao et al., 2001). 
Activin signalling is antagonised by the presence of follistatin, an extracellular binding protein, 
which can bind to activin thereby obstructing the association between activin and its specific 
receptors (Thompson et al., 2005).  
Similarly, overexpression of inhibin (the product of an α and   β   subunit)   can block activin 
signalling by associating with the type II activin receptors (Zhu et al., 2012). Inhibin null mice 
demonstrated a significant increase in the proliferation of granulosa cells with an elevated 
incidence of ovarian tumour. Furthermore, these effects were accompanied with enhanced 
activin signalling (Matzuk et al., 1992). Interactions   between  TGFβ   signals   that   regulating  
early follicle development are illustrated in Figure 1.6. 
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Figure 1.6. A  model   for  TGFβ  signalling   in the follicle. Different TGFβ superfamily members are 
implicated in the regulation of follicle growth. These members and their receptors are detectable in 
different follicle compartments including oocytes, granulosa cells, and theca cells. Follicle growth is 
regulated in part through the interaction of these factors with their specific receptors in an autocrine 
(white arrows) and paracrine (black arrows) manner. Adapted from (Knight and Glister, 2003). 
1.7.2. Synthesis and structure of TGFβ  
Intracellularly, TGFβ proteins (TGFβ1-3) undergo several processes before secretion to the 
ECM as biologically non-functional structures. TGFβ members are produced as a single 
precursor pro-TGFβ (pre-pro-TGFβ). Two of these monomers then associate by their 
interaction between three conserved disulphide bonds forming a dimeric pro-TGFβ (Annes et 
al., 2003; Gray and Mason, 1990). A fundamental stage of TGFβ synthesis is the proteolytic 
breakdown of pro-TGFβ by the endopeptidase, furin convertase, which splits the pro-TGFβ 
protein to produce a non-covalently linked structure called the small latent TGFβ complex 
(SLC) (Blanchette et al., 1997; Dubois et al., 1995). A particular glycoprotein (Emilin1) which 
interacts with elastic fibres in the ECM can antagonise furin function. Emilin1 knockout in 
mice caused increased TGFβ signalling in blood vessels and hypertension was revealed 
(Zacchigna et al., 2006). The SLC consists of a latency-associated peptide (LAP) and the 
mature TGFβ as a dimer. LAP is essential to enable the passage of TGFβ through the cell 
membrane to ECM (Brown et al., 1990). 
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Extracellularly, the   SLC   binds   to   the   large   latent   TGFβ-binding protein (Ltbp) by two 
disulphide bonds (covalent binding) between LAP (cysteine 33 residues) and the third 8-Cys 
repeat of the Ltbp form a large latent complex (LLC) (Hyytiainen et al., 2004) (Figure 1.7). 
 
Figure 1.7. Schematic illustrating synthesis and structure of the latent TGFβ complex. TGFβ members 
are produced as a precursor protein (pre-pro- TGFβ). Two pro-TGFβ are connected with each other by 
disulphide bond before being cleaved by furin to produce the small latent TGFβ complex (SLC). In the 
ECM, Emilin1 antagonise furin function. SLC is composed of two parts, latency-associated peptide 
(LAP) and mature TGFβ, connected together by non-covalent bonds. SLC associates with the latent 
TGFβ binding protein by a disulphide bond to form the large latent complex (LLC). The LLC is stored 
in the extracellular matrix by its association with other structures such as fibrillin and fibronectin. 
Adapted from (Hayashi and Sakai, 2012).  
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TGFβ   ligands can be secreted either in the form of LLC or SLC (Hyytiainen et al., 2004; 
Saharinen et al., 1996). However, secretion of small latent TGFβ complexes associated with 
Ltbp (LLC) and also the free Ltbp isoform from cells occurs more readily than unbound small 
latent TGFβ complexes (SLC) (Miyazono et al., 1991). After secretion, TGFβ signalling cannot 
be initiated as LAP covers the epitopes of the mature TGFβ preventing access to its particular 
receptor (Annes et al., 2003). 
Ltbp1 and Ltbp3 can create covalently linked complexes with all TGFβ members (TGFβ1-3) 
while Ltbp4 can only bind to TGFβ1 and Ltbp2 cannot associate with any TGFβ members 
(Penttinen et al., 2002; Saharinen and Keski-Oja, 2000). However, more recently, a study 
indicated a possible association between Ltbp2 and the microfibrils proteins, fibrillin1 and 2, 
suggesting that Ltbp2 is important for elastic fibre assembly in the ECM (Hirai et al., 2007). In 
the ECM, the LLC associate with the elastic microfibrils by binding of the C‑ terminal region 
of Ltbp1, 2, 4 to the N‑ terminal region of fibrillin1 and 2 (Isogai et al., 2003). In addition, for 
further anchoring of the LLC complex to the ECM, the N-terminal domain of LTBP1 and 4 
connects to other components of the ECM, such as fibronectin (Dallas et al., 2005; Nunes et 
al., 1997). 
1.7.3. Activation TGFβ ligands 
All TGFβ  members are secreted and stored as inactive structures (LLC/SLC complex) in the 
ECM because LAP prevents the interaction between epitopes of mature TGFβ and TGFβ 
receptors (Annes et al., 2003). Thus, activation of latent TGFβ (Figure 1.8) is an essential stage 
that regulates TGFβ bioavailability, which requires releasing of active TGFβ by disrupting the 
association  between  LAP  and  mature  TGFβ  (Hyytiainen et al., 2004). Different mechanisms 
and factors have been reviewed in relation to the activation process (Koli et al., 2001; Saharinen 
et al., 1999). However, it is difficult to evaluate whether these mechanisms/ factors function as 
principal activators or if they simply act to enhance the activation process. For example, 
plasmin has the potential to release the active TGFβ from LAP but also acts to enhanced the 
dissociation of LLC from the ECM by its proteolysis effect on the hinge region of Ltbp (Annes 
et al., 2003; Taipale et al., 1992). Several other proteases are essential to release the bioactive 
TGFβ,  such  factors  include  elastase,  mast-cell chymase, and BMP1-like metalloproteinases, 
which act by directly targeting the complex of Ltbp and LAP (LLC), as well the interaction of 
Ltbp and the ECM (Ge and Greenspan, 2006).  
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Additionally, structures termed ‘ligand  traps’, which are structurally diverse ligand-interacting 
proteins, function as obstacles to prevent the contact between TGFβ ligands and their receptors. 
Examples of such ligand traps include noggin, chordin, gremlin, follistatin and DAN/Cerberus 
(Fenwick et al., 2011; Shi and Massague, 2003).  
 
Figure 1.8. Schematic model for secretion and activation of latent TGFβ complex. The majority of 
inactive TGFβ is secreted from cells in the form of LLC (associated with Ltbp). This complex binds to 
the ECM via the N-terminal of Ltbp. The first step of activation by a protease is through cleavage of 
Ltbp from ECM at the hinge region, a protease sensitive part. The following step includes releasing of 
the mature TGFβ from LAP by another proteolytic agent. Subsequently, TGFβ can interact with the 
specific signalling receptors for activation of the signalling pathway. Adapted from (Koli et al., 2001). 
 
In vivo,  active  TGFβ  is  also  released  from  LAP  or  latent  TGFβ  complex  in  response  to tissue 
destruction and remodelling (Kyriakides and Maclauchlan, 2009). For example, 
thrombospondin type 1 motif (TSP1) and matrix metalloproteinase (MMP2, and MMP 9) are 
proteases that promote TGFβ  activation  during  tissue  damage  and  healing   (Bourd-Boittin et 
al., 2011; Yu and Stamenkovic, 2000). In vitro, in addition to protease treatment, activation of 
TGFβ can be achieved by the exposure to high temperature, extreme changes in pH, or by 
disruption of the ECM (Bourd-Boittin et al., 2011; Brown et al., 1990). The absence of binding 
between Ltbp and ECM elements, fibrillin and/or fibronectin, leads to increased of TGFβ  
activity and Smad signalling, while the lack of, or regulation of latent  TGFβ  activators  and/or  
Ltbp causes a reduction in the activation process (Loeys et al., 2010).  
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The released/activated  TGFβ   ligand   initiates   signalling  by  binding and assembling receptor 
complexes, which leads to phosphorylation of internal factors (Shi and Massague, 2003). 
1.7.4. TGFβ superfamily receptors  
The biological effect of all TGFβ superfamily ligands is mediated by cell membrane receptors 
classified as activin receptor-like kinases type I (Alk1- Alk 7) and serine/ threonine kinase 
receptors type II (TGFβRII, BmprII, ActrII, ActrIIb, and AmhrII) (Moustakas and Heldin, 
2009; Schmierer and Hill, 2007). These receptors consist of three distinct regions including an 
extracellular ligand-interacting cysteine-rich domain, a transmembrane domain, and an 
intracellular cytoplasmic domain, which has serine/ threonine kinase activity (Groppe et al., 
2008) (Figure 1.9). Alk4, Alk5 and Alk7 have a high affinity for TGFβ  and  activin signalling; 
that is, factors that activate Smad2 and Smad3 (Feng and Derynck, 1997), while Alk1, Alk2, 
Alk3, and Alk6 are generally activated by Bmps and Amh, which lead to signalling via Smad1, 
Smad5, and Smad8 (Persson et al., 1998). Activated serine/threonine kinase receptors can 
activate the canonical Smad pathway and also Smad-independent pathways; for example, 
mitogen-activated protein kinases MAPK (Javelaud and Mauviel, 2005).  
 
Figure 1.9. Diagram illustrating activation of the TGFβ pathway. At the level of the cell membrane, 
TGFβ receptors consist of an extracellular TGFβ ligand binding cysteine-rich domain, which connects 
to a short transmembrane domain and the long intracellular Ser/Thr kinase domain, which can interact 
with R-Smads. TGFβ signalling is initiated upon stimulation of the phosphorylated (yellow stars) 
TGFβRII receptor by the activated TGFβ ligand (1). Once stimulated (2), the TGFβRII receptor 
activates the serine/threonine kinase activity of TGFβRI by phosphorylation (3). Then, the activated 
TGFβRI recruits and phosphorylates the R-Smads transcription factors (4). 
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Additionally, beta glycan receptor III (TGFβRIII) is a co-receptor that has the potential to 
associate with some TGFβ ligands to enhance interaction with signalling receptors (TGFβRI 
and TGFβRII); however, TGFβRIII cannot mediate internal signalling as it lacks an internal 
kinase domain (Esparza-Lopez et al., 2001). Other studies have demonstrated the expression 
of TGFβRIII receptor caused suppression of TGFβ  signalling  and  inhibition  of  metastasis in 
models of breast and prostate cancer (Elderbroom et al., 2014; Turley et al., 2007). The 
inhibitory effect of TGFβRIII on TGFβ/ Smad signalling was further evaluated using cell lines 
where both TGFβRI and TGFβRII independently associates with TGFβRIII, preventing the 
interaction of Smads with the activated TGFβRI receptor (Tazat et al., 2015). 
1.8. Smad family 
The Smad family consists a family of eight closely related proteins which mediate the signal 
transduction of TGFβ superfamily proteins (Shi and Massague, 2003). Smads were first 
identified through genetic studies on the fruit fly Drosophila melanogaster where an 
intracellular protein termed "Mad" was found to mediate decapentaplegic signalling (Mothers 
Against Dpp), a TGFβ superfamily member (Sekelsky et al., 1995). Then, after the 
identification of an orthologous gene in Caenorhabditis Elegans (Small body size), the names 
of the two genes were combined to "Smad" (Derynck et al., 1996). Functionally, Smads have 
been categorised into three subgroups: Firstly, receptor-activated Smads (R-Smad) including 
Smad1/2/3/5/and 8. Secondly, Smad4 is the common mediator Smad (Co-Smad) that interacts 
with activated R-Smad to facilitate nuclear import and has an essential role in the association 
with transcriptional factors. Thirdly, Inhibitory Smads (I-Smad) include Smad7 that 
exclusively blocks the Smad2/3 pathway (inhibit TGFβ1-3, GDF9 and Activin signalling), and 
Smad6 which primarily inhibits the Smad1/5/8 pathway (inhibit BMPs and AMH signalling) 
(Kimura et al., 2000; Miyazono et al., 2001; Shi and Massague, 2003).  
Smad proteins, consist of 400 - 500 amino acid residues in length and have three precise 
domains including a Mad homology domain-1 (MH1) at the N-terminus, which is required for 
nuclear translocation, DNA binding and regulation of transcription (Moustakas et al., 2001). 
The MH1 domain, binds particular sequences (5'-AGAC-3') of DNA called Smad binding 
elements SBE (Dennler et al., 1999). However, Smad2 is unable to bind DNA because the 
MH1 domain in this protein contains an additional 30 amino acid sequence enriched with 
serine/ threonine known as TID (Yang et al., 2009). The next domain is the central linker which 
contains numerous of essential peptides including prolines and serine/ threonine that serve as 
sites of phosphorylation for signalling pathways other than TGFβ, such as mitogen-activated 
23 
 
protein kinases (MAPK)/ Extracellular signal-regulated kinases (ERK) and c-JUN NH(2)-
terminal kinase JNK (Mori et al., 2004; Wicks et al., 2000). The linker of Smad3 contains a 
site called a transactivation domain (TA), which is essential to promote transcription and the 
physical association with coactivators (Prokova et al., 2005). 
The third domain is a Mad homology domain-2 (MH2), located in the C-terminus and is 
responsible for the interaction of R-Smad with other Smads/receptors and also with co-
activators and co-repressors. The MH1 domain is absent in the I-Smads but is evident in the 
structure of Co-Smad and R-Smad, while MH2 domain is present in all three Smad sub-types 
(Shi and Massague, 2003; ten Dijke and Hill, 2004; Xu et al., 2007). 
1.8.1. Expression of Smads in the ovary 
In rat ovaries, both Smad2 and Smad3 are expressed in small follicles, in particular in 
primordial follicles, indicating a possible influence of TGFβ signalling during these early 
stages (Xu et al., 2002a). In the mouse ovary, Smad4 is expressed in oocytes of non-growing 
(primordial) and growing follicles (Pangas et al., 2006). Likewise in primate ovary, Smad2/3 
and Smad4 have been detected in oocytes and pre/granulosa cells of primordial and primary 
follicles at the mid and late gestation period, respectively (Billiar et al., 2004). In mice, the 
Smad6 protein was shown to be strongly expressed in the oocyte of small quiescent follicles; 
however, in growing follicles, the staining was relatively weaker in the oocyte, granulosa, and 
theca cells, suggesting that the reduction in Smad6 expression in growing follicles is to permit 
TGFβ signalling through Smad1/5/8 (Gueripel et al., 2004). Unlike Smad6, the staining pattern 
of the Smad7 protein in the mouse ovaries was shown to be increased in both granulosa cells 
and oocytes of multi-layered follicles (Quezada et al., 2012), where staining for Smad2/3 are 
decreased (Fenwick et al., 2013). 
More recently, a detailed analysis of Smad2/3 staining in the mouse ovary in our laboratory 
has identified that these proteins appear to be localised in the nuclei of granulosa cells of 
primordial follicles, possibly indicating their crucial role in the maintenance of the primordial 
follicle phenotype. In addition, Smad2/3 becomes excluded from the nuclei of granulosa cells 
of primary/ pre-antral follicles that have initiated growth, suggesting that the exclusion of 
Smad2/3 from the nucleus of granulosa cells is a key molecular event in follicle activation 
(Figure 1.10; Fenwick et al. unpublished). This observation underpins the general hypothesis 
that  TGFβ  signalling  plays  an  important  role  in  small  follicles  and  that modulation of the Smad 
pathway is a key aspect of early follicle development. This will be explored in more detail 
throughout this thesis. 
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Figure 1.10. Localisation of Smad2/3 in granulosa cells of small follicles in the mouse ovary. Smad2/3 
are localised (green) in the cytoplasm of granulosa cells (GC). Nuclei (n) were counterstained with 
DAPI (Blue). Nuclear exclusion of Smad2/3 during follicle activation and growth is highlighted by the 
grey scale image (A'-C') of the green channel, where saturated pixels are coloured red. By comparison 
with earlier follicle stages (A: primordial and B: transitional), the staining pattern of Smad2/3 in nuclei 
of granulosa cells of the primary follicle (C) was largely reduced.  
1.8.2. Functional role of Smad pathway in the ovary 
Mutations in specific Smad genes have provided important information on the role of these 
factors in the regulation of ovarian function and fertility (Pangas and Matzuk, 2004; Tomic et 
al., 2002; Xu et al., 2002a). In reviewing the literature, the role of Smad2 and Smad3 in the 
regulation of the early follicle development is not clearly understood (Li et al., 2008b). In one 
model, Smad3 null mice were affected by colorectal cancer accompanied with rapid loss of 
body weight (Zhu et al., 1998), while Smad2 null mice die during embryonic period (7.5 to 
12.5 dpc) with extensive development of malignant tumours (Hamamoto et al., 2002). Smad3 
deficient mice exhibit a reduced number of growing follicles accompanied with a high 
percentage of primordial follicles, more atretic follicles, and degenerative oocytes, indicating 
that Smad3 is essential for primordial follicle growth (Tomic et al., 2002). A reduction in 
Smad3 also impairs follicle differentiation at the later stages of follicle development as reduced 
levels of oestrogen receptor beta and inhibin alpha subunits were evident in these mice. 
Moreover, deletion of Smad3 results in a decline in the ability of granulosa cells of growing 
follicles to respond to FSH stimulation (Gong and McGee, 2009). It has been suggested that 
Smad3 might substitute for Smad2 and vice versa when individual genes are mutated in mice 
(Li et al., 2008b). Therefore, double conditional mutants in granulosa cells (under the control 
of the cell-specific Amhr2 promoter) were generated. 
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This study revealed that the absence of both Smad2 and Smad3 in granulosa cells causes early 
ovarian failure and infertility manifested by a massive decrease in the population of primordial 
follicle, increase the percentage of atretic follicles, anovulation, and defects in cumulus 
differentiation, indicating their essential role in ovarian function and maintenance of female 
fertility (Li et al., 2008b). Interestingly, conditional deletion of Smad1, 5 and 8 in the granulosa 
cells revealed a considerable prevalence of granulosa cell tumours accompanied with 
upregulation of Smad2 and Smad3 signalling. This suggests that the Smad2/3 pathway might 
be implicated in the progression of the ovarian tumours while Smad 1/5/8 may function as 
tumour suppressors (Pangas et al., 2008). 
Deletion of Smad1 and Smad5 individually results in embryonic death. However, these studies 
showed that Smad1 null embryos exhibited major defects in allantois development and a 
considerable reduction in the establishment of primordial germinal cells (Tremblay et al., 
2001). Similarly, Smad5 knockout mice exhibited a defective proliferation of primordial 
germinal cells (Chang and Matzuk, 2001). Smad8 knockout mice are fertile; however, signs of 
vascular thickness and hyperplasia were observed (Huang et al., 2009). Knockout of Smad4 in 
granulosa cells causes defective cumulus cell differentiation, disordered oocytes growth and 
early luteinisation (Pangas et al., 2006). 
1.8.3. Nucleocytoplasmic translocation of Smads 
TGFβ signalling involves the translocation of Smads between the cytoplasm and nucleus 
through the nuclear pores (Brown et al., 2007). Nuclear pores contain essential nucleoproteins 
(importins) that associate with the activated R-Smad in an energy-dependent manner to 
enhance their translocation into the nucleus (Moustakas and Heldin, 2008).  
The MH1 domain in both R-Smads and co-Smad contains a specific site termed the nuclear 
localisation signal (NLS), which can associate with specific importin proteins, for example, 
importin   α   specifically   interacts with Smad4,   importin   β   with Smad1 and Smad3, while 
importin 7 and 8 can specifically interact with Smad2, 3, and 4 (Xu et al., 2007; Yao et al., 
2008). The association between R-Smads and Smad4 is thought to be essential for nuclear 
translocation of R-Smads (Shi and Massague, 2003). However, in some cell lines, Smad2 and 
Smad3 are detectable in the nucleus in  response  to  stimulation  by  TGFβ1  even in the absence 
of Smad4 (Fink et al., 2003). 
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Another study suggested that the shuttling (import and export) of Smad2 and Smad3 between 
the cytoplasm and nucleus is enhanced by the interaction of the MH2 domain with some 
proteins found in nuclear pores such as CAN/Nup214 and Nup153 (Xu et al., 2002b). In 
addition, to enhance the exclusion process, the linker domain of Smad4 and the MH2 domain 
of Smad1 and Smad3 contain nuclear export signals (NESs) that can associate with exportin 
proteins (Inman et al., 2002).  
Several exportin proteins have been identified; for instance, exportin1 is required for the 
exclusion of Smad1 and Smad4, while exportin4 is specific for Smad3 (Dai et al., 2009). 
Locations of these factors in the structure of Smads are shown in Figure 1.11. Another 
mechanism for the exclusion of Smad2 and Smad3 from the nucleus is by protein phosphatase 
1A, magnesium-dependent alpha (Ppm1a), which acts to dephosphorylate Smad2 and Smad3 
leading to dissociation with Smad4 (Lin et al., 2006). The dephosphorylated Smad2 and Smad3 
are exported from the nucleus by another exportin factor called RAN-binding protein3, 
RANBP3 (Dai et al., 2011). Upon a persistent stimulation of TGFβ, R-Smads constantly 
translocate between the cytoplasm and the nucleus. This occurs because the excluded inactive 
R-Smads can be re-phosphorylated as long as the receptor (TGFβRI) remains active (Inman et 
al., 2002; Xu et al., 2002b).  
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Figure 1.11. The structure of different Smad proteins showing some of the functional sites. The R-
Smad and co-Smad proteins contain two well-recognised domains, the Mad homology domain-1 (MH1) 
and -2 (MH2), while the I-Smad lacks for the MH1 domain. The MH1 domain of Smad2 contains a 
group of amino acids sequence (TID, black shape) enriched with serine/threonine that prevent Smad2 
from interaction with DNA. In addition, nuclear localisation signals (NLS, red shapes) are included in 
the MH1 domain of both R-Smad and Co-Smad, where Co-Smad also contains another functional 
structure called nuclear export signals (NES, green shape). The MH1 and MH2 domains are joined by 
a medially situated structure, which is enriched with proline and is essential for the activation of a non-
Smad pathway called the linker domain. The linker of the Smad3 includes a site for the association with 
coactivators called transactivation domain (TA, white block), while the Smad4 linker contains a nuclear 
export signal (NES), which associate with exportin1 to enhance nuclear translocation. Upon the TGFβ 
stimulation, the TGFβRI becomes activated which then activates by phosphorylation (P) of Smad2 and 
Smad3 at their MH2 C-terminal serine residues (SSMS or SSVS motif, respectively). The MH2 domain 
of Smad2 and Smad3 also can interact with CAN/Nup214 and Nup153, which are essential for the 
nucleocytoplasmic translocation of Smads. Smad3 also include a site that can associate with the 
exportin4 that promotes the nuclear exclusion. Adapted from  (Brown et al., 2007; Inman et al., 2002).  
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1.9. TGFβ/Smad signalling pathway  
Signalling via R-Smads is thought to be a common signalling pathway for most TGFβ members 
(Drummond et al., 2003; Pangas and Matzuk, 2004). The intracellular signal for TGFβ1-3, 
GDF9, Nodal, and Activin are mediated through the phosphorylation of Smad2 and 3, while 
the BMPs and AMH utilise Smad1, 5, and 8  reviewed by (Kaivo-oja et al., 2006) (Figure 1.12). 
 
Figure 1.12. Simplified  schematic  model  of  TGFβ  superfamily  and  signalling  components  in  the  ovary. 
Adapted from (Akhurst and Hata, 2012; Moustakas and Heldin, 2009). 
As  shown  in  Appendix  I,  TGFβ  signalling  is  initiating  through  extracellular activation of TGFβ  
ligands followed by their association with the serine/ threonine kinase type II receptor, which 
undergoes auto-phosphorylation (Groppe et al., 2008).  Then,  the  activated  TGFβRII  receptor  
recruits  TGFβRI  by  phosphorylation  on  its  glycine-serine motif to form a stabilised oligomeric 
receptor complex (Schmierer and Hill, 2007). Intracellularly, the MH2 domain of inactive 
Smad2 and Smad3 (but not Smad1 or Smad5) interact with an accessory protein called Smad 
anchor for receptor activation (SARA) that promotes recruitment and trapping of Smad2/3 to 
the  activated  TGFβRI  receptor  complex.  Inhibition  of  SARA  causes  downregulation  of  TGFβ  
signalling in some models (Qin et al., 2002; Tsukazaki et al., 1998). However, others argued 
that  TGFβ  could signal through Smad2/3 pathway even in the absence of SARA, suggesting 
that SARA is not essential for Smad2/3 activation (Bakkebo et al., 2012; Goto et al., 2001). 
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TGFβ1-3 can stimulate the expression of a cytoplasmic protein termed PML (Promyelocytic 
leukaemia tumour suppressor) which essential for the interaction and binding of SARA to 
Smad2/3, thus PML participates in   the   regulation  of  TGFβ   /Smad2/3  signalling   (Lin et al., 
2004). Consequently, the type I receptor kinase is able to activate the R-Smad by 
phosphorylation in their two serine residues located at their C-terminus SSXS motif (Miyazono 
et al., 2001). Dissociation of SARA  and  TGFβ  receptors   from  the  complex  occurs after the 
activation of Smad2 and Smad3 (Wu et al., 2000). Unlike R-Smads, Smad4 is not activated by 
type I receptors, as the C-terminus of Smad4 does not include the phosphorylation site (two 
serine residues). However, the C-terminal domain of the Smad4 is essential for the interaction 
with the MH2 domain of the activated R-Smads to form a heteromeric complex (Shi and 
Massague, 2003).  
Then, the heteromeric complex (activated R-Smad and Co-Smad) translocate into the nucleus 
where it cooperates with different transcriptional coactivators or corepressors to modulate 
genes responsible for cell proliferation, differentiation or apoptosis (Schmierer and Hill, 2007; 
Shi and Massague, 2003; ten Dijke and Hill, 2004). Several transcriptional coactivators have 
been identified such as SMIF, CBP/p300, and ARC105; while examples of corepressors 
include c-Myc, p53, c-Ski, SnoN and FoxH1/FAST (Ross and Hill, 2008). According to the R-
Smad pathway used by different  TGFβ  ligands,  Smad6/  or  Smad7  is  stimulated  to  inhibit  or  
suppress  of  TGFβ  signalling  (Li, 2015).  Smad7  is  a  specific  negative  regulator  of  TGFβ  (1-3), 
Gdf9, and Activin (Quezada et al., 2012; Yan and Chen, 2011), whereas both Smad6 and 
Smad7, inhibit Bmp and Amh signalling (Bai et al., 2000; Kimura et al., 2000). 
1.10. Non-Smad pathway 
In addition to the Smad-dependent signalling, TGFβ can also signal through the non-Smad 
pathway via the activated TGFβ receptors (ten Dijke and Hill, 2004). Several non-Smad 
pathways have been well reviewed including P38, JNK, PI3K, ERK, NF-KB and AKT (Mu et 
al., 2012; Zhang, 2009). Crosstalk between both Smad-dependent and independent pathways 
is possible to coordinate cell growth by regulation of Smad transcription and nuclear 
translocation (Derynck and Zhang, 2003). The mechanism of their interaction is representing 
by the ability to phosphorylate the serine and threonine residues in the linker region of R-
Smads.  
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For example (Figure 1.13), activated ERK pathway can target the nuclear Smad2 and Smad3 
at their linker region to prolong the process of transcription of the targeted genes (Hough et al., 
2012). In the ovary, non-Smad pathways have been identified to promote follicle development 
including PI3K (John et al., 2008; Zheng et al., 2012) and AKT (Altomare et al., 2004).  
 
Figure 1.13. Non-Smad pathway. In addition to Smad signalling, activated TGFβ receptors can induce 
the activation of various non-Smad pathways such as P38, JNK, PI3K, ERK, and AKT. After activation, 
these pathways regulate gene transcription in the nucleus. However, both Smad2 and Smad3 may also 
phosphorylated by non-Smad pathways at the Smad linker region. This process can either enhance or 
prevent nuclear translocation of Smad2/3, prolong the activity of Smad in the nucleus and prevents 
nuclear exclusion. 
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1.11. Intracellular regulation of the TGFβ signalling 
The TGFβ/Smad signalling pathway can be modulated at different cellular levels including 
extracellularly (as previously described), at the cell membrane level, and/or intracellularly 
where various inhibitory factors have been identified (Table 1.1) (Lin et al., 2006; Moustakas 
and Heldin, 2009; Schmierer and Hill, 2005; Wrighton et al., 2009). TGFβ signalling is 
regulated at the receptor level by different processes such as dephosphorylation, ubiquitination, 
sumoylation, degradation or acetylation (Dai et al., 2011; Inoue and Imamura, 2008; Lonn et 
al., 2009). As described earlier, regulation through the interaction of TGFβ signalling 
components with other pathways is possible. Activated TGFβ or Bmp signals are also capable 
of inducing a self-regulatory feedback mechanism by upregulation of the inhibitory Smad7 or 
Smad6/7, respectively (Moustakas and Heldin, 2009). In addition to blocking the activation 
process of Smad1/5/8 by activated TGFβRI (Goto et al., 2007), Smad6 functions to inhibit Bmp 
signalling by competition with Smad4 to prevent the formation of a heteromeric complex with 
activated R-Smad. In the nucleus, Smad6 also acts as a transcriptional co-repressor by 
association with transcription factors, homeobox (Hox) c-8 (Bai et al., 2000).  
In order to block the stimulated TGFβRI and to prevent the generation of hetero-complex 
between Smad2/3 and Smad4, the exclusion of Smad7 from the nucleus into the cytoplasm is 
induced via an interaction with Smad ubiquitination-related factor Smurf1/Smurf2 (Liu et al., 
2002). In the nucleus, Smad7 can inhibit the complex between nuclear R-Smads and DNA 
leading to dissociation of the nuclear Smad2/ Smad3 and Smad4 complex, thereby influencing 
translocation between nucleus and cytoplasm (Zhang et al., 2007).  
Furthermore, through proteasomal and lysosomal pathways, the Smurf protein can enhance 
degradation and induce dissociation of the TGFβRI and Smad2/3 complex and also promote 
expression of Smad7 (Zhang et al., 2001). Interaction of Gadd34–Pp1c with Smad7 can 
antagonise TGFβ signalling by dephosphorylating of the activated TGFβRI (Shi et al., 2004). 
The two major co-repressors Ski/SnoN can interfere with the formation of the heteromeric 
complex by associating with Smad4. This process leads to a considerable reduction in the 
binding sites in the heteromeric complex. Moreover, it recruits histone deacetylases (HDACs) 
to the nuclear Smad complex, which results in suppression of transcription of target genes (He 
et al., 2003).  
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The role of the nuclear protein phosphatases (Ppm1a) is also important in two sequential events 
during Smad2/3 nuclear export (Dai et al., 2011). Ppm1a can interact with nuclear 
phosphorylated Smad2/3 and eliminate their C-terminal SSXS phosphorylation site (Lin et al., 
2006). Elimination of the phosphate group from these R-Smads causes dissociation of the 
heteromeric complex and eventually exclusion of Smad proteins from the nucleus (Schmierer 
and Hill, 2005). This process is followed by dephosphorylation of Ran-binding protein-3 
(RanBP3) by Ppm1a to stimulate its functional activity in the targeting and exclusion of 
inactive Smad2/3 from the nucleus (Dai et al., 2011) (Figure 1.14). 
 
Figure 1.14. Diagram illustrating the mechanism of Smad2/3 nuclear export by Ppm1a and RanBP3. 
In addition to its ability to dephosphorylate of nuclear R-Smad (1), Ppm1a also interacts (2) with 
RanBP3 to stimulate its association with dephosphorylated Smad 2/3 in the nucleus (3); eventually, the 
export activity of RanBP3 promotes the exclusion of Smad2/3 from the nucleus. 
Serine/threonine kinase receptor associated protein (Strap) has a dual role in antagonising 
TGFβ signalling mainly by its interaction with Smad7, but not Smad6, to recruit phosphatases 
to the receptor complex. At the level of the cell membrane, Strap function to block 
phosphorylation of Smad2/3 and receptor activation (Datta and Moses, 2000; Wrighton et al., 
2009). FK506-binding protein is another TGFβ signalling inhibitor, which functions by 
interfering with the glycine-serine (GS) rich motif of the TGFβRI receptor to prevent its 
association with the TGFβRII receptor. FK506-binding protein forms a complex with Smad7 
preventing phosphorylation of R-Smad by the activated TGFβRI (Yamaguchi et al., 2006). 
Trans-membrane prostate androgen induced RNA (Tmepai) specifically antagonises Smad2/3 
pathway and its expression is induced by TGFβ signalling (Singha et al., 2014).  
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The inhibitory effect of this protein is achieved either by direct association with the activated 
TGFβRI or by competing with the accessory binding protein (SARA) for association with 
Smad2 and Smad3. In cell lines, knockout of Tmepai caused prolonged TGFβ signalling, 
indicated that expression of Tmepai is regulated by a self-regulatory mechanism (Watanabe et 
al., 2010). Another protein, NEDD4-2 inhibits TGFβ signalling by three mechanisms; firstly, 
by forming a complex with Smad7, which then promote association with the TGFβRI resulting 
in receptor degradation. Secondly, it is able to associate with Smad2 and Smad3 leading to 
degradation of Smad2, but not Smad3; however, Smad3 is then unable to interact with the 
receptor. Thirdly, upregulation of NEDD4-2 can inhibit the transcriptional activity stimulated 
by TGFβ or Bmp signalling (Kuratomi et al., 2005). Notch4 intracellular domain (Notch4ICD) 
is another protein that acts to prevent complex formation by the interaction with Smad2, 
Smad3, and Smad4, but it binds more efficiently to Smad3 (Sun et al., 2005). The inhibitory 
actions of the above TGFβ signalling inhibitors are summarised in Table 1.1. 
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Table 1.1. Direct/ indirect inhibitory mechanisms of various TGFβ signalling regulator. 
Sm
ad
 in
hi
bi
to
rs
 
In
te
ra
ct
io
n 
w
ith
 
re
ce
pt
or
s 
H
et
er
om
er
ic
 
co
m
pl
ex
 fo
rm
at
io
n 
In
te
rf
er
en
ce
 w
ith
 
tra
ns
cr
ip
tio
n 
D
e-
ph
os
ph
or
yl
at
io
n 
References 
Smad 6 + + + - (Bai et al., 2000) 
Smad 7 + + + - (Liu et al., 2002; Lonn et al., 2009) 
Ppm1a - - - + (Schmierer and Hill, 2005) 
Gadd34 + - - - (Shi et al., 2004) 
Smurfs + - + - (Zhang et al., 2001) 
Ski/SnoN - + + - (He et al., 2003) 
Strap + + - - (Wrighton et al., 2009) 
Fkbp12 + - + - (Yamaguchi et al., 2006) 
Mapk1 - + - - (Kretzschmar et al., 1999) 
Tmepai + + - - (Watanabe et al., 2010) 
Nedd4-2 + - + - (Sun et al., 2005) 
Notch - + - - (Kuratomi et al., 2005) 
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1.12. Conclusion and aims 
Primordial follicles are relatively quiescent structures that contribute to the reproductive 
lifespan in females. Periodically, some of these small follicles are recruited to leave the 
quiescent state and develop further to terminate by either ovulation or atresia. It has been 
suggested that primordial follicle maintenance, activation and growth are regulated by various 
growth   factors  within   and   between   neighbouring   follicles.  Among   these   factors,   the  TGFβ  
superfamily that signals through Smad proteins has an essential influence on the regulation of 
primordial  follicle  activation.  However,  the  mechanism  that  operates  to  regulate  TGFβ/Smad 
signalling during follicle development is not well understood. 
In   other  TGFβ   responsive   cells,   a range of different internal inhibitory factors is regulated 
TGFβ  signalling. However, in the ovary, the expression and role of these inhibitors in early 
follicle development are almost entirely unknown. In the mouse ovary, recent observations 
from our lab have revealed that R-Smad proteins are detectable in a stage-specific manner; in 
particular, the exclusion of Smad2/3 proteins from the nucleus of granulosa cells appears to 
coincide with the initiation of primordial follicle growth. 
Therefore,  we  hypothesised  that  inhibitors  of  the  TGFβ  pathway  may  also  be  detectable  in  the  
ovary and these could have a functional relevance in the process of early follicle development. 
The initial aim of this study is to determine the expression of candidate inhibitory factors during 
early follicle development. Based on findings from the first aim, the study will evaluate the 
role  of  specific  TGFβ  inhibitory  factors  in culture models of early follicle development using 
various tools for modifying the expression of the target gene. 
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Chapter 2 
 Materials and Methods 
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2.1. Animals and ovary dissection 
Mouse ovaries and follicles from the C57BL/6 genetic background were utilised for all studies 
in this thesis. All tissue donor mice were housed and maintained in the Biological services unit 
at the University of Sheffield. Prior to dissection, mice were killed by Schedule 1 procedures 
(Cervical dislocation and exsanguination) according to the Animals and Scientific Procedures 
Act, 1986 and associated codes of practice 
Ovaries were dissected from neonatal, prepubertal and adult female mice before being 
transferred  in  isolation  media  containing  Leibovitz’s  media  L15  (Gibco)  with  1%  (w/v)  bovine  
serum albumin BSA (Sigma). Ovaries were cleanly dissected using acupuncture needles 
(AcuMedic) or insulin needles under aseptic conditions in the laminar flow hood fitted with a 
dissecting microscope (Leica) with a heated stage at 37ºC. Ovaries were dissected free from 
the ovarian bursa, oviduct and periovarian fat in drops of isolation media. Ovaries were 
prepared for either culture, preantral follicle isolation and culture, RNA extraction, or fixation 
according to the procedures below. 
2.2. Culture protocols 
All instruments, chemicals and buffer/solution recipes used in this study are listed in Appendix 
II-IV. 
2.2.1. Ovarian fragments culture  
Culture media were prepared immediately prior to each particular experiment before ovaries 
were dissected. The utilised culture media (MEM-α  media; Gibco) was supplemented with 
10% fetal bovine serum (FBS; ThermoFisher), penicillin   (75μg/ml;;   Sigma   PENK), 
streptomycin  sulphate  (100μg/ml;;  Sigma≠56501)  and  insulin-transferrin-sodium selenite (ITS; 
5μg/ml,  5μg/ml,  5ng/ml,  respectively;;  Sigma- I1884). Culture media in all experiments was 
filter  sterilised  through  a  0.2  μm  pore,  25  mm  diameter  filter (Corning Costar-Sigma-Aldrich). 
Culture plates of 24-wells (Corning Costar- Sigma-Aldrich) were utilised and 1ml of media 
was added to each of the selected wells before being incubated at 37ºC with 5% CO2 at least 
for 30 minutes, to equilibrate the temperature and pH.  
Ovaries from d4 old mice were used for all fragments culture where each ovary was dissected 
into 6-8 pieces using blunt acupuncture needles in drops of isolation media. Equivalent sized 
fragments (3-5 pieces) were transferred into each well for maintenance in a culture similar to 
(Maiani et al., 2012). In all  groups,  at  72  hours  of  incubation,  half  of  the  culture  media  (500μl)  
was carefully removed and were replaced with an equivalent volume of fresh media. 
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Cultured ovary fragments were imaged using an inverted light microscope (Olympus CKX41 
with a Nikon camera DS-Fi1), where images were used to identify the effect of treatments on 
follicle growth by measuring oocyte diameters using ImageJ (http://imagej.nih.gov/ij/). At the 
end of culture, fragments either were fixed for immunostaining or were collected for RNA 
extraction. 
2.2.2. Preantral follicle culture 
Ovaries from d16 mice were cleanly dissected in isolation media in a laminar flow hood fitted 
with a dissecting microscope (Leica) with a heated stage at 37ºC in accordance with previously 
published protocols (Fenwick et al., 2013). Preantral follicles were mechanically isolated using 
blunt acupuncture needles (AcuMedic) in drops of isolation media in a 75mm dish. 
Approximately 15-25 preantral follicles per ovary were carefully selected under the microscope 
for culturing. Only rounded follicles with relatively similar size and (visually) undamaged 
basement membrane were selected. The selected follicles were rinsed in a drop of clean pre-
warmed isolation media before being transferred to a 96-well plate (Nunclon) using a modified 
curved glass pipette fixed to a mouth pipette. Each individual preantral follicle was carefully 
transferred to  a  single  well  (1  follicle/well)  containing  100μl  of  culture  media.   
The culture media (MEM-α  media; Gibco) was supplemented with BSA 0.1% (w/v) (Sigma), 
penicillin (75μg/ml;;   Sigma   PENK),   streptomycin   sulphate   (100μg/ml;;   Sigma)   and   insulin-
transferrin-sodium selenite (ITS; 5μg/ml,   5μg/ml,   5ng/ml,   respectively;;   Sigma). Preantral 
follicles from each single ovary were cultured in a single plate; therefore, each plate represents 
a single subject. Cultured follicles were incubated at 37°C with 5% CO2, and were imaged 
under a light microscope (Olympus CKX41 with a Nikon camera DS-Fi1) at 0, 24, 48, 72 hours 
of treatment. In all experiments, at 48 hours of culture, 50μl  of  media  was  replaced  with  fresh  
media for each group. At the end of culture, follicles from each treatment were collected for 
fixation in formalin 10% (Sigma- Aldrich) or snap frozen in liquid nitrogen until processing 
for RNA extraction. 
2.3. RNA extraction (whole ovaries, fragments and follicles) 
After dissection, whole ovaries were rinsed in drops of clean isolation media, transferred into 
Eppendorf tubes by a glass pasture pipette, immediately snap freezing in liquid nitrogen and 
stored at -80ºC until processing. To facilitate tissue lysis, ovaries from d8 and d16 were 
dissected into 3-4 fragments and then fragments were re-collected into an Eppendorf tube and 
processed for RNA extraction.  
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Adult ovaries were also dissected to four fragments, and each fragment was processed 
individually. Cultured ovary fragments and follicles were processed without prior mechanical 
fragmentation. Total RNA was extracted from all samples using Qiagen RNeasy Micro Kits 
(QIAGEN, Crawley, UK) according   to  manufacturer’s   instructions. Briefly, 75μl  of  Buffer  
RLT  (β-ME -RLT) was added to each Eppendorf tube containing ovary samples and vortexed 
for 5 minutes. To improve capturing of low concentrations of RNA, 5μl  of  carrier RNA (4ng/μl)  
was  added  to  each  sample  and  vortexed  for  2  minutes.  Then,  to  precipitate  the  RNA,  75μl  of  
70% ethanol was added to each sample and well mixed by pipetting before being transferred 
into RNeasy Mini Spin Columns. After centrifugation (15 seconds at 8000xg), samples were 
washed  with  350μl  Buffer  RW1  and  centrifuged  at  8000xg (10.000 rpm) for 15 seconds.  
To prevent genomic DNA contamination, 80μl  DNase  I  (Qiagen;;  Crawley,  West  Sussex,  UK)  
was directly added to the membrane for 15 minutes at room temperature. Samples were washed 
again  in  buffer  RW1  followed  by  500μl  Buffer  RPE  to  remove  traces  of  salts,  then  columns  
were briefly centrifuged. Membranes were washed with 80%   ethanol,   (500μl)   and   were  
centrifuged at the maximum speed for 5 minutes. Nuclease-free  water  (14μl)  was  added  to  the  
membrane and centrifuged at the maximum speed for 1 minute to elute the RNA sample. 
Purified extracted RNA samples were stored at -20ᵒC, until being tested for integrity and 
concentration. 
2.4. cDNA synthesis  
Extracted total RNA from ovaries, ovary fragments and cultured follicles were tested for 
concentration and integrity using a Bio-analyser (Agilent; G2938B). The Bioanalyser assess 
RNA sample through the fluorescent evaluation of electrophoretic separation of the RNA and 
outcomes are presented as an electropherogram and gel image. Only high-quality RNA samples 
were selected for cDNA preparation to be used for both gene qualification (RT-PCR) and 
quantification (qPCR). Samples were considered to be good quality if the RNA integrity 
number (RIN) was between 8-10 and the RNA electrophoresis revealed the absence of 
degradation products. RNA samples with a RIN number less than 8 and/or presence of 
degradation in the electrophoresis gel were excluded, Figure 2.1.  
  
41 
 
 
Figure 2.1. Examples of extracted RNA samples assessed by the Agilent Bio-Analyser. To consider 
whether the RNA sample is of sufficient quality for gene analysis, several criteria were followed. For 
high quality samples (A), the RNA electrophoresis gel reveals clear well-defined 18S and 28S bands 
and the absence of degradation products. The RNA integrity number (RIN), as determined from the 
electropherogram, is between 8-10. Low-quality samples (B) revealed degraded products, which are 
reflected by a low RIN number. 
For each specific experiment, equal quantities of total RNA was converted to cDNA using the 
Superscript III First strand synthesis system (Invitrogen, 18080-051) in according with the 
manufacturer's instructions. The RNA mixture was prepared on ice by adjusting the volume of 
each sample to  8μl with nuclease-free water (Qiagen). Then,  1μl  of  random hexamers (50ng/μl) 
and  1μl  of  10mM  deoxynucleotides triphosphates (dNTPs; Invitrogen) were added to the RNA 
mixture. Random hexamers were added to prepare the single-stranded RNA for extension by 
reverse transcriptase and to increase the sensitivity of cDNA synthesis. To inactivate the 
DNase, reaction mixes were mixed by pipetting and were incubated in a thermal cycler 
(Geneflow) for 10 minutes at 65°C, with a final holding at 4°C. 
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Samples  were  placed  on  ice  for  1  minute  before  adding  10μl  of  cDNA synthesis mix consisting 
of  2μl  of  10x   reverse transcriptase buffer, 4μl  of  25mM MgCl2,   2μl  of   0.1M  DTT,   1μl  of  
recombinant ribonuclease   inhibitor   (RNase  OUT  40U/μl;;   Invitrogen  P/N51535)   and 1μl of 
200U/μl   reverse   transcriptase.   The   reaction   mixture   (20μl)   was   incubated   at   25°C   for   10  
minutes, followed by 50 minutes at 50°C, 85°C for 5 minutes, and then 4°C. To increase the 
volume, 20μl  of  nuclease-free water was added to each prepared ovary cDNA, then aliquoted 
into four tubes, and stored at -20°C. 
2.5. Primer design 
Primers were designed to detect mouse (Mus Musculus) transcripts for each candidate genes 
using the sequences available from the databases from the National Centre for Biotechnology 
Information NCBI (http://www.ncbi.nlm.nih.gov/nucleotide/).  
Transcript sequences were entered into the Primer3 Plus online software at 
(http://www.bioinformatics.nl/cgibin/primer3plus/ primer3plus.cgi/). All primers used in the 
present study were designed to include between 19-21 nucleotide, melting temperature (TM) 
ranged 55-56ºC, primer GC content between 40-60% and with minimum self and pair 
complementarity. To reduce the likelihood of genomic DNA amplification, primers were 
designed to span an intron. Primer specificity was checked using the basic local alignment tool 
(BLAST) available through NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
Primers were reconstituted in nuclease-free water to obtain a stock concentration of 100μM  
and tubes were heated at 65ºC for 15 minutes. In order to prepare a working solution for each 
primer pair, a volume of 20μl  from  each  primer  set  was  added  to  60μl  of  nuclease-free water, 
briefly mixed and stored at -20°C. For RT-PCR and qPCR, primers were used at a final 
concentration of 500nM. 
2.6. Polymerase chain reaction (PCR) 
All cDNA samples were qualified by PCR using primers designed to detect the ubiquitously 
expressed control gene, Gapdh. PCR mixtures were prepared on ice in a reaction volume of 
25µl. Each PCR mixture consisted of 1µl of cDNA (cDNA concentration was normalised for 
each individual experiment) as a template, 12.5µl of 2x Taq Red PCR Mix (Bio-Line),  0.5μl 
(500nM) of premixed forward and reverse primers, and the volume was completed by 11µl of 
nuclease-free water. For the negative control, nuclease-free water (1µl) was added instead of 
cDNA template; Gapdh primers was utilised as a positive control for the PCR reactions. 
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Samples were cycled in a thermal cycler (GeneFlow) by initial denaturation at 95°C for 3 
minutes, followed by 32 cycles of denaturation at 95°C for 15 second, annealing at 58°C for 
15 seconds, extension at 72°C for 10 seconds, with a final hold at 4°C. 
2.7. Agarose gel and electrophoresis  
A 2% agarose (w/v) (Bioproducts) was prepared in 1X TAE (Tris (Hydroxymethyl) 
aminomethane; BDH Prolabo) by heating in the microwave for 2-3 minutes. To visualise DNA 
bands, 0.01% (v/v) gel red nucleic acid stain (Biotium) was added to the cooled agarose 
solution before being poured into the gel cassette where it was kept to set at room temperature 
for 20 minutes. The gel was covered in 1X TAE buffer. DNA hyper ladder  5μl  (Bioline, BIO-
33057) and 12.5µl of amplified PCR products were loaded into the gel wells. A non-template 
(negative) control was included in each experiment. Samples were run at 80 volts for an hour 
and 45 minutes. Bands were visualised and imaged by an ultraviolet transilluminator 
(Geneflow). 
2.8. Quantitative polymerase chain reaction (qPCR) 
Relative expression levels of candidate gene transcripts were determined by qPCR using an 
Applied Biosystems 7900HT Fast instrument (Applied Biosystems Inc.). For each sample, two 
technical replicates were prepared in a 384-well plate (Applied Biosystems). Each single 
reaction  mix  (20μl)  included  nuclease-free water, 2X SensiFAST SYBR Hi ROX Mix (Bioline) 
or KAPA SYBR Green (KAPA Biosystems) and ROX dye (KAPA Biosystems), and 500nM 
of premixed forward and reverse primer. The equivalent concentration of ATP synthase subunit 
beta Atp5b (1μl)  (Primerdesign)  or Hprt1 were used as housekeeping genes. For each gene, an 
equal concentration of cDNA was added (1µl) to 19μl  of  reaction  mix  using  automated  pipettes.  
Control groups (non-template) were included in each qPCR experiment where nuclease-free 
water was added instead of cDNA. qPCR plates were sealed by the optical adhesive cover 
(Applied Biosystems) and centrifuged (Fisher Scientific-Accuspin 3R) at 500rpm for 1 minute. 
Thermal cycles were initiated by denaturation for 2 minutes at 95°C, followed by cycles of 5 
seconds at 95°C, annealing for 10 seconds at 58°C, and extension at 72°C for 12 seconds. Melt 
curve data were collected for all PCR products to confirm consistency and specificity. For each 
technical   replicates,   the  average  cycle  number  at   threshold  (CT)  were  recorded.  Then,  ΔCT  
values were determined by subtracting the average CT value of the internal reference gene 
Atp5b or Hprt1 from the averaged values of targeting gene.  
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To  calculate   the  ΔΔCT  values,  ΔCT  values  of   the   treatment  groups  were  averaged  and   the  
number  was  subtracted  from  the  ΔCT  of  the  control group. The fold changes in gene expression 
were calculated using the equation 2-ΔΔCT (Livak and Schmittgen, 2001).  
2.9. Tissue processing protocols 
2.9.1. Fixation, embedding and sectioning of whole ovaries 
Freshly dissected mouse ovaries (all ages) were immediately immersed in 10% neutral buffered 
formalin solution (v/v, Sigma) for 24 hours, and then transferred into 70% ethanol (v/v) until 
being processed in paraffin blocks. Ovaries were dehydrated by immersing in 70% ethanol, 
90% ethanol (v/v) followed by three changes in 100% ethanol for 20 minutes each. Tissue was 
cleared in Histochoice solvent- clearing agent (Sigma) for 60 and 30 minutes, respectively. 
Ovaries were transferred to embedding molds and melted paraffin was poured in molds for 60 
minutes at 60ºC before applying the plastic cassette and allowing the blocks to cool on ice. 
Paraffin blocks were sectioned at 5µm using a manual processing microtome (Reichert-Jung). 
Sections were mounted on positively charged slides in a water bath at 45ºC and were dried 
overnight at 37ºC.  
2.9.2. Fixation, embedding and sectioning of cultured follicles 
At the end of culture, follicles from each group (5-7 follicles) were fixed in a single well of a 
96-well plate using 10% neutral buffered formalin (Sigma) for 30 minutes. After washing with 
PBS, follicles were placed in a drop of preheated (60ºC) 1% (w/v) low gelling temperature 
agarose (Sigma). As the agarose semi-congealed, a drop of nuclear fast red stain (Sigma) was 
applied to aid visualisation of the follicles. Each gel was cut into small cube containing follicle 
samples (Figure 2.2). Agarose cubes were submerged in Eppendorf tubes containing 70% 
ethanol prior to processing in paraffin embedding as described in 2.9.1. Embedded follicles 
were sectioned at 5µm and sections were mounted on positively charged slides. 
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Figure 2.2. An example of preantral follicles embedded in agarose.  
2.9.3. Immunofluorescence staining in ovary and follicle sections 
Immunofluorescence staining was performed to support PCR data of some candidate genes and 
to localise their proteins to specific cells and follicle types in the ovary. Several troubleshooting 
of some staining problems were stated in Appendix V. Ovary or follicle sections were dewaxed 
(2x5minutes) in Histochoice (Sigma), rehydrated in a graded series of ethanol solutions of 
100%, 95%, and 70% (3 minutes each), and washed in distilled water (5 minutes). To unmask 
the antigen, sections were microwaved in 0.1 M citrate buffer (pH 6.0) for 20 minutes. Sections 
were washed in PBS (2x5 minutes each) before blocking with CAS (CAS-Block; Invitrogen) 
for 15 minutes at room temperature. Primary antibodies were diluted in the blocking solution 
at an appropriate concentration that was previously optimised by titrating. 
Antibodies were applied to sections and incubated overnight at 4ºC in a humidified chamber. 
Negative controls were included for each staining, where equivalent concentrations of non-
immune mouse IgG or Rabbit IgG (Vector) were used to determine non-specific staining. For 
double labelling (colocalisation), both primary antibodies or non-immune mouse IgG and 
Rabbit IgG (controls) were prepared in the same tube and were incubated together. After the 
overnight incubation, sections were washed in PBS three times for 10 minutes. Fluorescent 
secondary antibodies (Invitrogen) were diluted 1:200 in PBS, added to the sections and 
incubated in dark humidified chamber at room temperature. 
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For double labelling, both specific secondary antibodies were prepared and applied at the same 
time. After 45 minutes of incubation, slides were washed in PBS twice for five minutes each. 
A coverslip was mounted to each slide after addition of 30μl  of  Prolong  Gold  anti-fade reagent 
with DAPI (Invitrogen). Slides were allowed to dry in the dark for at least 1 hour before storing 
at 4ºC prior to imaging. Stained ovary sections were imaged using Leica inverted SP5 confocal 
laser scanning microscope (Leica Microsystems, Wetzlar, Germany). Images presented in this 
study were taken from sections stained in the same run, using the same laser and gain settings. 
Stained follicles were imaged with either an Olympus IX73 inverted microscope supplemented 
with Photometrics-CoolSNAP HQ camera, or with an inverted Widefield fluorescence 
microscope (Leica DMI4000B).  
The double labelling protocol was often assessed  by  colocalisation  of  Smad2/3  (0.25μg/ml,  
Santa Cruz sc-133098) and Ddx4 (5µg/ml; Abcam, ab13840) proteins in d8 ovary section as a 
reliable and consistent positive control (Figure 2.3). In addition, positive control staining was 
also included for preantral follicle staining, see Appendix VI. 
  
47 
 
 
Figure 2.3. Immunofluorescent colocalisation of Smad2/3 and Ddx4 in the ovary. In order to evaluate 
the protocol of double staining used in this study, Ddx4 and Smad 2/3 were used as positive control of 
staining in day8 ovary sections. Ddx4 (A-green) was specifically localised in the oocytes (Oo); while 
Smad 2/3 (B-red) were detected in the granulosa cells (GCs) with high intensity of staining in primordial 
follicles (PFs). Merged image (C) revealed the specific localisation of both proteins. Negative control 
ovary sections (D) were treated with a mixture of non-immune Rabbit and Mouse IgG. Both stained 
and control sections were treated with Alexa Donkey anti-Mouse 555 and Donkey anti-Rabbit 588 
secondary antibodies. Nuclei (blue) were stained with DAPI.  Scale  bar  100μm. 
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2.9.4. Immunofluorescent staining of cultured ovary fragments 
At the end of culture, media was removed, and cultured fragments were double washed (two 
minutes each) with PBS. Ovary fragments were fixed in neutral buffered formalin (Sigma) for 
30 minutes, followed by washing twice with PBS for two minutes each. To enhance cell 
permeability, fragments were treated with 0.25% (v/v) Triton (Sigma) in PBS for 10-15 
minutes, followed by three further washes of PBS for three minutes each.  
To reduce nonspecific binding, fragments were incubated in CAS-Block (Invitrogen) for 20 
minutes at room temperature. A mixture of Rabbit anti-Ddx4 (5µg/ml; Abcam, ab13840) and 
Mouse anti-Amh (1:400; MCA2246; AbD Serotec, Oxford, UK) was added to wells overnight 
at 4ºC. After washing in PBS (3x5 minutes), Alexa Fluor 555 Donkey anti-Mouse IgG and 
Alexa Fluor 488 Donkey anti-Rabbit (both 1:400) secondary antibodies were added for 45 
minutes. Ovary fragments were washed in PBS (2x2 minutes each) and were counterstained 
with 10μg/ml  DAPI  (Thermo Scientific) for 10 minutes. Then, the DAPI solution was replaced 
with PBS. Stained tissues were imaged with an Olympus IX73 inverted microscope. 
2.9.5. Haematoxylin- Eosin staining 
Hematoxylin and eosin staining was utilised for the staining of d4, d8, d13, d16 and adult ovary 
sections. The purpose of staining was either for follicle classification or to show the histological 
tissue characteristic in these ages. The protocol of staining included dewaxing the slides in 
Histochoice (2x5 minutes, Sigma), followed by a series of rehydrating steps in different 
concentrations of ethanol (99%, 95%, and 70% for 5 minutes each). After one minute of 
washing under tap water slides were submerged in Gills haematoxylin II stain (Surgipath) for 
90-120 seconds and were rinsed under tap water to remove extra staining for three minutes. 
Then, slides were submerged in aqueous eosin 1% (Diagnostics) for five minutes followed by 
30 seconds washing in tap water. Sections were dehydrated in 70% ethanol and 95% ethanol 
for 10 seconds each, followed by two steps in 99% ethanol for 30 seconds each. To clear 
sections and remove ethanol, sections were submerged two times in Histochoice (Sigma) for 1 
and 3 minutes, respectively. Finally, sections were mounted with DPX (Merck) and 
coverslipped. Stained sections were imaged with an Olympus CKX41 microscope and Nikon 
DS-Fi1 camera. 
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2.10. Identification rate of follicle growth 
2.10.1. Measurement of the cultured preantral follicles 
Preantral follicles were imaged by inverted light microscopy (Olympus CKX41 with a Nikon 
camera DS-Fi1) at 0h, 24h, 48h and 72h. Images were utilised for estimation of follicle 
diameters where two measurements were taken from the basal lamina of the granulosa cells 
(basement membrane) (Figure 2.4). The vertical and horizontal measurements were averaged 
and were presented as follicle diameter.  
 
Figure 2.4. Light microscopy image of cultured preantral follicle showing a method of follicle 
measurement. ImageJ software was utilised to measure follicle diameter by averaging the vertical and 
horizontal diameter taken from the basement membrane (BM). Theca cells (TCs) were excluded from 
measurement. Scale  bar  100μm. 
2.10.2. Oocyte measurements in cultured ovary fragments  
In order to identify the effect of different treatments on follicle growth, cultured fragments 
were imaged using an Olympus CKX41 with a Nikon camera DS-Fi1. The accurate 
measurement of oocyte size was determined with the ImageJ software after calibration 
certificates using a stage micrometre (Graticules PYSER-SGI). In order to identify oocyte 
diameter, a vertical and horizontal line was recorded for each oocyte (Figure 2.5). The two 
measurements were averaged and were presented as the diameter of the oocyte. Only round, 
clearly identifiable oocytes were measured, while atretic or misshapen oocytes were not 
included. 
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Figure 2.5. An example of a light microscopy image of a cultured ovary fragment showing the method 
of oocyte measurement. Both vertical and horizontal lines (white arrows) were estimated from the 
external surface of the oocytes using ImageJ software. The two measurements were averaged and the 
estimated number was presented as the diameter of a single oocyte. Atretic oocytes (white circles) were 
excluded from measurements. Scale bar = 200μm. 
2.11.  Classification of oocytes 
Haematoxylin and eosin stained sections from immature mouse ovaries at d4 (n=5), d8 (n=8), 
d13 (n=5) and d16 (n=7) were used to stage oocytes and apply this information to classify 
oocytes from cultured ovary fragments. For all ages, one stained section was used for the 
measurement of oocyte diameters using ImageJ software (Appendix VII). Oocyte diameters 
were estimated only in follicles that had a clearly identifiable oocyte nucleus. In addition to the 
oocyte diameter, oocytes were classified by considering the morphology and number of 
granulosa cells layers contained within the follicle. An oocyte that was surrounded by a 
monolayer of flat cells was considered non-growing. Oocytes surrounded by one layer of 
granulosa cells that included both cuboidal and flat cells were scored as transitional. Large 
oocytes with at least one complete layer of cuboidal granulosa cells were classified as growing 
(Figure 2.6-A).  
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Data were plotted and presented as mean ±1 SD where each single point represents a single 
oocyte (n=992 non-growing, n=292 transitional, n=331 growing). Classification of oocytes was 
based on the mean ±1SD above and below the transitional group specified by the shaded area 
on the graph (Figure 2.6-B). Thus, oocytes were categorised according to the diameter either 
as non-growing (<18.3μm), transitional (18.3-25.7μm) or growing (>25.7μm). 
 
Figure 2.6. Classification of oocytes from H&E stained mouse ovaries. Paraffin-embedded ovary 
sections from immature mouse ovaries at d4 (n=5), d8 (n=8), d13 (n=5), and d16 (n=7) were stained 
with haematoxylin and eosin. Only oocyte (Oo) that had a clearly recognised nucleus (N) and 
pre/granulosa cells (GCs) were included (A). Any oocyte smaller than one standard deviation from the 
mean of the transitional category was defined as non-growing (NG: <18.3μm),   and  conversely   any  
oocyte larger than one standard deviation from the mean of the transitional category to be defined as 
growing (G: >25.7μm).  Any  oocyte  diameter  between  these  boundaries  was  defined  as  transitional  (T:  
18.3μm-25.7μm).   Across   all   ages,   992   non-growing, 292 transitional and 331 growing preantral 
follicles were measured. These criteria were used to classify oocytes in treated ovarian fragment 
cultures. 
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Chapter 3 
Identification and expression of receptor-regulated Smads 
and candidate Smad inhibitors during early follicle 
development. 
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3.1. Introduction 
The mammalian ovary is a multifunctional structure containing follicles at different growth 
stages (Hirshfield, 1991). The earliest stage of follicle development is the quiescent primordial 
follicle where a relatively small sized oocyte is surrounded by a single layer of flattened 
granulosa cells (McGee and Hsueh, 2000). Even though the primordial follicle represents a 
fundamental unit of the ovary that determines the length of the reproductive lifespan (Kim, 
2012; Zheng et al., 2014) factors responsible for maintaining their quiescent state or regulating 
early follicle growth remain unclearly defined; many studies have revealed that these two 
processes are controlled by various local signalling pathways including the TGFβ  pathway 
(Kezele et al., 2002; Kim, 2012; Wang et al., 2014). 
In the ovary, several studies have investigated   the   role   of   the   TGFβ   superfamily   and   its  
respective mediator elements in follicle development (Li et al., 2008b; Pangas, 2012). The 
TGFβ  superfamily  regulates  a  variety  of  cellular  function,  such  as  cell  survival  and  apoptosis,  
and  comprises  more   than  30  structurally   related  members   including  TGFβ,  Activin/Inhibin,  
Nodal, Bmp, Gdf9, and Amh (Shi and Massague, 2003; ten Dijke et al., 2000).  Canonical  TGFβ  
signalling is initiated by the interaction between  TGFβ  ligands  with  a  receptor  complex  leading  
to the activation of R-Smads by phosphorylation (Bakkebo et al., 2012; Derynck and Zhang, 
2003). In order for translocation into the nucleus, phosphorylated R-Smads associate with the 
common mediator Smad4 (Inman et al., 2002).  
In many instances, the Smad signalling pathway activates a self-regulatory mechanism by 
inducing the expression of inhibitory factors (Quezada et al., 2012; ten Dijke and Hill, 2004). 
In other tissues, many factors are identified as intracellular Smad inhibitors, which attenuate or 
inhibit  TGFβ/Smad signalling at different levels through various molecular mechanisms (Lonn 
et al., 2009). For example, Strap and Smad7 cooperate to inhibit signalling at the receptor level 
by preventing the interaction of Smad2/3 with the activated receptors (Datta and Moses, 2000). 
SnoN, Smurf1, and Smurf2 have the potential to inhibit Smad2/3 phosphorylation and interfere 
with their nuclear translocation (Inoue and Imamura, 2008; Moustakas and Heldin, 2009), 
while Ppm1a can inhibit transcription by dephosphorylation of R-Smads (Dai et al., 2011) 
(Figure 3.1).  
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Figure 3.1. Intracellular negative regulatory  mechanisms  of  TGFβ/Smad2/3. Inhibition or attenuation 
of  TGFβ/  Smad2/3  signalling  is  achieved  at  different  cell  levels  and  mechanisms.  Some  of  the  Smad  
inhibitors have the potential to antagonise signalling at more than one level. Mechanisms of signalling 
include preventing the interaction of Smad2/3 with the activated receptor complex (1), inhibition of the 
heteromeric complex formation between Smad2/3 and Smad4 (2), dephosphorylation of activated 
Smad2/3 and enhancing their exclusion from the nucleus (3), or by inhibition of gene transcription by 
interrupting the association between Smads and DNA (4). 
In the ovary, R-Smad elements are differentially localised in granulosa cells of both the 
quiescent and growing follicles (Billiar et al., 2004; Fenwick et al., 2013), and their role in the 
follicle development has been investigated using various culture models (Ding et al., 2013; Li 
et al., 2008b; Tomic et al., 2004). However, the negative regulatory mechanism for R-Smads 
and its impact on follicle development are yet to be defined. Thus, we hypothesise that Smad 
inhibitors, particularly those regulate the Smad2/3 pathway, might also be detectable in the 
ovary and be associated with early follicle development. This study was carried out using 
mouse ovaries and isolated follicles at different developmental stages to achieve several aims 
including the expression of nine candidate Smad2/3 inhibitors (selected from the literature as 
being important in other tissues) in isolated follicles and oocyte samples. Secondly, to 
determine the expression profile of these candidates in ovaries containing different proportions 
of primordial and early preantral follicles. Finally, to determine the relationship between key 
R-Smad inhibitors and Smad2/3 during early follicle development. 
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3.2. Materials and Methods 
3.2.1. Instruments and chemicals 
All instruments, chemicals, and buffer recipes used in this chapter listed in Appendix II-IV. 
3.2.2. Tissue collection (ovaries and follicles) 
Mouse ovaries from d4, d8, d16 and adults mice were used in this chapter for mRNA and 
protein expression. Ovaries were dissected as described in 2.1. In order to identify the 
histological  features  of  each  age  group,  ovary  sections  (5μm)  were  stained  with haematoxylin 
and eosin (section 2.9.5). In addition, isolated follicles at different stages of development 
ranged from primordial to large antral follicles, and oocyte samples (Appendix VIII) were used 
for RNA extraction and gene analyses. These follicles were mechanically isolated from 
neonatal, juvenile and adult mouse ovaries and immediately stored at -80ºC. 
3.2.3. RNA extraction, cDNA synthesis and RT-PCR/qPCR  
Total RNA was extracted from ovaries and follicles using Qiagen RNeasy Micro Kits (Qiagen; 
Crawley, West Sussex, UK), as described in 2.3. For follicle and oocyte samples, since these 
samples consist of a small amount of starting materials, the extracted RNA was concentrated 
first by vacuum centrifugation for 6.5 minutes before being stored at -20ᵒC. For each sample, 
the entire volume of extracted RNA was reverse transcribed and utilised for cDNA synthesis. 
Follicle and oocyte cDNA samples were diluted 1x with RNase/ DNase free water. All samples 
were subjected to 32 cycles of amplification to detect Gapdh as an indicator of cDNA quality. 
RNAs extracted from all ovary samples were tested for integrity and concentration using the 
Bioanalyser (Agilent).  
Similar criteria shown in chapter 2 (Figure 2.1) were followed to identify a high-quality RNA 
for cDNA synthesis. For all ovary samples (n=7ovary/age group, 6 for the adult group), equal 
quantities (50ng/μl)  of analysed RNA were used for the preparation of cDNA according to the 
methods described in section 2.4. All ovary cDNA samples were diluted 2x with a volume of 
20μl  of  RNase/DNase free water before being utilised for gene expression. All cDNA samples 
were checked for quality using RT-PCR prior to their use in qPCR reactions (Figure 3.2).  
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Figure 3.2. Qualification of ovary cDNA samples by RT-PCR. Agarose gel images showing the 
expression of Atp5b (120bp) in day4 and adult ovaries and expression of Gdf9 (139bp) in days8 and 16 
samples. For negative control (-ve), RNase/ DNase free water was added rather than cDNA. 
 
Primers used to determine the expression of Smads and candidate Smad inhibitory factors by 
RT-PCR and qPCR are presented in Table 3.1. In addition, primers for seven positive control 
genes, which are known to be expressed in specific follicle cells and oocytes, were also 
designed and related to the follicle samples. For example, Amh, and its receptor (Amhr2) is not 
detectable in oocytes and primordial follicles, while its expression is largely increased in 
granulosa cells of early growing to the preantral stage with a noticeable decline in later 
advanced stages (Durlinger et al., 2002; Weenen et al., 2004). Conversely, Gdf9 is exclusively 
expressed in the oocyte, thus, it should be expressed by all follicle samples, but not in isolated 
granulosa cells (Hanrahan et al., 2004). Cyp17a is a specific marker of theca cells (Vitt et al., 
2000), while Kl1 and Kl2 are expressed in granulosa cells of all growing follicles (Parrott and 
Skinner, 2000). Similar protocols described in chapter 2 were followed for RT-PCR reaction 
mix preparation/ PCR running (2.6), gel electrophoresis (2.7), and qPCR reactions (2.8) using 
specific annealing temperatures as listed in Table 3.1. 
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Table 3.1. Oligonucleotide primer sequences used to amplify mRNAs of candidate genes by RT-PCR 
and qPCR. Primers were designed and prepared as previously described in 2.5. 
 
Gene Primer  sequences  (5’  →3’) Annealing Temperature  
Product 
size 
(bp) 
Amh F: GGGGCACACAGAACCTCT R:  GCACCTTCTCTGCTTGGTTG 60 124 
Amhr2 F: ACAGCATGACCATATCGTTCG R: GAGTCAAGTAGTGGCATAAGGAG 56.4 122 
Cyp17a F: GATCGGTTTATGCCTGAGCG R: TCCGAAGGGCAAATAACTGG 57 81 
Exportin 4 F: TAACTTAGGGCGGCAAAGGA R: TAAAACGACATCAGCTGCCG 59 193 
Fshr F: ACAACTGTGCATTCAACGGAAC R: GACCTGGCCCTCAACTTCTT 58.4 187 
Gapdh F: CTGCCGTCTAGAAAAACC R: GGTATGACAACGAA 58 120 
Gdf9 F: TCACCTCTACAATACCGTCCGG R: GAGCAAGTGTTCCATGGCAGTC 59 139 
Kl1 F: GATTCCAGAGTCAGTGTCAC R: CCAGTATAAGGCTCCAAAAGCAA 58 192 
Kl2 F:TTGTCAAAACCAAGGAGATCTGCG R:  CTTTGCGGCTTTCCCTTTCTC 58 471 
Ppm1a F: GTGAGAACATCCCCAGC R: TCGGTTGACGCAGAATCA 58 167 
Ranbp3 F: AACTCCAGGCTCAGCATTCT R: GAGCATCAAGTCAGCTCAGC 59 154 
Ski F: ACACAGCACAACGTCTCTAC R: CAAGCAGAGAACCAGCTACG 57.5 171 
Smad 1 F: ACCTGCTTACCTGCCTCCT R: GCCTGAACATCTCCTCTGCT 59 114 
Smad 2 F: CGTCCATCTTGCCATTCAC R: GTCCATTCTGCTCTCCACCA 60 102 
Smad 3 F: GTCAAAGAACACCGATTCCA R: TCAAGCCACCAGAACAGAAG 85.5 154 
Smad 4 F: CGGCGATTGTGCATTCTCAG R: CCTGGAAATGGTTAGGGCGT 60 209 
Smad 5 F: CCTTGCTCATCTCCCTGTCT R: CCGTGAATCTCCTTTCTGTG 85.8 173 
Smad 9 F: GTCTGACCTTGCAGATGGCT R: TAGGTGCCAGGCTGAGAGAT 60 235 
Smad7 F: AGTCAAGAGGCTGTGTTGCTGT R: CATTGGGTATCTGGAGTAAGGA 60 130 
Smurf1 F: CAGACAGCAACATCGTCAGG R: CAGGTGAATGGTGAACAGCC 58 164 
59 
 
Smurf2 F: AGTGTAACTCAGCCTGGTGG R: GAAAGCAGCGTCTCCTTAGC 59 164 
SnoN F: GCACCTGTGACTCAACCTTG R: CTCCAGCTTCTGTCTTGCCT 59 152 
Strap F: GGCTACTTTCTGATCAGCGC R: CTGAGACCGCATCCCATACT 59 187 
 
3.2.4. Tissue processing and staining 
Mouse ovaries at specific ages (d4, d8, d16 and adult) were dissected, processed for paraffin 
embedding and sectioned for staining. Protocols described in chapter 2 were followed for 
localisation and colocalisation of different proteins (Table 3.2) by immunofluorescence 
staining (2.9.3). For negative control, equivalent quantities of non-immune Rabbit and/or 
Mouse IgG (Vector) were used to determine non-specific staining in ovary sections. 
Table 3.2. Primary and secondary antibodies used for immunofluorescent staining 
Primary antibody Company 
Dilution and/ 
or 
concentration 
Secondary antibody 
(Invitrogen) 
Rabbit anti- Ppm1a Abcam Ab154489 
1:200 
1.25μg/ml 
Alexa fluor 488 
Donkey anti-Rabbit 
Rabbit anti- Smad 1/5/8 Santa Cruz  sc-6031-R 
1:400 
0.5μg/ml 
Alexa fluor 488 
Donkey anti-Rabbit 
Mouse anti-Smad2/3 Santa Cruz  sc-133098 
1:800 
0.25μg/ml 
Alexa fluor 555 
Donkey anti-Mouse 
Rabbit anti-Smad2/ 3 
Cell 
Signalling 
≠5678 
1:400 Alexa fluor 488 Donkey anti-Rabbit 
Mouse anti- Strap Santa Cruz  sc-136083 
1:300 
0.3μg/ml 
Alexa fluor 555 
Donkey anti-Mouse 
3.2.5. Statistical analysis 
Data (CT values) from qPCR were normalised relative to the expression of the internal 
housekeeping gene (Atp5b; PrimerDesign, Southampton, UK). Fold changes relative to d4 
ovaries were calculated using the 2-ΔΔCT method, as described in 2.8. One-way ANOVA with 
Bonferroni post-hoc test was used to compare gene expression in d8 and d16 ovaries relative 
to d4. Results were presented as mean ± SEM and difference were considered statistically 
significant if P<0.05. 
  
60 
 
3.3. Results 
Follicle stages presented in ovaries of immature (d4, d8 and d16) and adult mice were 
determined with haematoxylin and eosin staining, where primordial follicles are obviously 
decreased with age (Figure 3.3) 
 
Figure 3.3. Haematoxylin and eosin staining of ovary sections from d4, d8, d16 and adult mice. In the 
d4 ovary, the non-growing primordial follicles (PFs) constitutes the majority of the follicle population. 
At d8 several follicles are activated to grow (GFs), while at d16 more growing and multi-layered 
follicles have developed. In d8 and d16 ovaries, growing follicles are located in the middle of the ovary, 
while primordial follicles are generally situated closely to the ovary surface. In the adult ovary, the 
population of primordial follicles is markedly decreased and more advanced stages of follicle growth 
(large GFs), including antral follicles, are evident. Scale bar 200µm. 
3.3.1. Expression of control genes in follicle samples. 
Seven factors, which are essential for follicle development and growth, were used as positive 
controls for isolated tissue samples taken from the ovary. These samples were assayed to 
confirm the initial follicle staging during isolation. Kl and Kl2 isoforms were similarly 
expressed in all stages of growing follicles from primary to the large antral follicle and with a 
light band in cumulus oocyte complex COCX sample (a mature oocyte surrounding by somatic 
cumulus cells). Amh, a granulosa cell-specific gene and its receptor, Amhr2, were detectable in 
all growing stages but was absent in the primordial follicles, large antral, and oocyte samples. 
Gdf9, an oocyte-specific gene, was detected in all samples where multiple oocytes were 
present. The large pre-antral and large antral follicle samples only contained two and one 
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oocytes, respectively, and this was insufficient to detect Gdf9 mRNA. Fshr was expressed in 
all growing follicles except the large antral follicle and oocytes. The androgen biosynthesis 
enzyme, Cyp17a, which is normally expressed in theca cells, was only detectable in the 
advanced stages of the growing follicles, particularly in the large pre-antral follicles. These 
results (Figure 3.4; Appendix IX) provide confirmation of the initial staging of the follicle and 
oocyte samples, as PCR expression generally reflected the known cell and follicle stage-
specific expression. 
 
Figure 3.4. Expression of mRNA of control genes in follicles and oocytes samples. Follicle samples 
were mechanically isolated from mouse ovaries. The non-growing primordial follicles were obtained 
from a postnatal d4 ovary where the ovary was cut into small fragments. Oocytes (n=12) and growing 
follicles including primary, secondary and preantral stages (n= 5 follicles each) and were isolated from 
d 16 ovary. Large preantral, antral follicles and COCX (n= 2, 1, 6, respectively) were isolated from 
mature mouse ovaries. After isolation, all follicle and oocyte samples were immediately snap frozen 
and stored at -80ºC for RNA extraction. The red line in Fshr2 gel represents to a pasted ladder. For 
negative control (-ve), RNase/ DNase free water was added rather than cDNA. 
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3.3.2. Expression R-Smad mRNA in follicle samples 
Transcripts for the R-Smad (Smad 1, 2, 3 and 5) were expressed in all stages of follicle growth 
and oocyte samples by RT-PCR. However, by comparison with Smad1 and Smad5, expression 
of Smad2 and Smad3 were stronger in the primary and secondary follicle samples. Weak bands 
were detected for all R-Smad transcript in primordial and COCX samples (Figure 3.5). 
 
Figure 3.5. Expression of R-Smad transcripts in follicle and oocyte samples using RT-PCR. Smad2 and 
Smad3 were detectable with stronger bands in the earlier stages of follicle development relative to 
Smad1 and Smad5. Red lines in gels represent to pasted ladders. Negative controls consist of RNase/ 
DNase free water instead of cDNA. 
 3.3.3. Expression and quantification of R/Co-Smad transcripts in ovary samples 
Transcripts for Smad1, 2, 3, 4, 5 and 8 were detected in cDNA derived from immature and 
adult ovary samples (Figure 3.6). Smad1 and Smad2 were weaker in d4 and d8 ovary samples, 
while the intensity was increased in d16 and adult samples. In d4 ovary, Smad3 produced the 
strongest band compared with other Smads. Smad8 expressed with weak bands in immature 
ovaries, while a strong band was revealed in adult ovary sample. Smad4 was expressed with a 
band in d4 ovary, while the intensity was obviously increased in d8, d16 and adult ovaries. In 
general, expression bands of Smad3 and Smad5 were more constant than Smad1, Smad2 and 
Smad8 in all ovary samples.  
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Figure 3.6. Expression of R-Smad and co-Smad transcripts by RT-PCR in mouse ovaries. The intensity 
of Smad1 and Smad2 bands appeared to increase with age, while the intensity of Smad3 and Smad5 
were more consistent in ovary samples. Smad4 expressed with a small band in d4, but with stronger and 
consistent bands in older age groups. In contrast to adult sample, Smad8 lightly expressed in immature 
ovary samples. The red line in Smad5 gel represents to a pasted ladder. Negative controls (-ve) were 
included where RNase/ DNase free water was added rather than cDNA. 
In addition, qPCR was performed to identify the relative mRNA expression of Smad1, 2, 3, 4, 
5 and Smad8 in ovaries of different ages (Figure 3.7). Adult ovary samples were also assayed 
to provide more information on the expression levels of R-Smads in mature ovaries. However, 
since adult ovaries contain numerous antral follicles, atretic follicles and corpora lutea, 
structures which are mostly absent from juvenile ovaries, adult ovary samples were not 
considered comparable and were therefore excluded from statistical analyses of the qPCR data. 
Amh (positive control) transcript levels were significantly increased in the d16 ovary, which 
contains a high proportion of multi-layered growing follicles relative to d4 ovary (P<0.001). 
Expression of Smad2, 4 and Smd8 remained constant with age; however, the level of Smad3 
mRNA was reduced in d16 relative to d4 (P< 0.05). In contrast to Smad3 expression, the 
expression levels of both Smad1 and Smad5 were significantly increased in the d16 ovary 
relative to d4 (P<0.01 and P<0.001, respectively). 
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Figure 3.7. Relative mRNA expression of R-Smads, Co-Smad and Amh in mouse ovaries. qPCR was 
used to determine the relative expression of R/Co-Smads in d4, d8, d16 and adult ovaries. Data were 
normalised relative to the expression of the internal housekeeping gene, Atp5b, and expressed as fold 
changes relative to d4 ovary. Statistical differences were assessed using one-way ANOVA with 
Bonferroni post-hoc test, where adult samples were not included in statistics. Data were represented as 
mean ± SEM (n=6 for Smad1, 2, 3, 5 and Amh; n=5 for Smad4 and Smad8). Asterisks (*P<0.05, 
**P<0.001and ***P<0.001) indicate statistically different at P< 0.05.  
65 
 
3.3.4. Expression of Smad inhibitors in follicle and oocyte samples 
As a first step for further investigations, the expression of nine candidate Smad2/3 inhibitors 
was analysed in follicle samples. With the exception of Smad7 and Smurf2, all candidates were 
detectable in growing follicles from secondary to large antral stages. However, by comparison 
with other genes, Strap, Ski and Ppm1a transcripts were detectable in all follicle stages, but 
with lower intensity bands in primordial follicles. In the oocyte sample, six inhibitory factors 
were expressed including Strap, Ski, Ppm1a, Exportin4, Smad7 and Smurf1 (Figure 3.8; 
Appendix X). 
 
Figure 3.8. Expression of Smad inhibitor in follicles, cumulus-oocyte complexes and oocytes by RT-
PCR. Red lines in gels represent to pasted ladders. For negative control (-ve), RNase/ DNase free water 
was added rather than cDNA. 
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3.3.5. Expression and quantification of Smad inhibitors in the ovary 
Immature (d4, d8 and d16) and adult mouse ovaries, which contain different populations of 
primordial and growing follicles were utilised for the expression of candidate Smad inhibitors 
by RT-PCR. Transcripts for all of the inhibitors were detectable in the d4 ovary where the 
majority of follicles are primordial.  Among other candidates, Strap and Ski were detected with 
higher intensity in all age groups. Generally, transcripts for all inhibitors in the adult and d16 
ovaries were expressed with more obvious bands than in d8 or d4 ovary samples (Figure 3.9).  
 
Figure 3.9. Expression of Smad inhibitors in postnatal and adult ovaries by RT-PCR. Red lines in gels 
represent to pasted ladders. For negative controls (-ve), RNase/ DNase free water was added rather than 
cDNA. 
Data from qPCR revealed differential expression patterns of Smad inhibitors at various ovary 
ages. Smad7, Smurf1 and Smurf2 transcript levels were reduced in d16 ovaries relative to d4 
ovaries (P< 0.01), while no significant difference in their expression was found in d8 ovary 
relative to d4 (P>0.05). Likewise, the expression level of Ski and Strap mRNA were 
significantly reduced in d16 ovaries relative to d4 (P< 0.05). No differences in expression levels 
were detectable for SnoN, Exportin4, Ppm1a and RanBP3 in the different age groups (Figure 
3.10). 
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Figure 3.10. Expression levels of Smad inhibitors in mice ovaries at different ages. Data were 
normalised relative to the expression of the internal housekeeping gene, Atp5b, and expressed as fold 
changes relative to d4 ovary. Data were represented as mean±SEM. The biological replicates for Smad7, 
Smurf1, Smurf2, SnoN, RanBP3 were six samples each, where five replicates were utilised for the 
expression of Strap, Ski, Exportin4 and Ppm1a. Statistical differences were assessed using one-way 
ANOVA with Bonferroni post-hoc test. Asterisks (*P<0.05, **P<0.01) indicate statistically different at 
P < 0.05. 
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3.3.6. Localisation of R-Smads 
Immunofluorescent localisation of R-Smad proteins was applied to identify the expression 
pattern of these proteins in ovary sections of d4, d8 and d16. Localisation of R-Smad proteins 
in these ovary sections was associated with the stage of follicle growth. For example, a high 
intensity of staining was observed for Smad2/3 proteins in the ovary section of d4, where the 
majority of follicles are primordial. Similarly, in d8 and d16 ovaries, Smad2/3 staining was 
expressed in primordial and small growing follicles located at the marginal region of the 
ovaries. 
In multilayer follicles located at the ovary centre (secondary follicles), the staining intensity of 
Smad2/3 proteins appeared to be reduced. Conversely, Smad1/5/8 proteins were undetectable 
in primordial follicles, while the staining was more prominent in granulosa cells of multi-
layered pre-antral follicles of d8 with more intensity in the d16 ovary. Follicles positive for 
Smad1/5/8 staining appeared to be more localised at the centre of ovary section. 
High power imaging showed that Smad2/3 proteins are strongly localised in pre-granulosa and 
granulosa cells of primordial to primary follicle stages, respectively. In primordial and 
transitional follicles, weak staining for Smad2/3 proteins was detectable in the cytoplasm of 
oocyte and became undetectable in more advanced stages. 
Smad2/3 and Smad1/5/8 expression overlapped in follicles that had begun to develop a second 
layer of granulosa cells. Smad2/3 and Smad1/5/8 were not localised in any other ovary 
compartments including theca cells, blood vessels, stroma or surface epithelium (Figure 3.11). 
In non-growing, primordial follicles, Smad2/3 was evident in the nucleus of the pre-granulosa 
cells while the intensity of nuclear staining was reduced in granulosa cells from transitional 
and larger growing follicles, where clear cytoplasmic staining was still evident (Figure 3.12). 
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Figure 3.11. Localisation of R-Smad proteins in d4, d8 and d16 mouse ovaries. Smad2/3 proteins (red) 
were strongly detected primordial (PFs), transitional (T), and primary (P), while Smad1/5/8 (green) 
were localised in multi-layered follicles starting in secondary follicles (S). Higher power images (lower 
panels) represent a zoomed area from a d16 ovary. For the negative control, a mixture of equivalent 
quantities of non-immune Rabbit and Mouse IgG were applied to determine non-specific staining in 
ovary sections. Nuclei were counterstained with DAPI  (blue).  Scale  bar  200μm  (large  panels),  or  50μm  
(small panels) 
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Figure 3.12. Immunofluorescent localisation of nuclear and cytoplasmic Smad2/3 in small follicles. 
Nuclei were counterstained with DAPI (blue) (A) and follicle stages are labelled in B. According to the 
stage of follicle growth, both nuclear (N-Smad2/3) and cytoplasmic (C-Smad2/3) were detectable 
(labelled in C) by high-power confocal microscopy in the d16 ovary. In primordial follicles (PFs), 
Smad2/3 were localised in the nuclei of pre-granulosa cells (PGCs, circle shapes). The nuclear exclusion 
of Smad2/3 into the cytoplasm (white margin shapes) occur as these follicles initiated to grow into 
transitional (TF, Square shapes) and complete exclusion was found in granulosa cells (GCs) of growing 
follicles (GF). Scale  bar  25μm. 
3.3.7. Localisation of Ppm1a and Strap protein in the ovary. 
One of the objectives of the present study was to identify factors that have the potential to 
inhibit R-Smads particularly at the early stages of follicle development. RT-PCR  revealed that 
Strap and Ppm1a are detectable in all follicle growth stages including primordial follicles 
(Figure 3.8) and in postnatal ovaries (Figure 3.9) where Smad2 and Smad3 mRNA and proteins 
were also detected. Thus, the aim of this section was to identify the staining pattern of Strap 
and Ppm1a proteins in immature (d4, d8 and d16) ovary sections. For the localisation of Ppm1a, 
numerous attempts were made to successfully label this protein by immunohistochemistry by 
changing different optimisation parameters; however, the signal to noise ratio was consistently 
low, thus, specific staining for Ppm1a protein was not achieved (data not shown). 
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 In order to identify whether Strap is detectable and have the potential to interact with Smad2/3; 
these proteins were co-localised in ovary section of previously defined ages. Low power 
images revealed specific staining of Strap in all ovary ages. Moreover, Strap protein was 
detectable in all stages of small follicles. At low power microscopy, both Smad2/3 and Strap 
were co-localised in follicles located in the medulla and ovary margin of d4 ovary section, 
where the majority of follicles are primordial; while this pattern of staining was mainly 
observed towards the marginal aspect of d8 and d16 ovaries, where primordial and early follicle 
stages are located (Figure 3.13). 
In primordial follicles, similar to Smad2/3, high-power confocal microscopy revealed that 
Strap protein is detectable in the cytoplasm of the oocyte and pre-granulosa cells. However, in 
d8 and d16 ovaries, as follicles initiated in the growing process, Strap protein was also 
detectable in granulosa cells of growing follicles. In the oocytes, Strap staining was reduced in 
the oocytes of follicles at the secondary stage. In all age groups, both Strap and Smad2/3 
proteins were co-localised with the strongest staining in granulosa cells of transitional to 
primary follicle stages, whereas this pattern of staining was reduced in preantral follicles, where 
staining for Smad2/3 was largely reduced. Strap protein was also detectable in stroma and theca 
cells, but not in blood vessels or surface epithelium (Figure 3.14). 
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Figure 3.13. Colocalisation of Strap and Smad2/3 proteins in the immature mouse ovary. Ovaries from 
d4, d8 and d16 mice were stained for Strap (red) and Smad2/3 (green). Negative control sections were 
supplemented with a mixture of non-immune Rabbit and Mouse IgG. Nuclei were counterstained with 
DAPI  (blue).  Scale  bar  200μm. 
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Figure 3.14. Co -localisation of Strap and Smad2/3 proteins in small follicles. In all age groups, positive 
detection of Strap (red) and Smad2/3 (green) proteins were co-localised in the cytoplasm of the oocyte 
(Oo) and pre-granulosa cells of the primordial follicle (PFs). As these follicles started to grow, Strap 
protein appeared to be mainly detectable in granulosa cells (GCs), where it colocalised (yellow arrows) 
with Smad2/3 (green). Negative control sections were supplemented with a mixture of non-immune 
Rabbit and Mouse IgG. Nuclei were counterstained with DAPI  (blue).  Scale  bar  25μm. 
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3.4. Discussion 
3.4.1. Expression of Smad inhibitors 
In the ovary, a considerable amount of literature has identified the critical role of the intra-
ovarian   TGFβ/Smad signalling as a major regulatory mechanism of follicle activation, 
development and apoptosis (Fenwick et al., 2013; Knight and Glister, 2006; Li et al., 2008b; 
Pangas, 2012). Phosphorylation of the R-Smads through the activated receptors at the cell 
membrane   level   is   a   vital   process   for   mediating   the   intracellular   signals   of   the   TGFβ  
superfamily (Groppe et al., 2008). Many Smad inhibitors have been identified to function and 
cooperate with I-Smads (Smad6 and Smad7) to regulate both the duration and strength of the 
TGFβ   signalling   through   different   mechanisms   such   as   dephosphorylation, ubiquitination, 
sumoylation, degradation, and acetylation (Inoue and Imamura, 2008; Lonn et al., 2009). 
Factors that might influence the termination or attenuation of the Smad pathway in the early 
stages of follicle development have not been identified. Therefore, the purpose of this chapter 
was to analyse the expression of candidate Smad regulators in this context. 
RT-PCR analysis confirmed the expression of all of the candidate genes in the whole ovary at 
the d4, d8 and d16 as well as in adult samples. To determine whether any of these candidate 
genes are associated with early follicle development, samples of isolated follicles at a range of 
stages also were screened by RT-PCR. All of the candidate factors were expressed in multi-
layered follicles; however, the study identified three inhibitors, Strap, Ski and Ppm1a, which 
were clearly detectable in all follicle stages including primordial follicles and oocyte samples. 
The presence or absence of transcripts of Smad inhibitors in some follicle stages suggests that 
these factors might function in a stage-specific manner. In immature ovaries, data from qPCR 
revealed different expression between these Smad inhibitors at various ovary ages. For 
instance, relative to d4, transcripts level for Smad7, Smurf1, Smurf2, Ski and Strap were 
significantly reduced in the d16 ovary, while no statistical variation was determined in the 
expression of Ppm1a, Exportin4, SnoN or RanBP3. 
Since changes in expression are associated with major changes in the follicle composition of 
these ovaries, and since RT-PCR showed the presence of certain candidates in isolated follicles, 
we can assume that factors such as Strap (and possibly Ski) play an important role in early 
follicle development. Potential mechanisms of these inhibitory factors to inhibit Smad 
signalling have been reviewed in section 1.11.  
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These findings may provide initial   information   that   TGFβ-Smad signalling can negatively 
regulate by a complex of different factors that might have roles in follicle development. For 
example, the synergistic interaction between Ppm1a and Ranbp3/Exportin4 to enhance the 
exclusion of phosphorylated Smad 2/3 from the nucleus into the cytoplasm (Dai et al., 2011; 
Lin et al., 2006). In adult mouse ovaries, the expression of Ppm1a mRNA is stable; however, 
the expression is increased during oocyte maturation, suggesting a role of Ppm1a during 
advanced stages of follicle growth (Chuderland et al., 2012). The association between Smad7 
and  Smurf1/Smurf2  ubiquitin  ligases  to  block  TGFβ  receptors  at  the  cell  membrane  level  is  
also an important mechanism for inhibiting R-Smad phosphorylation (Kuratomi et al., 2005; 
Liu et al., 2002). A similar interaction has been reported between Smad7 and Strap (Datta and 
Moses, 2000; Wrighton et al., 2009), and between Ski and SnoN (He et al., 2003). 
Several studies have reported the localisation of these inhibitors in ovaries in different animal 
species. In adult rat ovaries, Ski protein was detected in granulosa cells of atretic follicles, but 
not in growing follicles, suggesting a role of Ski in follicle degeneration (Kim et al., 2006). In 
immature mouse ovaries, SnoN was localised in the stromal cells; however, in mature ovaries, 
SnoN protein was detected in theca cells of multi-layered follicles and atretic follicles (Xu et 
al., 2009). In mouse ovaries, Smad7 mRNA and protein were detected in granulosa cells of 
growing follicles and oocytes where upregulation of Smad7 in granulosa cells was associated 
with increased apoptosis rate (Quezada et al., 2012). Even though these factors have been 
broadly described as Smad2/3 inhibitors, however, it is still unknown whether both of these 
Smads are acting at the same time, or if they operate independently (Brown et al., 2007). 
3.4.2. Expression of R/Co-Smad mRNA and protein  
The initial aim of this chapter was to identify the expression of R/Co-Smads in mouse ovaries 
at different ages, as well as in isolated follicles at various developmental stages. Transcripts for 
all R-Smads were detected by RT-PCR throughout all stages of follicle development and in 
whole ovary samples from immature and adult mice, suggesting a relevant role in ovarian 
function. By RT-PCR, Smad2 and Smad3 were more obvious in primordial to secondary 
follicle samples, whereas, Smad1 and Smad5 were more obvious in multi-layered follicle 
stages, including secondary to the large antral follicle. Expression of R-Smad transcripts has 
previously been reported in mature mouse ovaries (Tian et al., 2010), rats (Drummond et al., 
2002), zebrafish (Wang and Ge, 2003) and in primate ovaries (Billiar et al., 2004). 
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Moreover, qPCR data revealed that expression levels of Smad3, but not Smad2, was 
significantly reduced in d16 relative to d4 ovaries; However, another study revealed no 
statistical variation in the expression of Smad2 nor Smad3 mRNA levels between growing and 
mature mouse oocytes (Tian et al., 2010). In this study, comparisons were performed between 
whole ovary samples at d4, where the majority of follicles are non-growing, with older ovaries 
(d8 and d16) containing both non-growing and growing and follicles. Relative to d4, mRNA 
expression of Smad1 and Smad5, but not Smad8, were dramatically increased in the d16 ovary. 
Conversely, in another study in the rat, Smad5 was significantly reduced in d12 ovaries relative 
to d4, while Smad1 was reduced in d8 ovaries (Drummond et al., 2002), suggesting a possible 
species variation. As the Smad4 is essential for nuclear translocation of all R-Smads, it was not 
surprising that expression level of Smad4 did not vary among various ovary ages (Brown et al., 
2007; Moustakas and Heldin, 2008). 
Similar to a previous investigation in mouse ovaries (Fenwick et al., 2013), colocalisation of 
Smad2/3 and Smad1/5/8 in ovary sections revealed that these proteins are precisely localised 
in granulosa cells in a stage-specific manner. In the current study, Smad2/3 proteins, but not 
Smad1/5/8, were also localised in oocytes of the earliest stages of follicle development. Similar 
protein expression was found in oocytes of baboon ovaries (Billiar et al., 2004) and in rats 
(Drummond et al., 2002). Another study in rat ovary indicated that Smad2 and Smad3 proteins 
are detectable with a high intensity of staining in granulosa cells of preantral and small antral 
follicles, but with less intensity in fully grown antral follicles (Xu et al., 2002a). In the present 
study immature mouse ovaries were utilised where follicle stages beyond the secondary stage 
were not present; however, by comparison with earlier stages, staining for Smad2/3 appeared 
to be reduced in the secondary stage.  
Expression of Smad2/3 and Smad1/5/8 proteins was consistent with their mRNA expression in 
ovaries at different ages. For example, Smad2/3 proteins were specifically localised in pre-
granulosa/granulosa cells of primordial and primary follicles, respectively, and staining 
intensity was reduced in multi-layered follicles; while Smad1/5/8 proteins were detectable in 
granulosa cells of multi-layered, preantral, follicles, but not in primary nor primordial follicles. 
Interestingly, Smad2/3 and Smad1/5/8 proteins co-localised in follicles that had developed a 
second layer of granulosa cells. This may indicate the cooperative influence of the two different 
canonical  branches  of  the  TGFβ  superfamily  as  follicles initiate growth. 
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In primordial follicles, Smad2/3 proteins were localised in the nuclei of pre-granulosa cells and 
the intensity of staining was reduced in follicles that began to grow. A similar pattern of 
staining was observed in rat ovaries where nuclear translocation of these proteins was enhanced 
by  TGFβ  and  activin   treatments   through  phosphorylation   (Xu et al., 2002a). In mammalian 
cells,   the   exclusion   of   Smad2/3   from   the   nucleus   is   essential   for   termination   the   TGFβ  
signalling (Dai et al., 2009). As mechanisms that promote follicle activation are still unclear, 
further work is required to identify factors responsible for the nuclear exclusion of Smad2/3. 
Taken together, data from R-Smad mRNA and protein expression studies here suggests that 
the Smad pathway is active in the ovary. In particular, it supports evidence that Smad 2/3 are 
essentially implicated in  the  mediating  of  TGFβ  and  Gdf9  signalling  during  the  earliest  stages  
of follicle development (Dai et al., 2009; Yan et al., 2001). Concerning Smad1/5/8, the 
increased expression of Smad1 and Smad5 mRNA and Smad1/5/8 proteins in granulosa cells 
of multi-layered preantral follicles suggests their important role in mediating Bmp and Amh 
ligands (Durlinger et al., 2002; Kaivo-oja et al., 2006). 
3.4.3. Localisation of Ppm1a and Strap proteins 
Based on the mRNA expression of R-Smads and Smads inhibitors, both Ppm1a and Strap were 
selected for further investigation including protein localisation and colocalisation with 
Smad2/3 in immature ovary sections. Ppm1a protein was undetectable in immature mouse 
ovaries by immunofluorescence. In a previous study in adult mouse ovary, Ppm1a was 
localised in the oocyte and with less intensity in granulosa cells of growing follicles, where the 
intensity of protein was increased in mature oocytes (Chuderland et al., 2012). In this study, 
failure to detect Ppm1a might be due to either poor quality antibody or the fact that the 
expression of the protein in immature ovaries is very low. 
Consistently with mRNA expression by RT-PCR, Strap protein was localised in follicles that 
ranged from primordial to preantral follicle stages. Strap and Smad2/3 proteins were 
colocalised in immature ovary sections at different ages to identify the specific follicle stage 
where these proteins are interact. This will provide useful evidence to identify both age and 
ovary tissue that can utilise for in vitro culture model. Colocalisation of Strap and Smad2/3 
revealed a high intensity of staining in pre/ granulosa cells from primordial to primary stages. 
In addition, both were co-localised in the oocytes of primordial to transitional follicles. These 
results support data obtained by qPCR indicated that expression of both Strap and Smad3 were 
significantly reduced with age. 
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In addition, the decreased intensity of colocalisation in growing follicles might explain by the 
reduction of Smad2/3 staining in more advanced follicle stages. The higher staining pattern in 
small follicles indicates the possible interaction between Strap and Smad2/3, which may inhibit 
the Smad2/3 pathway and consequently promote early follicle growth. Functionally, Strap can 
interact  with  Smad7  to  form  a  stabilised  complex  on  the  phosphorylated  TGFβ  Type  I  receptor  
preventing phosphorylation of Smad2 and Smad3 (Wrighton et al., 2009). In addition, 
phosphorylated Strap has the potential to associate with inactive Smad2 and Smad3, but not 
Smad1/5/8, to inhibit their interaction with the Type I receptor (Datta and Moses, 2000). In 
contrast with the significant decline of Strap mRNA by qPCR, there was no obvious reduction 
in Strap staining in multi-layered follicles of d16 ovary sections; suggesting that Strap might 
have other cellular functions. For example, Strap can promote cell growth by stimulation of 
pathways which function to enhance cell proliferation such as PDK1/PI3K (Reiner and Datta, 
2011) and Erk (Halder et al., 2006). Moreover, Strap also has an anti-apoptotic function by 
inhibition of the tumour necrosis factor alpha (TNF-α)  (Seong et al., 2005). As these pathways 
are a part of a complex system that regulates early follicle growth (John et al., 2008; Reddy et 
al., 2009), Strap might also have an essential role in the development of the preantral follicle. 
A previous study conducted on the fish ovary, Silver Crucian Carp, indicated that Strap is only 
expressed in fully grown oocytes, but not in the early-developing oocytes (Wen et al., 2001). 
In the present study, Strap was only detected in the oocytes of primordial follicles; the 
difference in protein expression might relate to species variation. 
For this chapter, several limitations were specified; for example, to some extent, the biological 
replicates of ovary samples for each age group assessed by qPCR were relatively small. More 
samples would increase the statistical power and would provide flexibility to omit samples that 
were subject to technical variation rather than repeating the experiment several times. In 
addition, the relatively low amounts of RNA that could be obtained from the isolated follicle 
and oocyte samples limited the number of genes that could be analysed by qPCR. Inconsistency 
between some RT-PCR gels and the qPCR data is attributed to the use of an individual ovary 
sample, while in qPCR at least five samples were utilised to quantify gene expression. In 
addition, gel images are a reflection of samples that have cycled 32 times, where is unknown 
whether samples were reached a plateau, or in other words, the gel images can only be used to 
determine the presence or absence of mRNA; while using of qPCR can show relative 
expressions. 
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In conclusion, this chapter provides useful information on the expression of R-Smads mRNA 
and proteins in different ovary ages. The study proposed that exclusion of Smad2/3 from the 
nucleus of pre-granulosa cells might be essential in the process of primordial follicle growth. 
In addition, nine Smad inhibitors were detected in the immature ovaries of different ages and 
follicles at various stages of development, which might indicate that Smad signalling is not 
only inhibited by I-Smads but also through different inhibitory factors. In particular, Strap was 
found to coincide with the expression of Smad2/3, raising the possibility that this candidate 
plays an important regulatory   role   in   TGFβ/Smad   signalling   during   primordial   follicle  
activation and preantral follicle growth. The functional impact of Strap and other candidates 
on the regulation of the early follicle development has not yet been studied. Thus, future 
experiments will focus on the effect of Strap modulation on the primordial follicle activation 
and preantral follicle growth.  
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Chapter 4 
Functional role of Serine-Threonine Kinase-Receptor 
Associated Protein (Strap) in regulation of early follicle 
growth 
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4.1. Introduction 
Mechanisms that maintain the primordial follicle in a dormant non-growing state or that initiate 
growth are unclear. It is suggested that primordial follicle activation and the early stages of 
follicle development are largely regulated by interactions of locally secreted factors (Kim, 
2012; Knight and Glister, 2006). Even though it is not fully understood, it has determined that 
TGFβ signalling participate in these two process; for example, incubation of human ovarian 
cortical tissue in a medium supplemented with a low concentration of exogenous activin caused 
inhibition of follicle activation, while higher concentration increased follicle activation (Ding 
et al., 2010). In addition, Gdf9,  another  TGFβ  member, is also believed to be important for the 
transition of primordial to the primary follicle growth. In a study in rats, exogenous Gdf9 
treatment caused an increased proportion of growing follicles with a dramatic decrease in the 
proportion of primordial follicles (Vitt et al., 2000). 
In chapter 3, R-Smads and nine of their potential negative regulators were analysed for 
expression in immature ovaries and different stages of early follicle growth. In particular, the 
detection of Strap in granulosa cells of small follicle was found to coincide with the expression 
of Smad2/3 in the same cells. In addition, transcripts of Strap and Smad3 followed the same 
expression pattern, being reduced in d16 ovaries relative to d4. In tissues other than ovary, 
Strap negatively regulates the Smad2/3 pathway by the stabilising Smad7, but not Smad6, to 
the  activated  TGFβ  receptors  complex  preventing  the  interaction  between  the  receptor  complex  
and inactivating Smad2/3 (Datta et al., 1998; Datta and Moses, 2000). Another study indicated 
that Strap has the potential to interact with the activated cytoplasmic complex of Smad2/3 and 
Smad4 preventing its translocation into the nucleus (Halder et al., 2006). In addition to its Smad 
inhibitory function, Strap regulates a wide range of molecular mechanisms and genes involved 
in cell proliferation (Chen et al., 2004) and survival (Jung et al., 2010). For example, Strap can 
act as an anti-apoptotic factor by inhibiting tumour necrosis factors alpha (TNF-α) and has the 
potential to enhance phosphoinositide-dependent kinase-1 (PDK1) signalling (Seong et al., 
2005). Dysregulation of strap expression is also associated with some pathological disorders 
including cancer; for example, upregulation of Strap results in persistent PDK1/PI3K 
signalling, indicating that Strap might normally operate to stimulate pathways that enhance cell 
proliferation (Reiner and Datta, 2011). Moreover, upregulation of Strap is associated with 
elevated Erk signalling accompanied with downregulation of p21Cip1, a cell cycle suppressor 
protein, which together acts to enhance cell proliferation and consequently tumour progression 
(Halder et al., 2006). 
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With regards to  canonical  TGFβ  signalling,  even  though  TGFβ1-3, Gdf9, activin, and nodal 
are capable of signalling through the Smad2/3 pathway (Kaivo-oja et al., 2006; Li et al., 2008b), 
the functional impact of Strap, as a Smad inhibitor, on follicle activation and development is 
currently unknown. The hypothesis of this chapter is that Strap has a relevant functional role 
in the process of follicle activation and development through the inhibition of Smad2/3 
pathway.  
The aim of this part is to assess the impact of modification in Strap expression on early follicle 
development. To achieve this aim both ovary fragments and preantral follicle culture models 
will be utilised. The expression and/or function of Strap will be manipulated by different 
molecular protocols including the inhibition of Strap expression by Small interfering RNA 
(siRNA), inhibition of Strap bioactivity using anti-Strap antibodies or by enhancing Strap 
function by exogenous recombinant protein supplementation. The effects of these treatments 
on early follicle development are evaluated using morphological and gene expression criteria. 
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4.2. Material and Methods 
Similar procedures and materials described in section 2.1 were followed for ovary dissection 
and manipulation. 
4.2.1. Ovary fragments culture model 
Immature d4 ovaries enriched with primordial follicles were fragmented and maintained in 
vitro in accordance with the procedure outlined in section 2.2.1. This approach was used as a 
model to evaluate the functional role of Strap on primordial follicle growth. Three different 
treatments were used in this model in accordance with the following: 
4.2.1.1. Knockdown of Strap mRNA by siRNA treatment  
Equivalent size ovary fragments (3-5 pieces) were cultured in 1ml of MEM-α  media (Gibco) 
supplemented with 10% FBS (ThermoFisher), 100µg/ml Streptomycin sulfate (Sigma), 
75µg/ml Penicillin (Sigma) at 37ºC with 5% CO2. After 72 hours of incubation, media was 
replaced and supplemented with either 1µM Accell Mouse Strap siRNA (E-045977-00; 
Dharmacon), 1µM Accell green non-targeting siRNA (D-001950-01-05; Thermo Scientific), 
1µM Accell non-targeting siRNA (D-001910-10-05; Thermo Scientific), or without siRNA 
(Figure 4.1). Doses were used according to the manufacture instruction. 
After 96 hours of incubation, cultured fragments were imaged with an Olympus CKX41 with 
a Nikon camera DS-Fi1. Ovary fragments from one plate were used for immunofluorescent 
staining, as described in 2.9.4. Ovary fragments from the other two plates (with the exception 
of Accell green non-targeting siRNA treated group) were used to determine the effect of siRNA 
treatment on Strap mRNA levels between groups by qPCR. To increase the amount of the yield 
RNA, ovary fragments of each individual treatment/control groups were pooled in a single tube 
and were processed for RNA extraction. 
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Figure 4.1. The layout of the ovary fragment culture with Strap siRNA. After 3 days in culture media, 
ovary fragments were incubated for additional 4 days with or without Strap siRNA treatment. Images 
were obtained at two-time points during culture to identify the effect of treatments on oocyte/follicle 
development. At the end of culture, plates (n=3) were utilised either for RNA extraction (n=2) or 
immunofluorescent colocalisation of Amh and Ddx4. 
 
4.2.1.2. Inhibition of Strap protein by immunoneutralisation  
Ovary fragments from d4 ovaries were prepared and cultured in 24-well plates as described in 
2.2.1. Each well contained 1ml of MEM-α culture media (with supplements as described 
above) and either 1µg/ml or 10µg/ml of Rabbit anti-Strap IgG (AB1) (Sigma; AV48038) or 
the equivalent concentration of non-immune Rabbit IgG (Vector). Additional control wells 
without IgG were also included on each plate (Figure 4.2).  
Cultured fragments were imaged with an Olympus CKX41 with a Nikon camera DS-Fi1 at 4 
and 7 days after the addition of treatments. To determine the effect of treatments on follicle 
growth, images were used for oocyte measurements. After this, samples were fixed and were 
processed for immunostaining for Amh and Ddx4, as described in section 2.9.4. 
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Figure 4.2. The layout of ovary fragment culture for Strap immunoneutralisation. Ovary fragments 
were incubated for 7 days in culture media with either 1µg/ml or 10µg/ml of Rabbit anti-Strap IgG, an 
equivalent concentration of non-immune Rabbit IgG or without any treatment (control). Fragments 
were imaged at 4 and 7 days of culture and images were used for oocyte measurements. At the end of 
culture (day 7), plates (n=3/each concentration) were utilised for immunofluorescent colocalisation of 
Amh and Ddx4. 
 
4.2.1.3. Supplementation of Strap protein (rhStrap) 
Recombinant Human Unrip full-length protein (Abcam; designated rhStrap) was utilised to 
enhance Strap function in the culture of d4 ovary fragments. Ovary fragments in control 
untreated group were incubated in 1ml of MEM-α   medium   (Gibco)   with supplements as 
described above. Treated groups were cultured in 1ml of culture media that also included either 
100ng/ml or 200ng/ml rhStrap (Abcam) (Figure 4.3). Controls also included an equivalent 
volume of rhStrap diluent L-Glutathione–Tris solution (Appendix IV). The cultures (plates, 
n=3) were incubated at 37ºC with 5% CO2. Cultured ovary fragments were imaged with 
(Olympus CKX41 with a Nikon camera DS-Fi1) at 4 and 7 days of culture. At the day 7, 
cultures were terminated and samples were fixed for immunofluorescent staining according to 
section 2.9.4. 
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Figure 4.3. The layout of ovary fragment culture for rhStrap supplementation. Ovary fragments were 
incubated for 7 days in culture media with either 100ng/ml or 200ng/ml rhStrap or with diluent only 
(control). Fragments were imaged at 4 and 7 days of culture and images were utilised for oocyte 
measurement. At the end of culture (day 7), plates (n=3) were utilised for immunofluorescent 
colocalisation of Amh and Ddx4. 
4.2.2. Preantral follicle culture model  
Preantral follicles were mechanically isolated from d16 ovaries and used to identify the effect 
of Strap siRNA or rhStrap treatments on follicle growth.  
4.2.2.1. Strap siRNA treatment 
4.2.2.1.1. Preparation of siRNA media for Strap knockdown 
The aim of this experiment was to determine the effect of Strap mRNA knockdown on preantral 
follicle growth. Preantral follicles were mechanically isolated from d16 ovaries and cultured in 
96-well plates (4 plates), as previously described 2.2.2. According to the manufacturer's 
guidelines, it was recommended that cells/tissues exposed to Accell siRNA could be 
maintained in culture media without supplements, and/or with the proprietary basal culture 
medium (Accell delivery medium). Therefore, an initial experiment was carried out to 
determine whether these variables would have an impact on basal preantral follicle growth. 
Results of this experiment specified that growth supplements to be added to the Accell delivery 
used for Strap siRNA treatment (Appendix XI). For the main experiment, each plate included 
four lines of treatment where a single line consisted of five individual follicles cultured in 100µl 
of media. Groups consisted of the following (i) Accell delivery media only (control), (ii) 1µM 
Accell Mouse Strap siRNA (E-045977-00; Dharmacon), (iii) 1µM Accell non-targeting siRNA 
(D-001910-10-05; Thermo Scientific) and (iv) 1µM Accell green non-targeting siRNA (D-
001950-01-05; Thermo Scientific).  
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All groups were supplemented with 0.1% (w/v) BSA  (Sigma),  75μg/ml  penicillin   (Sigma),  
100μg/ml  streptomycin  sulphate  (Sigma)  and  insulin-transferrin-sodium  selenite  ITS  (5μg/ml,  
5μg/ml,  5ng/ml,  respectively;;  Sigma) (Figure 4.4).  
Seven plates (n=7) were prepared and cultured at 37°C with 5% CO2. Half of the culture media 
was refreshed after 48 hours of incubation. Follicles were imaged at regular time points (0h, 
24h, 48h, and 72h) using light microscopy (Olympus CKX41 with a Nikon camera DS-Fi1). 
To identify the effect of treatments on follicle growth, images were utilised for the estimation 
of follicle diameter by ImageJ software, as described in 2.10.1. The experiment was applied 
twice where follicles from the first one (n=20 follicles/group/4 plates) were utilised for RNA 
extraction, while follicles from the second experiment (n=21/group/3 plates) were utilised for 
paraffin embedding. 
 
Figure 4.4. The layout of Strap siRNA treatment in the preantral follicle culture. Lines of treatment 
included an untreated control group (1), 1µM Accell Mouse Strap siRNA group (2), 1µM Accell Non-
targeting siRNA group (3) and 1µM Accell green non-targeting group (4). Each well contained a single 
preantral follicle in 100µl of a particular reagent media. Cultured follicles were imaged at 0h, 24h, 48h 
and 72h to identify the effect of treatments on follicle growth. Each plate was filled according to the 
above layout with follicles from an individual d16 ovary and this was repeated 4 times (n=4). 
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4.2.2.1.2. RNA extraction, RT-PCR and qPCR of cultured ovary fragments and preantral 
follicles 
At the end of incubation (72 hours), cultured follicles (n=5) from each treatment line were 
collected in a single Eppendorf tube (4 tubes/ group), snap frozen in liquid nitrogen and stored 
at -80ºC for RNA extraction according to section 2.3. After extraction, RNA samples were 
evaluated for integrity and concentration using an Agilent 2100 Bioanalyser (Agilent), as 
shown in chapter 2 (see Figure 2.1). An equal amount (10ng/µl) of RNA from each sample was 
reverse transcribed into cDNA (section 2.4) and was assessed by RT-PCR for the expression 
Strap and Amh in order to confirm the RT reaction was successful. 
To identify the effect of siRNA treatments on Strap transcript levels, Strap was quantified by 
qPCR. In addition, Amh was also assessed as a positive control gene, since Amh is known to 
be expressed in granulosa cells of healthy preantral follicles (Weenen et al., 2004). Primer 
sequences for these genes are provided in Table  3.1.  Reaction  mixtures  (20μl)  consisting  of  2x  
Kapa SYBR Green  (10μl)  and  ROX  dye,  0.4  μl  (Kapa  Biosystems  Ltd.,  London,  UK),  0.5μl  
(500nM- final  concentration  in  reaction)  of  each  primer  set,  8.1μl  nuclease-free  water  and  1μl  
cDNA (or nuclease-free water for non-template sample) was added into wells of 384-well plate. 
Thermal cycles were started by initial denaturation for 3 minutes at 95°C, followed by a 
denaturation step for 40 cycles of 3 seconds at 95°C, annealing for 20 seconds at 58°C, and 
extension at 72°C for 10 seconds. 
Cultured ovary fragments (with the exception of Accell green non-targeting siRNA treated 
group) were collected, pooled together (fragments of 6 wells/group) to obtain sufficient RNA 
from each group and used for cDNA synthesis, using similar protocols mentioned above. Four 
technical replicates from each group were used to identify changes in Strap mRNA levels. 
qPCR  reaction  mix  (20μl)  were  prepared  using  2X  SensiFAST SYBR Hi ROX Mix (Bioline). 
Thermal cycles included an initial denaturation for 2 minutes at 95°C, followed by cycles of 5 
seconds at 95°C, annealing for10 seconds at 59°C, and extension at 72°C for 12 seconds. 
For both experiments, CT values were normalised against mouse Hprt1 (Atp5b for ovary 
fragments) and fold changes relative to control were estimated using the equation 2-ΔΔCT 
method (Livak and Schmittgen, 2001). 
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4.2.2.1.3. Staining of cultured preantral follicles 
An additional experiment was performed to confirm results of Strap knockdown on preantral 
follicle growth. A single plate was set up as above and cultured follicles were utilised for 
histological assessment. At the end of culture (72h), follicles from each group (5-7 follicles) 
were fixed in 10% neutral buffered formalin, embedded in low gelling temperature agarose, 
embedded in paraffin, and sectioned as described in 2.9.2. Follicle sections from control and 
Accell green non-targeting siRNA groups were compared to determine if follicles took up 
siRNA. These sections were dewaxed in Histochoice (Sigma), rehydrated in a graded series of 
ethanol solutions of 100%, 95%, and 70% (3 minutes each), and washed in distilled water (5 
minutes). Then, sections were mounted in ProLong Gold antifade reagent with DAPI 
(Invitrogen) and coverslipped.  
Sections were imaged by inverted Widefield fluorescence microscope (Leica DMI4000B). To 
determine the effect of Strap protein expression after siRNA treatment, immunofluorescent 
staining was performed on follicle sections for protein localisation using  0.3μg/ml  Mouse  anti-
Strap (Santa Cruz, sc- 136083) according to protocols described in section (2.9.3) and labelled 
with Alexa fluor 555 Donkey- anti-Mouse IgG (Invitrogen).  
4.2.2.2. rhStrap treatment  
The aim of this experiment was to identify the effect of rhStrap supplementation on cultured 
preantral follicle growth. Follicles were mechanically isolated from d16 ovaries (n=7) in drops 
of isolation media using acupuncture needles. Follicles were transferred into 96-well plates 
(Nunclon) where each well contained 100µl media with supplements, as described in 2.2.2. A 
single follicle was placed into each well, and for each plate, eight wells contained media with 
200ng/ml rhStrap (Abcam; ab132509), and other eight wells contained media without rhStrap 
(control).  
The product of rhStrap contains 0.31% Glutathione (Sigma- Aldrich) and 0.79% Tris HCL 
(Sigma- Aldrich), thus, equal quantities of diluent were prepared (Appendix III) and were 
added to control media only. Follicles were maintained for 72 hours at 37°C and 5% CO2 and 
imaged regularly using inverted light microscopy (Olympus CKX41 with a Nikon camera DS-
Fi1) to be used for growth assessment. Unhealthy follicles that lost their morphology at any 
stage of culture were excluded from measurement (Figure 4.5). 
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Figure 4.5. Examples of cultured follicles excluded from measurement. Only follicles with normal 
morphology (1) were measured for growth assessment. Follicles that were exhibited morphological 
features of deformity, such as abnormality in the basal lamina and extrusion of cells (2), a misshapen 
or obviously deformed oocyte (3), partial or complete extrusion of the oocyte (4-5, respectively) were 
omitted  from  growth  assessment,  scale  bar  =100μm.   
4.3. Statistical analyses 
The impact of Strap knockdown on preantral follicle growth was analysed by Kruskal-Wallis 
and  Dunn’s  multiple  comparisons  test.  The  effect  of  Strap  siRNA  treatment  on  Strap and Amh 
mRNA levels were assessed by qPCR and data were analysed using ANOVA with Bonferroni’s  
multiple comparisons test. Changes in preantral follicle growth rates between control and 
rhStrap protein treated group were evaluated at 24h, 48h and 72h relative to 0h using two-way 
ANOVA  with  Bonferroni’s  multiple  comparisons  test.  
For cultured ovarian fragments, the effect of treatments on oocyte growth at d4 and d7 of 
culture was analysed using a Kruskal-Wallis  and  Dunn’s  multiple  comparisons  test.  To  identify  
differences in proportions of oocyte growth stages (non-growing, transitional, growing) 
between treatments and control groups, data from three plates (n=3) were analysed using 
ANOVA with a post-hoc Bonferroni multiple comparisons test. All analyses were performed 
using Prism (v6.0d; Graphpad) with differences considered significant if P<0.05.  
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4.4. Results  
4.4.1. Effect of Strap siRNA treatment on the early follicle growth 
4.4.1.1. Ovary fragments model 
In order to identify the effect of Strap mRNA knockdown on follicle activation, immature d4 
ovaries containing a high proportion of primordial follicles were cultured. In addition to the 
untreated control group, ovary fragments were cultured with either1µM Accell Mouse Strap 
siRNA or 1µM Accell Non-targeting siRNA. After four days in culture, light microscopy 
images of the cultured fragments were utilised to obtain oocyte diameters, where only clearly 
identified oocytes were measured.  
The median diameter of all oocytes in the Strap siRNA treated group was significantly greater 
than in control and non-targeting siRNA-treated group (25.54µm  vs  23.23μm  and  23.75µm,  
respectively; P<0.05). The same effect was also observed when only oocytes classified as 
“growing”  were  considered  (i.e. all oocytes >25.7µm), where the median diameter of growing 
oocytes in the Strap siRNA group was greater than in control and non-targeting siRNA-treated 
group (36.04μm,  32.66µm  and  31.95μm,  respectively;;  P<0.05)  (Figure  4.6). 
 
Figure 4.6. Effect of Strap siRNA treatment on oocyte size in cultured ovaries. Ovary fragments from 
d4 ovaries were cultured for 96 hours in either siRNA targeting Strap mRNA, non-targeting (NT) 
siRNA or without any treatment (control). All measured oocytes included oocytes that classified as non-
growing (<18.3μm), transitional (18.3- 25.7μm) and growing oocytes  (>25.7μm)  from  three  cultured  
plates incubated under similar conditions. Differences between groups were evaluated using Kruskal- 
Wallis  and  Dunn’s  multiple  comparisons  test  *P<0.05. 
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When the proportions of oocytes in each category (non-growing, transitional, and growing 
oocytes) were considered by treatment, there was a reduced proportion of non-growing oocytes 
in the Strap siRNA treated group, relative to control and non-targeting groups (24.87%, 
30.51%, and 29.56%, respectively; P<0.001). In contrast, the percentage of growing oocytes 
was significantly increased in Strap siRNA group relative to control and non-targeting groups 
(46.27%, 41.78%, and 43.01%, respectively; P<0.001). However, statistical analysis showed 
no significant difference in the proportion of transitional oocytes between groups (Figure 4.7). 
 
Figure 4.7. Effect of Strap siRNA treatment on the proportion of oocytes in ovary fragment cultures. 
The proportion of oocytes treated with strap siRNA, non-targeting siRNA (NT) or control after 96 hours 
in culture. Data are presented as mean proportions of oocytes in each stage from three cultured plates 
(n=3). Data were evaluated using ANOVA with a post-hoc Bonferroni multiple comparisons test. *** 
P<0.001.  
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The next aim was to relate results of the oocyte measurements with the Strap mRNA expression 
levels between treated and control groups. Incubation of d4 ovary fragments for 96 hours with 
Strap siRNA caused a significant decrease in the expression of Strap mRNA relative to non-
targeting siRNA group and reduced by a half relative to its expression in control group (Figure 
4.8). 
 
Figure 4.8. Effect of Strap siRNA on the expression of Strap in ovary fragments. Fluorescent images 
represent an individual ovary fragment treated with non-targeting green siRNA at 0h and after 24h of 
culture. Image after 24h confirms the uptake of siRNA by the cultured fragment. A significant reduction 
in the expression of Strap level was revealed relative to non-targeting siRNA (NT siRNA) and its 
expression was reduced by approximately 50% relative to control. Expression of Strap mRNA was 
determined in relation to the internal reference gene Atp5b and expressed as fold change relative to a 
control group using the formula 2-ΔΔCT. Fold changes (mean ±SEM) are shown for four technical 
replicates (n=4). *P<0.05, One-way   ANOVA   and   Bonferroni’s   multiple   comparisons   test. Ovary 
fragment was imaged at the same setting of gain and exposure with an Olympus CKX41 with a Nikon 
camera DS-Fi1. Scale = 200μm. 
 
Cultured fragments from one plate were used for immunofluorescent colocalisation of Ddx4 
(oocyte marker) and Amh (to identify granulosa cells of growing follicles). In addition to the 
importance of using this staining protocol to recognise growing follicles, it also provides 
additional evidence that the ovary fragments culture model was able to maintain primordial 
follicle activation and early preantral follicle development. Although not quantified, Amh 
staining was more detectable in the Strap siRNA treated group than control and non-targeting 
siRNA groups, further supporting an increase in the proportion of growing follicles with Strap 
knockdown (Figure 4.9). 
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Figure 4.9. Immunofluorescent staining of cultured ovary fragments with or without siRNA. After 96 
hours of culture, control, non-targeting (NT) siRNA, and Strap siRNA ovary fragments were stained 
with both Ddx4 and Amh. Ddx4 (green) was localised in oocytes (Oo), while Amh (red) was localised 
in granulosa cells of growing preantral follicles (GFs), but not in primordial follicles (PFs). Scale bar = 
100  μm.   
4.4.1.2. Effect of Strap siRNA treatment on preantral follicle growth 
In order to identify the effect of Strap knockdown on preantral follicle growth, isolated 
preantral follicles were cultured in the presence or absence of 1µM Strap siRNA, 1µM Non-
targeting siRNA or 1µM labelled non-targeting siRNA. The siRNA uptake by follicles was 
examined by fluorescent microscopy of sections of cultured follicles where, unlike control, 
follicles treated with Accell green non-targeting siRNA showed green staining in the cytoplasm 
of granulosa cells (Figure 4.10). 
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Figure 4.10. Follicle sections confirming cellular uptake of siRNA. After 72h in culture, follicle 
sections from Control (A) and Accell green non-targeting siRNA treated group (B) were utilised to 
confirm the uptake of siRNA (white arrows, green stain). Sections were dewaxed, mounted in DAPI 
and cover-slipped. Follicle sections were imaged at the same setting of gain and exposure with an 
inverted Widefield fluorescence microscope (Leica  DMI4000B).  Scale  =  100μm.   
Considering the effect of Strap siRNA on preantral follicle size, there was no significant 
difference in the mean follicle diameter between treatment groups at any time point (24h, 48h 
or 72h). However, within groups, the mean follicle diameter was significantly increased during 
the first 24 hours of incubation in both control and non- targeting siRNA groups (P<0.01, 
P<0.05, respectively), but not in the Strap siRNA treated group at the same incubation time 
(P=0.1422). Fluorescent microscopy of preantral follicles treated by Accell green non-targeting 
siRNA clearly showed the penetration and uptake of siRNA throughout the culture, consistent 
with the staining observed in sections of follicles at the termination of culture (Figure 4.11). 
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Figure 4.11. Effect of Strap siRNA treatment on preantral follicle growth. Follicle diameters were 
estimated at 0h, 24h, 48h and 72h (n= 20 follicles/group). Follicle diameters were presented as mean ± 
SEM and were analysed using ANOVA with a post-hoc Bonferroni multiple comparisons test. *P<0.05, 
** P<0.01, NS non-significant. Fluorescent images taken throughout culture (B) show evidence of green 
non-targeting siRNA uptake by follicles in the culture at  different  time  points.  Scale  bar  100μm. 
To evaluate the effect of treatments on Strap expression, Strap transcript levels were assessed 
in  cDNA  (10ng/μl)   from  pooled   follicles  of each group. The expression level of Strap was 
significantly reduced relative to non-targeting siRNA group (P<0.05), however, the reduction 
was not statistically different when compared with the untreated control group. There was no 
significant difference in the expression of Amh among groups (Figure 4.12). 
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Figure 4.12. Expression of Strap and Amh in preantral follicles by qPCR. Each group is represented by 
four cDNA samples (n=4), where each sample was derived from five cultured preantral follicles after 
72 hours of culture. Data were normalised relative to the expression of the internal housekeeping gene, 
Hprt1, and expressed as mean fold changes (± SEM) relative to controls. *P < 0.05. 
For further evaluation of siRNA treatment, the expression of Strap protein was evaluated by 
immunofluorescent localisation in histological sections of cultured follicles. Images revealed a 
reduction in Strap staining in the siRNA treated follicles relative to non-targeting siRNA 
treated follicles (Figure 4.13). Collectively, these findings indicate that the Strap-specific 
siRNA treatment reduced the levels of both Strap mRNA and protein in the treated follicles in 
comparison to controls. 
 
Figure 4.13. Immunofluorescent localisation of Strap protein in cultured preantral follicles. Paraffin-
embedded sections of cultured follicles were stained for localisation of Strap (red) in a non-targeting 
siRNA follicle (A) and a siRNA treated follicle (B). Images were obtained with inverted Widefield 
fluorescence microscope (Leica DMI4000B). Scale  bar  =100μm.   
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4.4.2. Effect of immunoneutralisation of Strap protein in the ovary fragment model 
The model of d4 ovary fragments was used to assess the impact of Strap protein inhibition on 
early follicle growth using specific antibodies. Ovary fragments were cultured in  either  1μg/ml  
or 10μg/ml  anti-Strap IgG. Control groups included treatment with an equivalent concentration 
of non-immune IgG and no IgG. Oocyte diameters were measured from images at 4 and 7 days 
of incubation. After 4 days in  culture,  fragments  treated  with  1μg/ml  anti-Strap IgG showed no 
significant variation in the median oocyte diameter relative to control groups. Likewise, when 
only growing oocytes were considered at this time point, the median oocyte diameter in the 
anti-Strap group was not different to control nor non-immune IgG groups (33.64µm, 32.32µm 
and  30.99μm,  respectively).   
However, a slight, but significant increase in the median diameter of oocytes treated with 
1μg/ml  anti-Strap was found after 7 days when compared with control or non-immune IgG-
treated group   (25.18μm,   23.92μm   and   24.03μm, respectively; P<0.05 vs control or non-
immune IgG-treated). When only growing oocytes were considered at the 7 day time point, the 
median size of measured oocytes in the anti-Strap treated group was greater than the control 
and non-immune   IgG   group   (36.56μm,   32.70µm   and   31.68μm,   respectively;;   P<0.05   and  
P<0.01 versus control and non-immune IgG, respectively) (Figure 4.14).  
 
Figure 4.14. Effect  of  1μg/ml  anti-Strap IgG treatment on oocyte size. Day 4 ovary fragments were 
maintained  for  7  days  in  1μg/ml  anti-Strap  IgG  or  1μg/ml  non-immune  IgG  (1μg/ml  IgG)  or  no  IgG  
(control). Cultured fragments were imaged after 4 and 7 days of exposure to different treatments. All 
measured oocytes (non-growing,   transitional   and   growing)   or   only   growing   oocytes   (>25.7μm)   are  
plotted. Variation in the median oocyte diameter between groups at both time points was evaluated 
using Kruskal-Wallis  and  Dunn’s  multiple comparisons tests. *P<0.05, **P<0.01. 
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When the proportion of oocytes in each category (non-growing, transitional, growing) was 
considered by treatment, there were no differences at 4 days in culture. However, at 7 days 
there was a reduced proportion of non-growing  oocytes  in  the  group  treated  with  1μg/ml  anti-
Strap relative to control and non-immune IgG group (22.76%, 29.62% and 28.57%, 
respectively; P<0.001vs control or non-immune IgG-treated).  
The percentage of transitional staged oocytes was significantly  increased  in  the  1μg/ml  anti-
Strap group relative to control and non-immune IgG groups (30.2%%, 27.5% and 27.0%, 
respectively; P<0.001 vs control or non-immune IgG-treated). The percentage of growing 
oocytes was also significantly increased in the  1μg/ml  anti-Strap group relative to control and 
non-immune IgG groups (47%, 42.86% and 44.38%, respectively; P<0.001 vs control and non-
immune IgG groups) (Figure 4.15).  
 
Figure 4.15.  Effect  of  1μg/ml  anti-Strap on oocyte growth in the cultured fragments. Graphs show the 
proportion of oocytes treated with 1µg/ml anti-Strap, 1µg/ml non-immune IgG or control after 4 days 
or 7 days exposure. Data are presented as mean proportions of oocytes in each stage from three culture 
plates (n=3). Data were evaluated using ANOVA with a post-hoc Bonferroni multiple comparisons test. 
***P<0.001 vs control and non-immune IgG group. 
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At the end of culture, Amh staining was more detectable in the 1µg/ml anti-Strap treated group 
than the other two control groups, consistent with an increase in the proportion of growing 
follicles with anti-Strap treatment (Figure 4.16). 
 
Figure 4.16. Immunofluorescent staining of ovary fragments treated with 1μg/ml  anti-Strap IgG or non-
immune IgG. After 7 days in culture, ovary fragments were stained for the detection of Ddx4 (green) 
and  Amh  (red).  GFs:  Growing  follicles,  Oo:  oocytes,  PFs:  primordial  follicles.  Scale  bar=  100μm.   
To identify whether Strap function has affected early follicle development in a dose responsive 
manner, ovary fragments were treated with a higher concentration of anti-Strap IgG and non-
immune  IgG  (10μg/ml each). In comparison with the low concentration treatment, the effect 
of   10μg/ml   anti-Strap IgG was found to promote a significant increase in oocyte median 
diameter at 4 days, relative to control and non-immune IgG groups (P<0.05 each). Furthermore, 
after 7 days of treatment, this effect became more significant (P<0.001 vs control and P<0.01 
vs 10µg/ml non-immune IgG). 
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When only growing oocytes were considered, the median size of measured oocytes from the 
10µg/ml anti-Strap group was greater than control and non-immune  IgG  at  4  days  (33.68μm,  
31.07μm  and  31.13μm,  respectively;;  both  P<0.05).  The  effect  of  10µg/ml  anti-Strap treatment 
on the median size of growing oocytes further increased after 7 days of exposure relative to 
control and 10µg/ml non-immune  IgG  (34.51µm,  31.36μm  and  31.35μm,  respectively;;  P<0.01  
vs control and P<0.001 vs non-immune IgG) (Figure 4.17). 
 
Figure 4.17. Effect  of  10μg/ml  anti-Strap IgG treatment on oocyte growth. Day 4 ovary fragments were 
maintained  for  7  days  in  10μg/ml  anti-Strap  IgG  or  10μg/ml  non-immune IgG (10µg/ml IgG) or no IgG 
(Control). Cultured fragments were imaged after 4 and 7 days exposure to different treatments. All 
measured oocyte (non-growing,   transitional  and  growing)  or  only  growing  oocytes   (>25.7μm)  were  
plotted. Variation in the median oocyte diameter between groups at both time points was evaluated 
using a Kruskal-Wallis  and  Dunn’s  multiple  comparisons  test. *P<0.05, **P<0.01, ***P<0.001. 
When the proportion of oocytes in each category (non-growing, transitional, growing) was 
considered by treatment, there was a reduced proportion of non-growing oocytes in the group 
treated with 10µg/ml anti-Strap relative to the control and non-immune IgG groups at 4 days 
(28.15%, 33.88% and 33.33%, respectively; both P<0.001). Although there were no differences 
in the relative proportions of transitional oocytes, the percentage of growing oocytes was 
significantly increased in 10µg/ml anti-Strap group relative to the control and non-immune IgG 
groups (45.55%, 39.67% and 38.04%, respectively; both P<0.001). These effects of 10µg/ml 
IgG at 4 days were still evident at 7 days (Figure 4.18). 
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Figure 4.18.  Effect  of  10μg/ml  anti-Strap IgG treatment on oocyte growth in ovary fragment cultures. 
Graphs show the proportion of oocytes treated with 10µg/ml anti-Strap, 10µg/ml non-immune IgG or 
control after 4 days or 7 days exposure. Data are presented as mean proportions of oocytes in each stage 
from three culture plates (n=3). Data were evaluated using ANOVA with a post-hoc Bonferroni multiple 
comparisons test. ***P<0.001.  
Similar to observations with 1µg/ml anti-Strap, Amh staining was more detectable in the 
10µg/ml anti-Strap treated group than both control groups, again, consistent with an increase 
in the proportion of growing follicles with anti-Strap treatment (Figure 4.19). 
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Figure 4.19. Immunofluorescent staining of ovary fragments treated with a high concentration 
(10µg/ml) of anti-Strap IgG. At the end of culture, fragments were double stained with Ddx4 (green) 
and  Amh  (red).  GFs:  Growing  follicles,  PFs:  primordial  follicles.  Scale  bar=  100μm. 
4.4.3. Effect of Strap supplementation on early follicle development 
4.4.3.1. Ovary fragments model 
The ovary fragments (d4) model was also utilised to identify the effect of rhStrap protein 
supplementation on primordial follicle growth. In addition to control untreated group, the 
experiment was designed to culture fragments in 100ng/ml or 200ng/ml rhStrap. After 4 days 
exposure to rhStrap, there was no difference in the median oocyte diameter of ovaries treated 
with 100ng/ml rhStrap (23.09µm); however, there was a small, but significant increase in 
median oocyte diameter in the group treated with 200ng/ml rhStrap compared with control 
(23.74µm   and   22.76μm,   respectively;;   P<0.05).   This   effect   was   also   evident   after   7   days  
(P<0.05). When only growing oocytes were considered, there was a significant increase in the 
median follicle diameter of ovaries treated with 200ng/ml rhStrap vs control after 4 days 
(33.58μm  and  30.79μm,  respectively;;  P<0.01). 
105 
 
Both 100ng/ml and 200ng/ml rhStrap caused an increase in the median diameter of growing 
oocytes after 7 days vs control group (34.17μm;;  P<0.05 and 34.56μm;;  P<0.01 vs 31.9μm  in  
control group, respectively) (Figure 4.20). 
 
Figure 4.20. Effect of rhStrap on cultured ovary fragments. Day 4 ovary fragments were maintained 
for 7 days in culture either without treatment (control), 100ng/ml or 200ng/ml rhStrap. Cultured 
fragments were imaged after 4 and 7 days exposure to different treatments. All measured oocytes (non-
growing,  transitional  and  growing)  or  only  growing  oocytes  (>25.7μm)  were  plotted.  Variation  in  the  
median oocyte diameter between groups was evaluated using a Kruskal-Wallis  and  Dunn’s  multiple  
comparisons test. *P<0.05, **P<0.01. 
Interestingly, unlike results of Strap siRNA and protein inhibition, there was no statistical 
difference in the proportion of non-growing follicles between treatments at both 4 and 7 days. 
There was also no differences in the proportions of transitional or growing oocytes (relative to 
control) in groups exposed to 100ng/ml rhStrap after 4 or 7 days. However, ovary fragments 
treated by 200ng/ml rhStrap exhibited a reduction in the percentage of transitional oocytes at 
4 days (32.8% and 37.8%, respectively; P<0.01 vs control), with a corresponding increase in 
the proportion of growing oocytes (37.4% and 32.1%, respectively; P<0.01 vs control).  
After 7 days, a similar reduction in the proportion of transitional oocytes was found in the 
200ng/ml rhStrap treated group vs control (30.1% and 34.5%, respectively; P<0.05) or 
100ng/ml group (36.2%, P<0.01). However, there was a significant increase in the proportion 
of growing oocytes in the 200ng/ml group, relative to the 100ng/ml group (45.5% and 41.7%, 
respectively; P<0.05) (Figure 4.21).  
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Figure 4.21. Effect of rhStrap treatment on oocyte growth in the ovary fragments culture model. Graphs 
show the proportion of oocytes in untreated (control), 100ng/ml rhStrap or 200ng/ml rhStrap groups 
after 4 days or 7 days exposure. Data are presented as mean proportions of oocytes in each stage from 
three culture plates (n=3). Data were evaluated using ANOVA with a post-hoc Bonferroni multiple 
comparisons test. *P<0.05, **P<0.01. 
Localisation of Amh and Ddx4 in cultured fragments revealed that both rhStrap treated groups 
included many large growing follicles with relatively more Amh- positive granulosa cells than 
in control group. Even though, Ddx4 staining revealed the presence of high proportion of non-
growing follicles (primordial) in both treated groups (Figure 4.22). 
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Figure 4.22. Immunofluorescent staining of ovary fragments treated by rhStrap. After 96 hours of 
culture, ovary fragments were double stained with Ddx4 (green) and Amh (red). GFs: Growing follicles, 
PFs:  primordial  follicles.  Scale  bar=  100μm. 
4.4.3.2. Preantral follicle model 
Preantral follicles were isolated from d16 ovaries and utilised to evaluate the effect of 
recombinant human Strap protein (rhStrap) supplementation on follicle growth. Follicles were 
cultured for 72 hours in the absence or presence of 200ng/ml rhStrap (54 follicles each). Follicle 
diameters were measured at four-time points (0h, 24h, 48h, and 72h). Some follicles in control 
and in rhStrap group were excluded from measurements (6 and 10 follicles, respectively) due 
to morphological changes consistent with degeneration. 
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In both groups, follicle growth was evaluated by calculating the difference in follicle diameter 
at each time point relative to the culture starting time point (0h). Thus, the rate of growth for 
each group was compared. By comparison with untreated follicles, incubation in the presence 
of 200ng/ml rhStrap caused a significant increase in the mean difference in follicle diameter at 
48h (9.2 vs 16.3µm ±95% CI, confidence interval), control and Strap groups, respectively; 
P<0.01) and 72h (16.8 vs 26.7µm ±95% CI), control and Strap groups, respectively; P<0.001) 
(Figure 4.23). 
 
Figure 4.23.  Effect of rhStrap treatment on preantral follicle growth in vitro. Isolated preantral follicles 
were cultured for 72h either without treatment (Control n=48 follicles) or with adding 200ng/ml rhStrap 
(n=44 follicles) to the culture. Follicle diameters were measured every 24h and growth was calculated 
as the difference in diameter relative to 0h and presented as mean ± SEM at each time point. Data were 
analysed by a two-way  ANOVA  with  Bonferroni’s  multiple  comparisons  test.  **P<0.01,  ***P<0.001  
comparing control vs rhStrap group at 48h and 72h, respectively. Microscope images show examples 
of cultured preantral follicles from the control group (A) and rhStrap treated group (B). Scale bar= 
100μm. 
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4.5. Discussion 
The molecular mechanisms involved in the initial activation and growth regulation of the small 
gonadotrophin-independent follicles are poorly understood. Many studies have been indicated 
the   essential   role   of   canonical   TGFβ   signalling   pathway   (TGFβ/Smad signalling) as 
intraovarian regulators of follicle development (Li et al., 2008b; Pangas, 2012; Tian et al., 
2010).  As  TGFβ  signalling  regulates  a  wide  range  of  cellular  activities  including  proliferation,  
differentiation, migration, and degeneration (Rahimi and Leof, 2007), dysregulation of 
signalling results in several reproductive disorders, such as polycystic ovary, early ovarian 
failure and development of tumours (Hatzirodos et al., 2011; Li, 2015; Pangas et al., 2008).  
In other tissues, many Smad inhibitors have been identified to control both duration and 
strength of signalling (Inoue and Imamura, 2008; Lonn et al., 2009) by various mechanisms 
including dephosphorisation, ubiquitination and transcriptional co-repressors (Dai et al., 2011; 
Deheuninck and Luo, 2009; Elliott and Blobe, 2005). Strap is one of these factors that has 
potential   to   prevent   Smad2/3   phosphorylation   by   the   activated  TGFβRI   (Datta and Moses, 
2000). Previous studies have investigated the impact of Strap in tumourigenesis (Halder et al., 
2006; Reiner and Datta, 2011); however, nothing is known about the functional role of Strap 
in follicle development. In the previous chapter, Strap mRNA was detected and its protein was 
co-localised with Smad2/3 in immature mouse ovaries at different ages; which are densely 
populated with small (gonadotrophin-independent) follicles. Thus, it was hypothesised that 
Strap might have a biological role in early follicle growth.  
In previous studies, ex vivo mouse models have been developed to assess the impact of TGFβ 
signalling on follicle development (Fenwick et al., 2013; Wang et al., 2014). The present study 
was designed to determine the effect of modified Strap expression or activity on follicle growth 
using two different culture models including preantral follicle and d4 ovary fragments culture 
models. Small interfering RNA (siRNA) and immunoneutralisation by specific antibodies were 
used for Strap mRNA and protein inhibition, respectively; while supplementation of rhStrap 
protein was used to enhance the biological function of Strap in both culture model. Intriguingly, 
this model was amenable to various treatments including siRNA, as well as other 
macromolecules introduced to the culture media, such as recombinant protein and antibodies.  
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4.5.1. Ovary fragments culture model 
In this model, d4 ovaries, enriched with small non-growing follicles, were sectioned into 6-8 
equal sized pieces and utilised to assess the effect of Strap siRNA, neutralisation by antibody 
or protein supplementation on primordial follicle development. Even though this model causes 
loss of the normal physical architecture of the ovary, it still supports the developmental process 
and interaction of follicles in the presence of stromal cells. For instance, different stages of 
follicle growth were identified in cultured fragments and the immunofluorescent staining 
revealed specific localisation of Amh protein in granulosa cells of growing follicles. Unlike 
whole ovary culture (Eppig and O'Brien, 1996; Wang et al., 2014), this culture model 
overcomes several disadvantages of using whole ovaries; for instance, it makes it easier to track 
and visualise follicle growth under the microscope in real time, and, as cultured fragments 
flatten out, thus provides more space for follicles to grow.  
Intriguingly, this model was amenable to various treatments including siRNA, as well as other 
macromolecules introduced to the culture media, such as recombinant protein and antibodies. 
The mechanism that allows the entry of these substances into the cells to interact with target 
proteins is not clear but may involve non-specific receptor-independent endocytotic processes, 
such as clathrin-independent endocytosis or micropinocytosis (Maldonado-Baez et al., 2013; 
Mayor et al., 2014). In addition, fragmentation of the ovary into small pieces provides more 
accessible surface of the culture media to the ovary tissues. Regardless of the mechanism 
involved, we observed clear dose-dependent effects of these macromolecules on oocyte growth 
in this system. Since these outcomes were evaluated in relation to controls indicates that the 
observed differences were specific to the macromolecule introduced to the system, and may, 
therefore, be an invaluable model for testing the effects other exogenous compounds on early 
follicle development in vitro. 
Consequently, images of cultured fragments can be utilised to identify the effect of treatments 
by measurement of oocyte diameters and cells can be labelled and visualised in context, e.g. 
for Amh or Ddx4. A comparable culture model was previously utilised to evaluate the effects 
of chemotherapeutic treatments on primordial follicles (Maiani et al., 2012). In the study 
presented here, the effects of all treatments on follicle growth were evaluated by measurements 
of oocyte diameters. To make these in vitro measurements comparable to in vivo growth, a 
novel system of oocyte classification was determined to categorise oocyte growth according to 
their size, where oocytes were classified as non-growing   (<18.3μm),   transitional   (18.3μm-
25.7μm)   and   growing   (>25.7μm)   based   on   morphological   characteristics   ascertained   from  
microscopic sections. Thus, this model was found to be valid and appropriate to study the effect 
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of various treatments on early follicle development by providing quantitative data for analysis 
alongside protein staining.   
4.5.2. Effect of Strap downregulation and neutralisation on primordial and preantral 
follicle growth 
The functional impact of Strap on the development of mouse embryos was previously 
investigated, where deletion of Strap caused prenatal mortality (E10.5-E12.5) due to major 
congenital abnormalities including defects of the cardiovascular, neural and musculoskeletal 
system (Chen et al., 2004). Thus, in the present investigation, an ovary fragments culture model 
was used to assess the impact of Strap knockdown on the developmental process of small non-
growing follicles (primordial follicles) in vitro. At the end of treatment (96 hours), the median 
oocyte diameters in the Strap siRNA treated group were significantly higher than in control 
groups. Furthermore, exposure to Strap siRNA caused a significant decline in the proportion 
of the non-growing oocytes accompanied with an increase in the proportion of growing oocytes 
relative to control.  
In Strap siRNA treatment group, the increased proportion of growing oocytes was 
accompanied with immunofluorescent staining of many Amh-positive granulosa cells. Similar 
results  were  obtained  by  inhibition  of  Strap  protein  bioactivity  using  1  or  10μg/ml  anti-Strap 
IgG, where the higher concentration was more effective. These results suggest that Strap is 
involved in keeping primordial follicles in a quiescent state. The increase in the median follicle 
diameters in the treated groups (Strap siRNA or Anti-Strap IgG) relative to controls indicates 
that follicles in these groups were activated to grow earlier than in controls. The role of 
Smad2/3 proteins in small follicles is not clearly understood, but it is assumed that the loss of 
Strap leads to increased TGFβ  signalling. In the present study, it is somewhat surprising that 
promoting  of  TGFβ  signalling (by inhibition of Strap mRNA or protein bioactivity) results in 
enhanced follicle growth. Previous studies have demonstrated a growth suppressing effect of 
TGFβ  signalling  on  follicle  development (Ding et al., 2010) and tumour progression (Singha 
et al., 2014). However, the enhanced Smad2/3 pathway (by inhibition of Strap mRNA or 
protein) might consequently be an essential prerequisite for follicles to initiate growth.  
An in vitro study indicated that deletion of both Smad2/3 caused a significant decrease in the 
reproductive efficiency manifested by the failure of the small follicle to grow, ovulation, and 
improper expansion of cumulus cells (Li et al., 2008b). In addition, in mice at 3 months of age, 
deletion of exon 8 of Smad3 have significantly more non-growing follicles and fewer growing 
follicles than wild-type mice (Tomic et al., 2004).  
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These results suggest that adequate Smad3 expression is important for follicle activation. Strap 
siRNA was also utilised to assess the impact of Strap mRNA downregulation on cultured 
preantral follicle growth. After three days of exposure, the expression of Strap mRNA in the 
treated group was significantly reduced relative to the non-targeting siRNA, however, the 
reduction was not statistically different relative to control (Figure 4.12). After three days in 
culture, there was no significant difference in follicle size between Strap siRNA group and 
controls. However, at the first 24h exposure, the mean follicle diameter was significantly 
greater in control and non-targeting siRNA groups relative to the starting point at 0h, but not 
in the Strap siRNA group. This observation might reflect the short half-life of Strap siRNA, as 
fluorescent microscopy (Figure 4.11) of green non-targeting siRNA treated follicles revealed 
a decreased fluorescent signal in follicles with time, where the strongest intensity was at 24h 
of culture. In addition, it might explain the absence of significant difference in Strap transcript 
levels revealed by qPCR between the control and Strap knockdown groups.  
The difference in follicle size during the first 24h between groups might cause a prolonged 
TGFβ1-3/Smad2/3 signalling, which has an anti-proliferative impact on cells (Brown et al., 
2007). In addition, it might attributes to other biological roles of Strap in cells, as other studies 
indicated that Strap can regulate a wide range of signalling pathways (Halder et al., 2006; 
Seong et al., 2005). 
4.5.3. Effect of Strap protein on primordial and preantral follicle growth 
In contrast to Strap siRNA and protein neutralisation, incubation of ovary fragments in media 
supplemented with exogenous Strap protein (rhStrap) (100 or 200ng/ml) revealed no effect on 
the proportion of small non- growing oocytes relative to controls. However, a significant 
increase in the proportions of transitional and growing oocytes was evident in both treated 
groups relative to control. After 7 days of rhStrap exposure, a significant increase in the median 
diameter of growing oocytes was determined relative to control. These observations might 
indicate the essential impact of Strap on the growth of the small growing follicle. In addition, 
immunofluorescent staining revealed more Amh staining with the increased concentration of 
rhStrap, suggesting more growing follicle are present; although many non-growing oocytes 
were stained with Ddx4 in both rhStrap treated groups.  
  
113 
 
The overall effect of rhStrap on increased follicle size may associate with activation of 
pathways that can promote cell proliferation such as non-Smad pathway. For instance, in 
addition to the role of Strap as anti-apoptotic function (Jung et al., 2010), several reports have 
shown that the presence of Strap can activate the cell proliferative enhancing signals such as 
ERK/MAPK (Halder et al., 2006), and PDK1 (Seong et al., 2005) (Figure 4.24). In the ovary, 
it was indicated that activation of such non-canonical pathways can lead to the early depletion 
of the primordial follicles reserve due to an enhanced primordial follicle activation and follicle 
growth (John et al., 2008; Reddy et al., 2009; Reddy et al., 2008; Zheng et al., 2012). 
In ovary fragments culture, treatment with 200ng/ml rhStrap exhibited more impact on follicle 
growth than 100ng/ml rhStrap, thus a higher concentration of Strap protein was used to assess 
its influence in preantral follicle growth. Treated preantral follicles demonstrated a significant 
increase in size after 48h and 72h of exposure relative to the untreated group. A possible 
explanation for this effect might relate to the fact that Strap has the potential to control an 
extensive range of biological activities and intracellular signalling pathways, other than the 
canonical TGFβ (Reiner and Datta, 2011). For instance, upregulation of Strap has been linked 
to prompt tumour progression results in the activation of extracellular signal-regulated kinase 
(ERK) in different cell lines, inhibition of cell cycle suppressor proteins (p21Cip1) (Halder et 
al., 2006). Moreover, Strap can activate 3-phosphoinositide-dependent protein kinase 1 
(PDK1), which is responsible for various cellular activities including proliferation, migration, 
metastasis of a tumour and antagonising of the apoptotic processes induced by tumour necrosis 
factors-alpha TNF-α   (Seong et al., 2005). Furthermore,   in   the   absence  of  TGFβ   signalling,  
upregulation of Strap enhances the association of PDK1 with R-Smads, Smad4 and Smad7 
proteins (Seong et al., 2007).  Thus,  Strap  has  the  potential   to  regulate  TGFβ  signalling and 
consequently cellular growth by switching off the proliferative suppressor pathway (Smad 
pathway) and activate the proliferative pathway (non-Smad pathway) (Fleming et al., 2009; 
Halder et al., 2006).  
The non-Smad pathway has been identified as a part of the complex system that regulating 
early follicle growth (Reddy et al., 2008; Zheng et al., 2012). Thus, the increased size of 
cultured preantral follicle might be accounted for the effect of rhStrap by activation of cell 
proliferative pathways. In addition, analysed data from qPCR (Figure 3.7) and protein 
localisation (Figures 3.11) revealed that expression of Smad2/3 was reduced in the growing 
preantral follicles, suggesting that reduction in Smad2/3 expression is essential to promote the 
growth of the preantral follicle.  
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Figure 4.24. Functional role of Strap in the regulation of cell growth. Strap inhibits the anti-proliferative 
Smad2/3   pathway   by   recruiting   and   stabilising   Smad7   to   the   activated   TGFβ   receptors   to   prevent  
phosphorylation of Smad2/3. In addition, Strap blocks the nuclear translocation of the heteromeric 
complex by interaction with the activated R-Smad and Smad4. Conversely, Strap can promote cellular 
growth by activating the proliferative Smad-independent pathways accompanied with inhibition p21Cip 
resulting in progression in the cell cycle. Strap can also prevent cell apoptosis by inhibition of TNF-α  
(Seong et al., 2005). Thus, generally, Strap functions to enhance both cellular growth and survival by 
activation of the Smad-independent pathway and overcomes the growth suppression impact of the 
Smad-dependent pathway by inhibition of Smad2/3 and by blocking the nuclear translocation of 
activated heteromeric complex. 
Even though the ovary fragment culture was useful in these experiments, some drawbacks were 
apparent. For example, dissection of ovaries into many small pieces makes them unsuitable for 
imaging during the first 3 days until they have spread on the base of the well. Therefore, 
treatments should be applied after this times period; however, many of the oocytes would have 
already begun to grow so many primordial oocytes/follicles will be missed. In addition, if 
fragments are too large, it will limit the amount of microscope light to pass through the tissue, 
which consequently affects follicle counting/ measurements and resolution of immuno-staining 
will be difficult. Although the Amh staining was a valuable protocol to visualise the growing 
follicles in cultured fragments, it would be preferable to also quantify Amh and other genes that 
associated with follicle growth, such as Fshr, Cyp17a or Cyp19a. Moreover, it is not 
recommended to extend the culture of ovary fragments beyond 10 days, or more, as tissues will 
flatten too much and lose the relationships important with the 3-D architecture.  
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In conclusion, this is the first study that evaluated the effect of different Strap treatments on 
primordial and preantral follicle development. Strap is capable of regulating follicle 
development in a growth stage-specific manner demonstrated by a reduction in the number of 
activated primordial follicle and promote preantral follicle growth; however, it is proposed that 
the actions of Strap depends on the stage-specific expression of Smad2/3 and might be relevant 
with non-Smad pathway (Figure 4.25). 
 
Figure 4.25. Effect of Strap modulation on follicle growth. Granulosa cells of small single-layered 
follicles, which are relatively slow growing, express Smad2/3. Inhibition of Strap expression or 
neutralisation of its relative protein caused a reduction in the population of non-growing follicles, which 
might attribute to  the  prolonged  TGFβ  signalling and promote the transition of growth through the early 
follicle stages. However, supplementation of Strap can drive the non-Smad pathways such as PI3K and 
MAPK to promote cell proliferation and follicle growth. Further follicle growth is associated with a 
reduction in Smad2/3, which may be facilitated by the ascribed role of Strap in inhibiting TGFβ 
signalling.  
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Chapter 5 
Identification and regulation of transmembrane prostate 
androgen-induced RNA (TMEPAI) in the mouse ovary 
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5.1. Introduction 
In the ovary, the state of follicle dormancy and early follicle development are controlled by 
complex interactions of  locally  secreted  factors,  such  as  the  TGFβ  superfamily,  which  acts  to  
either suppress or activate follicle growth (Kim, 2012).  The  TGFβ  ligands  exert their effects 
through the activation of particular serine/threonine kinase receptors, which eventually activate 
the R-Smads (Moustakas and Heldin, 2009). After translocation into the nucleus, the biological 
effects  of  TGFβ/Smad  signalling  modulate  the  transcription  of  target  genes  (ten Dijke et al., 
2000).  TGFβ  signalling  can  regulate  gene  transcription  in  two  ways  including  the  canonical 
Smad pathway and non-Smad pathways, such as MAPK, PI3K/AKT, Rho (Derynck and 
Zhang, 2003; Mu et al., 2012).  In  addition,  the  duration  and  strength  of  TGFβ  signalling  can 
be modified through a self-regulating mechanism; for example, the expression of Smad 
inhibitors  can  be  induced  by  increased  TGFβ  signalling  (Quezada et al., 2012; ten Dijke and 
Hill, 2004). 
In prostate cells, Transmembrane prostate androgen induced RNA (Tmepai), also termed 
Pmepa1 (prostate transmembrane protein androgen induced 1) is modulated by androgens in a 
duration and dose-specific manner (Xu et al., 2000). Tmepai also has a negative impact on the 
growth of these cells, and the expression of Tmepai is regulated by androgens through a 
negative feedback mechanism (Xu et al., 2003). Overexpression of Tmepai through androgen 
signalling causes inhibition of androgen receptors by stimulation of Nedd4, which promotes 
ubiquitination and proteasome degradation of the androgen receptors (Li et al., 2008a). More 
recently, other studies have shown that Tmepai expression is not only induced by androgens, 
but  also  by  TGFβ/Smad signalling (Singha et al., 2014; Watanabe et al., 2010), as well as other 
signalling pathways, such as p53, Wnt, and EGF (Anazawa et al., 2004; Itoh et al., 2003). 
Tmepai is also overexpressed in tissues affected by various kinds of cancer; for instance lung, 
breast, colon, pancreas, prostate cancer, and renal cell carcinomas (Brunschwig et al., 2003; Li 
et al., 2008a; Rae et al., 2001; Singha et al., 2014; Vo Nguyen et al., 2014). The overexpression 
of Tmepai is associated with the advanced stages of tumour progression, suggesting that 
Tmepai enhances or permits proliferation of tumorigenic cells (Vo Nguyen et al., 2014). 
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Interestingly, Tmepai inhibits the  TGFβ/Smad  signalling  pathway  through  a  negative  feedback  
mechanism,  where   some  of   the  TGFβ   ligands   (including  TGFβ1-3 and Activin) induce the 
expression of Tmepai. Tmepai then inhibits TGFβ   signalling   by   competing  with   the  Smad 
anchor of receptor activation (SARA) for interaction with both Smad2 and Smad3 preventing 
Smad   phosphorylation   via   the   activated   TGFβ   receptor   complex   (TGFβRI   and   TGFβRII)  
(Azami et al., 2015; Watanabe et al., 2010). In addition, Tmepai can block TGFβ  signalling  by  
interacting  with  the  activated  TGFβRI  to  enhance  the  lysosomal  degradation  of  the  receptor  
(Bai et al., 2014). Another study found that Tmepai also inhibits the Smad3/4–c-Myc–p21-
signalling pathway leading to an enhanced proliferation of prostate cell tumours (Liu et al., 
2011). 
In contrast to the inhibitory impact on Smad signalling, Tmepai can activate PI3K/AKT 
signalling, which is regulated by PTEN. For example, in human breast cancer cells, Tmepai 
has the potential to block PTEN leading to increased phosphorylation of PI3K/AKT and 
cellular proliferation, growth and migration (Singha et al., 2014; Xie et al., 2016). Furthermore, 
deletion of Tmepai in breast cancer cells caused elevated expression of PTEN protein 
accompanied with a reduction in AKT phosphorylation. Conversely, increased Tmepai 
expression  by  TGFβ  treatment in cancer cells leads to decreased PTEN expression and AKT 
activation (Singha et al., 2014) (Figure 5.1). 
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Figure 5.1. Schematic  model   illustrating   the   role   of   Tmepai   in   regulating   TGFβ   signalling. TGFβ  
signalling  is  initiated  by  the  interaction  of  activated  TGFβ  ligand  with  TGFβ  I/II  receptors  followed  by  
the recruitment of Smad2 and Smad3, which is directed by the cytoplasmic protein SARA to the 
phosphorylated type I receptor for activation. After activation, Smad2/3 forms a complex with Smad4 
to enable their translocation into the nucleus to regulate the transcription of target genes (1). Increased 
TGFβ   signalling   causes   upregulation   of   Tmepai   expression   (2).   At   this   point,   Tmepai   negatively  
regulates   the   duration   and   intensity   of  TGFβ/Smad   pathway   in   two  ways;;   firstly,   it   competes  with  
SARA for association with Smad2 and Smad3 to prevent their activation. Secondly, Tmepai can block 
the nuclear translocation of the phosphorylated Smad2 and Smad3 (3). Tmepai also causes degradation 
of PTEN (4), a PI3K/AKT inhibitor, leading to the activation of non-Smad pathways (5) which function 
to induce cellular proliferation (6). Adapted from (Singha et al., 2014; Watanabe et al., 2010). 
In the ovary, expression, regulation and the impact of Tmepai on follicle development has not 
yet been investigated. Considering the loss of nuclear Smad2/3 with the onset of follicle 
growth, it is hypothesised that Tmepai may also be detectable in small follicles to account for 
this change in Smad expression. Furthermore, given that in other cell types, the  TGFβ/Smad  
signalling pathway can regulate Tmepai expression, it is proposed that the expression of this 
gene is under the control  of  relevant  TGFβ  members  in  small  follicles.   
The objectives of this chapter are to determine the expression of Tmepai mRNA and protein 
during early follicle development. Then, to evaluate the influence of enhanced TGFβ signalling 
(by GDF9 supplementation) and receptor inhibition (by SD208) on both the regulation of 
Tmepai expression and preantral follicle growth.  
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5.2. Materials and methods: 
5.2.1. Animals and tissues 
Ovaries were dissected from mice of different ages (d4, 8, 16 and adults) as described in 2.1. 
Ovaries were used for both mRNA and protein expression. In addition, preantral follicles were 
isolated from d16 ovaries, where similar procedures and materials specified in section 2.2.2 
were used for preantral follicle isolation, selection and culture. 
 5.2.2. Immunohistochemistry  
Ovary sections (5µm) from d4, d8, d16 and adult were prepared (section 2.9.1) for 
colocalisation of Tmepai and Smad2/3 proteins. Goat anti-Tmepai   (1μg/ml,  Santa  Cruz- sc-
85829) and Mouse anti-Smad2/3  (0.25μg/ml, Santa Cruz sc-133098) were used for staining 
according to the protocol described in section 2.9.3. For negative controls, equivalent quantities 
of non-immune Goat and Mouse IgG (Vector) were utilised to determine non-specific staining 
in ovary sections. Sections were incubated in a mixture of secondary antibodies including 
Alexa Fluor 488 Donkey anti-Goat IgG (1:400µl, Molecular probes, A11055) and Alexa Fluor 
555 Donkey anti-Mouse IgG (1:400µl, Molecular probes, A31570). Stained tissues (three 
experiments from three different ovaries) were imaged by a Leica inverted SP5 confocal laser 
scanning microscope (Leica Microsystems, Wetzlar, Germany). 
5.2.3. Preantral follicle culture 
Preantral follicle cultures were utilised to identify  the  effect  of  a  TGFβ  ligand  (recombinant 
mouse Gdf9, rmGdf9), an Alk5 inhibitor (SD208) or a combination of both treatments on 
Tmepai expression and follicle growth. This culture model was selected over the ovary 
fragment model, as both Tmepai quantification and protein staining were higher in the d16 
ovary contained many small growing follicles. GDF9  was  selected  among  other  TGFβ  ligands  
as it is highly expressed in preantral follicles in the ovary, is known to signal through the 
TGFβR1 (ALK5 receptor), and is mediated by the Smad2/3 pathway (Shi and Massague, 
2003).   SD208   is   an   inhibitor   of   the   TGFβRI   kinase   receptor   and   acts   by   preventing  
phosphorylation of Smad2/3 (Uhl et al., 2004). Follicles from each single ovary were cultured 
in wells of four lines (5 follicles per line) of different treatments. The culture media consisted 
of MEM-α   media with supplements (see section 2.2.2). Each single line represents an 
individual treatment group of (i) untreated control, (ii) 1µM SD208 (Sigma; S7071-5MG) 
(Wang et al., 2014) (iii) 250ng/ml rmGdf9 (R&D systems; 739-G9) (Fenwick et al., 2013) and 
a combination of 1µM SD208 with 250ng/ml rmGdf9 (Figure 5.2). 
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Dimethyl Sulfoxide (DMSO; Sigma- 472301) was used as a solvent for SD208, thus equivalent 
volumes of DMSO were added to the control and rmGdf9 treatment groups. All plates (11 in 
total) were cultured at 37°C in the presence of 5% CO2. 
 
Figure 5.2. The layout of cultured preantral follicles. Eleven plates were prepared, follicles from a 
single ovary were utilised for each individual plate. Follicles were cultured in four rows where each 
row consists of five follicles. For RNA extraction, follicles of each particular treatment were collected 
and were transferred into a single Eppendorf tube.  
Total RNA was extracted from cultured preantral follicles after 24h (n= 5 plates) as described 
in 5.2.2. The remaining six plates were cultured for a total of 72 hours to identify the effect of 
treatments on follicle growth. Half of the culture media was refreshed after 48 hours of 
incubation. Follicles were imaged at 0, 24, 48 and 72 hours using light microscopy (Olympus 
CKX41 with a Nikon camera DS-Fi1). Images were utilised for the measurement of follicle 
diameters by ImageJ software as described in 2.10.1. At the end of culture (72 hours), follicles 
were collected, fixed in 10% neutral buffered formalin (Sigma), embedded, sectioned and 
counterstained with DAPI. 
5.2.4. RNA extraction, RT-PCR and qPCR  
cDNA of d4, d8, d16 and adult ovaries (n=5 per age group) were prepared (RNA 25ng/µl) and 
used for gene expression by RT-PCR and qPCR as previously described (2.6 and 2.8, 
respectively). Total RNA was also extracted from cultured preantral follicles after 24 hours of 
incubation (n=5 plates), using Qiagen RNeasy Micro Kits (section 2.3). Five cultured follicles 
from each treatment line were individually pooled and snap frozen in liquid nitrogen and stored 
at -80ºC.  
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After extraction, RNA samples were evaluated for integrity and concentration using Agilent 
2100 Bioanalyser (Appendix XII). An equivalent concentration of RNA from each sample 
(12.5ng/µl) was reverse transcribed into cDNA (section 2.4) and tested by RT-PCR for the 
expression of Gdf9 as an oocyte-specific internal control. Primers used in PCR reactions, 
including sequences, annealing temperatures and product sizes for Tmepai, Gdf9, Strap and 
Smad3 are provided in Table 5.1. 
Table 5.1. Oligonucleotide primer sequences used for gene quantification by qPCR. 
Gene Primer  sequences  (5’  →3’) Annealing Temperature 
Product 
size 
(bp) 
Tmepai F: CTTGTCAAAGGCAGGGTGTC R: CTTTCCAACCAGCCACTTCC 59.0 165 
Gdf9 F: TCACCTCTACAATACCGTCCGG R: AGCAAGTGTTCCATGGCAGTC 59.0 139 
Strap F: GGCTACTTTCTGATCAGCGC R:  CTGAGACCGCATCCCATACT 59.0 187 
Smad3 F: GTCAAAGAACACCGATTCCA R: TCAAGCCACCAGAACAGAAG 58.5 154 
 
Samples were then utilised for quantification of Tmepai, Smad3 and Strap by qPCR (section 
2.8). Tmepai was considered for expression as it is a specific inhibitor of Smad2/3 (Singha et 
al., 2014) and it has not been expressed in the ovary, yet. As Strap has been identified as a 
Smad2/3 inhibitor and was the focus of the previous chapter, it was also assayed to identify 
whether  its  expression  is  related  to  TGFβ  signalling  in  this  model. Data from qPCR (ovary and 
follicle samples) were analysed as fold changes relative to a housekeeping gene (Atp5b) using 
the equation 2-ΔΔCT method (Livak and Schmittgen, 2001). 
5.2.5. Statistical analysis 
Data (CT values) from qPCR were normalised relative to the expression of the internal 
housekeeping gene (Atp5b). Fold changes relative to control were calculated using the 2-ΔΔCT 
equation method, as described in 2.8. Data were statistically analysed using one-way ANOVA 
with Bonferroni post-hoc test; the differences between groups was considered significant at 
P<0.05. The difference in preantral follicle size between treated groups and control was 
analysed by one-way ANOVA with Bonferroni post-hoc test of the cultured follicle, *P<0.05, 
**P<0.01, ***P<0.001 and ****P<0.001.  
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5.3. Results 
5.3.1. Expression of Tmepai mRNAs in immature and adult ovaries.  
Tmepai mRNA was detected in cDNA from mice ovaries at d4, d8, d16 and adult by RT-PCR, 
stronger bands of expression were detectable in d8 and d16 (Figure 5.3).   
 
Figure 5.3. Expression of Tmepai in ovaries at different ages by RT-PCR. For negative control (-ve), 
RNase/ DNase free water was added rather than cDNA. 
By qPCR analysis, levels of Tmepai mRNA were significantly higher in the d16 ovary, which 
contains a mixture of primordial and growing follicles relative to d4 ovary (P<0.05), which 
contains mostly primordial follicles. However, there was no significant difference in the 
expression levels of Tmepai in d8 or adult ovaries relative to d4. In the same samples, 
expression levels of Smad3 revealed a significant decline in the d16 and adult ovaries relative 
to d4 (P<0.05 and P<0.001, respectively) (Figure 5.4), which is consistent with findings in 
chapter 3. 
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Figure 5.4. Expression levels of Tmepai and Smad3 mRNA in immature and adult ovaries. Data were 
normalised relative to the expression of the internal housekeeping gene, Atp5b, and expressed as fold 
changes relative to d4 ovary. Statistical differences were assessed using one-way ANOVA with 
Bonferroni post-hoc test. Data (n=5) are presented as mean ± SEM. *P<0.05, ****P<0.0001.  
5.3.2. Colocalisation of Tmepai and Smad2/3 proteins  
Immunofluorescent staining was performed to identify the expression pattern of Tmepai 
protein and the relationship with Smad2/3 expression. In the d4 ovary sections, Tmepai protein 
was localised in granulosa cells of numerous growing follicles located in the medulla of the 
ovary. In addition, staining was also observed in some oocytes of primordial follicles located 
in the peripheral region of the ovary, but not in the stroma. Smad2/3 was localised as previously 
described (Figure 3.11) in granulosa cells of primordial and growing follicles (Figure 5.5).  
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Figure 5.5. Colocalisation of Tmepai and Smad2/3 proteins in d4 ovary. Tmepai (green) was detected 
in granulosa cells of growing follicles (GFs) located in the medial aspect of the ovary and in some 
primordial (PFs) located in the cortical area. Smad2/3 proteins (red) were localised with a strong 
staining in primordial and growing follicles. Tmepai and Smad2/3 were co-localised in growing and 
numerous non-growing follicles. The negative control section (-ve) was treated with a mixture of non-
immune Goat and Mouse IgG’s.  Nuclei were counterstained with DAPI  (blue).  Scale  bar  =  75μm. 
High power confocal microscopy of the positively stained growing follicles revealed that 
Tmepai protein expression is more evident in granulosa cells of follicles that have developed a 
complete layer of cuboidal granulosa cells. The intensity of staining was stronger in follicles 
that had begun to develop a second layer of granulosa cells. In single-layered, primary follicles, 
the localisation of Tmepai protein exhibited a high intensity of staining at the internal surface 
of granulosa cells close to the oocyte (Figure 5.6).  
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Figure 5.6. High power image of Tmepai and Smad2/3 in the d4 mouse ovary. Tmepai protein (green) 
was detected with a strong intensity in follicles that had developed a complete layer of cuboidal 
granulosa cells and also those that had started to develop a second layer of granulosa cells. Smad2/3 
was also detected in granulosa cells of these follicles, where this sometimes coincided with the 
exclusion of Smad2/3 (white arrows). Section was counterstained with  DAPI  (blue).  Scale  bar  =  75μm. 
In the d8 ovary section, as more growing follicles in the medulla are evident, the number of 
follicles that expressed Tmepai protein was increased. Similar to d4 staining, many of the 
positively stained follicles were located in the medulla of the ovary. Tmepai-positive follicles 
also exhibited decreased intensity of Smad2/3 staining. In addition, Tmepai-positive primordial 
follicles located at the marginal region of the ovary exhibited strong staining for Smad2/3, but 
a limited number of primordial follicles were positive to Tmepai staining. Similar to the 
observation in d4 ovary, strong staining for Tmepai has detected granulosa cells of follicles 
that had started to develop a second layer (Figures 5.7-8).  
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Figure 5.7. Tmepai and Smad2/3 immunolocalisation in the d8 mouse ovary. Tmepai (white arrows, 
green channel) was detected in granulosa cells of most of the growing follicles situated in the medulla. 
The intensity of Smad2/3 staining (red) in growing follicles was largely reduced relative to their strong 
staining in primordial follicles. Proteins were co-localised (yellow) in growing follicles. Negative 
control (-ve) was treated with a mixture of non-immune Goat and Mouse IgG’s. Nuclei were 
counterstained with DAPI  (blue).  Scale  bar  =  75μm. 
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Figure 5.8. High power confocal image of Tmepai and Smad2/3 in the d8 mouse ovary. Tmepai (green) 
was detected in growing follicles (GFs), with less evident in transitional (TFs) or primordial follicles 
(PFs). Strong staining for Tmepai was observed in granulosa cells that had begun to form a second layer 
(yellow arrows). These cells also exhibited relatively reduced nuclear Smad2/3 staining. Section was 
counterstained with  DAPI  (blue).  Scale  bar  =  75μm. 
The expression pattern of Tmepai was noticeably changed in d16 ovary sections (Figures 5.9-
10) where more follicles are starting to grow and more advanced stages of follicle development 
are apparent than in d4 and d8. Tmepai was precisely localised in granulosa cells of growing 
preantral follicles that contained more than two layers. These positively stained follicles were 
mainly located in the cortical region of the ovary, where also Smad2/3 were localised. In 
addition, the characteristic pattern of Tmepai staining between granulosa cells and oocytes 
observed in younger ages were not seen in the d16 ovary section. Tmepai was not localised in 
larger multi-layered follicles located in the medulla of the ovary.  
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Figure 5.9. Tmepai and Smad2/3 immunolocalisation in the d16 mouse ovary. Tmepai protein was 
localised in preantral follicles located in the cortical region (white arrows, green channel). Tmepai and 
Smad2/3 staining were reduced in larger preantral follicles located in the medulla. Negative control was 
treated with a mixture of non-immune Goat and Mouse IgG’s. Nuclei were counter-stained with DAPI 
(blue).  Scale  bar  =  75μm. 
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Figure 5.10. Confocal image of Tmepai and Smad2/3 in the secondary follicle. Tmepai protein (green) 
was localised in preantral follicles containing more than two layers of granulosa cells (white arrows). 
Smad2/3 staining (red) remained evident in the granulosa cells. Section was counterstained with DAPI. 
Scale  bar  =  75μm. 
In immature ovaries, as the detection of Tmepai and Smad2/3 were reduced in large growing 
follicles, adult ovaries containing larger preantral and antral follicles were also stained to 
confirm this stage-specific expression pattern. Accordingly, Tmepai and Smad2/3 proteins 
were undetectable in the large preantral or antral follicles that developed more than three layers 
of granulosa cells; however, both were positively co-localised in earlier stages of follicle 
growth. (Figures 5.11-12). 
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Figure 5.11. Colocalisation of Tmepai and Smad2/3 proteins in adult ovary. Tmepai (green) and 
Smad2/3 (red) were detectable only in follicles from primary to secondary stages located in both the 
medulla and cortical regions. However, both proteins were undetectable in more advanced stages. 
Negative control (-ve) was treated with a mixture of non-immune Goat and Mouse IgG’s. Nuclei were 
counterstained with DAPI (blue). Scale bar = 75μm.   
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Figure 5.12. High power images of Tmepai and Smad2/3 in adult mouse ovary. Tmepai protein (green) 
was undetectable in small growing follicles (SGFs) consisting of a complete layer of granulosa cells. 
Strong staining was observed in growing follicles (GFs), where it colocalised with Smad2/3 (red). Both 
Tmepai and Smad 2/3 were undetectable in larger growing follicles (LGFs). Section were 
counterstained  with  DAPI  (blue).  Scale  bar  =  75μm. 
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5.3.3. Regulation of Tmepai expression in preantral follicles 
5.3.3.1. Effect of TGFβRI inhibitor and rmGdf9 on growth of preantral follicles 
This   experiment   was   designed   to   determine   whether   modification   of   the   TGFβ   pathway  
through  the  inhibition  of  TGFβRI  receptor  or  by  recombinant  protein  (rmGdf9)  treatment  has  
an impact on preantral follicle growth. Preantral follicles were isolated from d16 mice ovaries 
and  cultured   for  72  hours   in   the  presence  of  SD208   (TGFβRI   inhibitor)   in   the  presence  or  
absence of rmGdf9 or rmGdf9 alone and compared with control. Images of a single cultured 
preantral follicle from each group are shown in Figure 5.13. By comparison with controls, 
cultured preantral follicles treated with rmGdf9 appeared to increase in size throughout the 
duration of culture. By comparison, follicles exposed to SD208 with or without rmGdf9 
appeared to decrease in size with time, accompanied with an acentric location of the oocyte 
and a decrease in the size of the granulosa cell layer relative to untreated follicles, which may 
be indicative of atresia. 
 
Figure 5.13. Representative  images  of  cultured  preantral  follicles  exposed  to  TGFβ  modifiers.  Follicles 
were incubated in either rmGdf9 (250ng/ml), SD208 (1µM), a combination of both, or control. Follicles 
were maintained for 72h in culture and images every 24h. Scale bar =100µm. 
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At the end of culture, some follicles from each group were counterstained with DAPI to show 
the morphology of the follicles. By comparison with control, follicles treated with rmGdf9 
appeared to have more granulosa cell layers. While follicles treated with SD208 with or without 
rmGdf9 exhibited a reduced number of granulosa cell layers. There was no visual effect on 
oocytes size between all groups (Figure 5.14). 
 
Figure 5.14. Effect of SD208 and rmGdf9 treatments on the morphology of cultured preantral follicles. 
Paraffin-embedded sections of cultured follicles were fixed, sectioned and counterstained with DAPI 
(blue).  Scale  bar  =100μm. 
To determine the effect of treatments on follicle growth, diameter measurements were made 
from follicle images at 0h, 24h, 48h and 72h. There was no difference in the mean follicle 
diameters   at   0h   of   culture   between   groups   (control   134.9μm,   rmGdf9   137.1μm, SD208 
138.1μm   and   rmGdf9+SD208   136.1μm).   The  mean   follicle   size   in   the   rmGdf9   group  was  
significantly greater than untreated follicles after 24h, 48h, and 72h of exposure (P<0.05, 
P<0.01, and P<0.0001, respectively). In contrast, treatment with SD208 with and without 
rmGdf9 caused a significant decrease in the mean follicle size after 24h (P<0.05 each) followed 
by further reduction at 48h and 72h of culture relative to the size of untreated follicles 
(P<0.0001 each) (Figure 5.15).  
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Figure 5.15. Effects of SD208 and rmGdf9 on preantral follicle growth. Preantral follicles were isolated 
from d16 ovaries and cultured in 96-well plates for 72 hours. Treatment groups included untreated 
control, rmGdf9, SD208 with or without rmGdf9. Follicles were imaged daily and diameters were 
measured using ImageJ. Exposure to rmGdf9 caused significant increases in the mean follicle size with 
time, while, at the same time points, treatment with SD208 (with or without rmGdf9) caused a decrease 
in mean follicle size relative to control. ANOVA with Bonferroni multiple comparisons test was used 
for statistical analysis. *P<0.05, ** P<0.01, **** P<0.0001 vs control group. Data (n=30 follicles each 
group) are presented as mean ± SEM and grouped by time (upper panel) or treatment (lower panel). 
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5.3.3.2. Gene analysis in cultured preantral follicles 
After  24  hours  of  exposure  in  different  conditions  designed  to  alter  TGFβ  signalling  (Figure  
5.1), follicles (n=5) from five plates were collected and cDNA was prepared and analysed for 
gene expression of Tmepai, Smad3, and Strap by qPCR. Results showed that expression of 
Tmepai transcript was significantly reduced in the SD208 and SD208 with rmGdf9 treated 
groups relative to untreated control (P<0.05 each). In comparison, treatment with rmGdf9 
revealed no significant changes in Tmepai expression relative control group (P=0.7375). 
Similarly, there was no changes in the expression levels of Smad3 or Strap in any treatment 
group relative to control. (Figure 5.16). 
 
Figure 5.16. Effect of SD208 and rmGdf9 on Tmepai, Smad3 and Strap expression in cultured preantral 
follicles by qPCR. Data were normalised relative to the expression of the internal housekeeping gene, 
Atp5b, and expressed as fold changes relative to untreated control. Data are represented as mean ± SEM 
(n=5 samples for each group), *P < 0.05. 
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5.4. Discussion 
In  the  ovary,  dysregulation  of  TGFβ/Smad  signalling  is  associated  with  many  pathological  and  
reproductive disorders such as polycystic ovary, early ovarian failure, cancer, vascular 
disorders, and fibrosis (Hatzirodos et al., 2011; Pangas et al., 2006; Shi and Massague, 2003). 
Thus,  in  responsive  cells  including  the  ovary,  both  duration  and  strength  of  the  TGFβ/Smad  
signalling are regulated by many inhibitory factors (Li, 2015; Moustakas and Heldin, 2009). 
Tmepai is one of these factors that has the potential to inhibit the Smad2/3 pathway in a self-
regulatory   feedback  mechanism,   where   its   expression   is   enhanced   by   some   TGFβ   ligands  
(Azami et al., 2015; Watanabe et al., 2010). In this study, we show that Tmepai is detectable 
in immature and adult mouse ovary in a follicle stage-specific manner and its expression is 
regulated by modifying TGFβ  signalling. 
5.4.1. Expression of Tmepai mRNA/ protein 
Immature mouse ovaries at d4, d8, d16 and from adults were utilised to determine the 
expression of Tmepai mRNA and protein. In d16 ovary samples, consisting of numerous 
growing preantral follicles, Tmepai was significantly increased relative to d4. However, the 
expression level of Smad3 was considerably decreased in the d16 ovary relative to d4. The 
inverse pattern of expression of Tmepai and Smad3 indicates that Tmepai might be associated 
with downregulation of Smad3. Elevated expression of Tmepai in d16 ovaries might be a 
consequence  of  the  active  TGFβ  signalling,  as  the  follicle  growth  at  this  age  is  mainly  regulated  
by gonadotrophin-independent signalling (Edson et al., 2009; Kim, 2012; Orisaka et al., 2009). 
In comparison with d16 ovaries, the decreased level of Tmepai expression in adult ovaries 
might reflect the increased number of advanced preantral/antral follicle stages where the 
growth of these follicles is largely controlled by hormones (Eppig, 2001; Picton et al., 2003). 
In the same ovary ages, immunofluorescent colocalisation of Tmepai and Smad2/3 proteins 
was in agreement with qPCR data. Tmepai protein was localised in a unique expression pattern. 
Specifically, in the d4 ovary, enriched with primordial follicles, only centrally located growing 
follicles expressed Tmepai protein in granulosa cells, while primordial follicles revealed 
positive staining in oocytes. The number of Tmepai positive follicles increased in d8 ovaries, 
reflecting the fact that more growing follicles are present relative to d4. Interestingly, in both 
age groups, positively stained follicles were situated in the medulla region of the ovary, 
whereas, in the d16 ovary, the location of Tmepai positive follicles was inverted, as Tmepai 
and Smad2/3 were co-localised in growing follicles located close to the ovary surface. 
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This might be attributed to the fact that in d4 and d8, all growing follicles are in the medulla, 
whereas in d16 more growing follicles are evident in ovary margin. However, these proteins 
were undetectable in follicles located in the medulla of the d16 ovary, as these follicles were 
developed more than three layers of granulosa cells, where Smad1/5/8 is expected to be active 
(Fenwick et al., 2013). Similarly, in adult ovary section, Tmepai and Smad2/3 were only co-
localised in earlier follicle stages, but not in advanced preantral stages and antral follicles. 
Variation in the location of Tmepai positively stained growing follicles between age groups 
reflect the programmed recruitment of follicles to initiate the growing process.  
In the mouse ovary, a study indicated that follicles in the medulla at the pre-pubertal period 
represent an early wave of follicles activated to grow shortly after birth, the second wave of 
primordial follicles located towards the cortex are activated to grow at the later ages (Mork et 
al., 2012). The expression of Tmepai protein in early growing follicles located in different 
ovarian regions might be associated with the growth of these different waves. In addition, this 
observation supports evidence that Tmepai is a specific inhibitor of Smad2/3, but not 
Smad1/5/8 proteins (Watanabe et al., 2010). Several mechanisms have been suggested for 
inhibition of Smad2/3 pathway by Tmepai; such as, by competing with SARA for association 
with Smad2/3 to prevent their activation by the type I receptor, inhibition of the cytoplasmic-
nuclear translocation of activated Smad2 and Smad3 (Watanabe et al., 2010), and by lysosomal 
degradation  of  TGFβRI  thereby  preventing  Smad2/3  phosphorylation (Bai et al., 2014). In this 
context, the unique expression pattern of Tmepai in early growing follicles might highlight a 
controversial issue whether its expression functions to enhance or inhibit follicle growth. 
Previous  studies  indicated  that  TGFβ/Smad  signalling activates the non-Smad pathway, such 
as PI3K, MAPK, ERK, which function to promote cell proliferation; however, the mechanism 
regulating this process is not clearly defined (Hough et al., 2012; Mu et al., 2012; Xu et al., 
2000). Another study raised a question on how TGFβ  signalling  is  altered  to  promote metastasis 
through the upregulation of Tmepai expression (Watanabe et al., 2010).  
A recent study explained and provided answers for these two questions and indicated that 
upregulation of Tmepai caused inhibition of the Smad2/3 pathway and induces activation of 
the non-Smad pathway, which is responsible for cell proliferation and survival, by inhibition 
of PTEN, an inhibitor of the non-Smad pathway (Singha et al., 2014). In the mouse ovary, 
inhibition of PTEN caused stimulation of the PI3K pathway and premature activation of 
primordial follicles followed by premature ovarian failure (Reddy et al., 2008).  
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Overexpression of Tmepai also inhibits apoptosis through the stimulation of AKT signalling 
that block the nuclear translocation of the forkhead box protein (FoxO) (Wilkes et al., 2005).  
In the present study, Tmepai protein was strongly expressed by immunostaining in growing 
follicles that were developing new granulosa cells. This might indicate that Tmepai has a key 
role in the proliferation of granulosa cells by switching off the Smad2/3 pathway, accompanied 
by turning on the non-Smad pathway.  
5.4.2. Regulation of Tmepai expression and the consequential effect on preantral follicle 
growth 
Enhanced  or  inhibited  TGFβ/Smad  signalling  has  become  as  a  validated  protocol  to  understand  
mechanisms that regulate cell  growth  in  TGFβ  responsive  tissues  including  follicle  growth  or  
the development of cancer (DaCosta Byfield et al., 2004; Pangas, 2012). Studies have 
demonstrated  that  Tmepai  expression  is  enhanced  by  TGFβ  signalling  (Azami et al., 2015; Bai 
et al., 2014; Liu et al., 2011). For example,  in  cancer  cell  culture,  inhibition  of  TGFβ  signalling  
by immunoneutralisation caused a substantial reduction in the expression of Tmepai (Vo 
Nguyen et al., 2014).   Therefore,   since   TGFβ   signalling   is   an   important   regulator   of   early 
follicle development (Kaivo-oja et al., 2006; Li et al., 2008b), it is hypothesised that, in the 
ovary, Tmepai expression is regulated in the same manner.  
To test the hypothesis, cultured preantral follicles were treated with a TGFβRI inhibitor 
(SD208), exogenous rmGdf9, a combination of both or without any treatment. Gdf9 is a 
member   of   the  TGFβ   superfamily   that   is   exclusively   expressed   in   oocytes,   is   essential   for  
preantral   follicle   development,   signals   through   TGFβRI   and   normally   activates   Smad2/3 
(Knight and Glister, 2006). Thus, Gdf9 was selected in these experiments to assess its role in 
regulating Tmepai expression. SD208 was previously used in mice ovary and brain cells 
cultures as  an  effective  nontoxic  inhibitor  of  TGFβ  superfamily  members that signals through 
a TGFβRI receptor (Uhl et al., 2004; Wang et al., 2014). Follicles were cultured either for 24h 
and utilised for gene analysis or for 72h and imaged every 24h to determine the effect of 
treatments on follicle development.  
Inhibition   of   TGFβRI   by   the   exposure   to   SD208  with   or   without   rmGdf9   demonstrated   a  
significant decrease in Tmepai expression level relative to untreated control. However, there 
were no changes in Tmepai level in follicles exposed to rmGdf9 relative to control, indicating 
that Gdf9 signalling is not essential for Tmepai expression or the utilised concentration was not 
sufficient to increase Tmepai expression.  
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Thus,  Tmepai  might  be  regulated  by  other  TGFβ  ligands,  as  a  previous  investigation  in  cell  
line indicated that Tmepai expression  is  primarily  induced  by  TGFβ  members  and  Activin,  but  
not through BMP signalling pathway (Watanabe et al., 2010).  As  TGFβ1-β3  also signal through 
the TGFβRI receptor (Lonn et al., 2009; Schmierer and Hill, 2007), it is logical to consider that 
inhibition of TGFβRI receptor caused inhibition of   TGFβ1-β3   signalling,   which   might  
consequently downregulate Tmepai expression. In the present study, gene expression was 
analysed in follicles that had been exposed to treatment for 24h; this might be an insufficient 
period for the induction of Tmepai by rmGdf9, or overexpression of Tmepai was induced earlier 
than 24h of exposure.  
A previous study in cell culture derived from colon tumour showed that overexpression of 
Tmepai was  detectable  after  two  hours  of  TGFβ  exposure  and  suggested  that  Tmepai can be 
determined as a unique marker of cellular differentiation and proliferation (Brunschwig et al., 
2003). Even though a significant reduction of Tmepai in both SD208 treated groups was 
observed, no changes were detected for Smad3 in any treatment group. This might indicate the 
presence of other Smad inhibitors, which function to prevent overexpression of Smad3. For 
example, in various tissues, several factors has been recognised as negative regulators of both 
duration  and  strength  of  TGFβ  signalling  such  as  Ppm1a  (Chuderland et al., 2012), Strap (Wen 
et al., 2001), Ski/ SnoN (Deheuninck and Luo, 2009), NEDD4 (Kuratomi et al., 2005), and 
Smurf1/2 (Inoue and Imamura, 2008).  
In the present study, nine Smad2/3 inhibitors were expressed in the immature and adult mouse 
ovaries (Figure 3.9). These factors might have an effect on the activity of Smad protein, such 
as phosphorylation, dimerization or translocation rather than the expression of the mRNA. For 
example, in a cell line, knockdown of Tmepai caused a significant increase in Smad2 and 
Smad3  phosphorylation  accompanied  with  prolonged  TGFβ  signalling  (Watanabe et al., 2010). 
Unlike Tmepai, Strap transcript levels were constant in all treated groups relative to control, 
suggesting that the expression of Strap is stable and is not associated with the disruption of 
TGFβ  signalling.  This  finding  is  consistent  with  a  previous  data  that  Strap can interact with 
TGFβRI and TGFβRII  even  in  the  absence  of  TGFβ  signalling  (Datta and Moses, 2000). In 
addition, even though both Tmepai and Strap are Smad2/3 inhibitors, these results provides 
evidence that the two factors are regulated by different mechanisms. 
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Regarding the effect of treatments on preantral follicle growth, follicles were maintained in 
culture for 72h and mean diameter was estimated every 24h. Follicles treated by rmGdf9 were 
significantly larger after 24hs of culture, followed by a further increase in size after 48 and 
72hs relative to the same time points of incubation in the untreated control group. A similar 
observation of increased follicle size was reported after 24h of treatment by rmGdf9 
(250ng/ml), but further increases in follicle size were not evident at later time points (Fenwick 
et al., 2013). The essential role of Gdf9 in follicle growth was investigated through the study 
of Gdf9 deletion in the ovary which revealed a reduction in proliferation of granulosa cells, 
inadequate oocyte development, and failure of theca cell formation (Elvin et al., 1999). 
Conversely, ovaries exposed to Gdf9 protein showed a significant increase in the transcript 
level of CYP17 (thecal cells marker) indicated that Gdf9 promotes follicle development (Vitt 
et al., 2000). Inhibition of TGFβRI receptor in follicles treated by 1µM SD208 with or without 
rmGdf9 caused a significant decrease in follicle size after 24h followed by a further decrease 
at 48h and 72h relative to control group. In addition, particularly after 48h and 72h of exposure, 
treated follicles showed major morphological changes manifested by decreased number of 
granulosa cell layers accompanied with the loss the central location of the oocyte in the follicle 
(Figures 5.14-15). These findings highlighted the association of Tmepai mRNA reduction with 
decreased preantral follicle growth. Previous studies have shown that overexpression of 
Tmepai was associated with growth progression and metastasis by activation the non-Smad 
pathways (Singha et al., 2014; Vo Nguyen et al., 2014).  
To exclude the possible cytotoxic effect of the SD208 diluent (DMSO) on follicle growth, an 
equivalent volume of DMSO was added to control and rmGdf9 groups, thus the reduction in 
follicle size might be a consequence of TGFβRI inhibition. Another type of TGFβRI inhibitor 
(SB505124) was previously used in preantral follicle culture, however, follicle size was 
reduced after 48h of exposure (Fenwick et al., 2013). Variation in response and effects on 
follicle growth from the present study might refer to the specificity of SD208 to inhibit TGFβRI 
receptor (Uhl et al., 2004). Another study utilised a different culture model where the impact 
of 1μM  SD208 on follicle growth was investigated on cultured prenatal (18.5dpc) and postnatal 
(3dpp) mouse ovaries. After 7 days of culture, ovaries demonstrated a significant increase in 
the population of activated follicles with larger oocytes accompanied with increased granulosa 
cell proliferation relative to control (Wang et al., 2014).  
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The difference in the effect of this inhibitor on follicle growth in the present study might reflect 
the different ovary culture model, which includes only primordial follicles, where Smad2/3 is 
the dominant pathway. In comparison to the preantral follicle, model used in this study where 
the expression of Smad2/3 is decreased. To exclude the possibility of toxic effects of SD208 
on the exposed preantral follicles, it is recommended to apply a dose response on similar culture 
model. This could have been evaluated by determining the expression of genes associated with 
apoptosis such as caspases and p53/63 or using TUNNEL stain to highlight DNA 
fragmentation. To provide more evidence that Tmepai expression is regulating by   TGFβ  
signalling, it might be essential  to  examine  the  effects  of  other  TGFβ  ligands  that  signal  through  
the  TGFβRI  receptor.  This study was unable to determine the effect of Tmepai modification 
on early follicle development, as we could not find appropriate Tmepai products for either 
protein supplementation or valid antibodies to be in culture models. Attempts were made to co-
localise Tmepai or Strap with Smad2/3 proteins in paraffin-embedded sections of preantral 
follicles exposed to SD208 or rmGdf9; however, images were not included, as staining was 
inadequate and some of the follicles were lost either during processing for paraffin embedding, 
sectioning or staining. 
In conclusion, this is the first study that has revealed the expression and regulation of Tmepai 
in the mouse ovary. Tmepai is expressed in a growth stage-specific manner particularly from 
primary to secondary stages, but not in primordial and advanced stages of follicle growth. 
Tmepai   expression   is   regulated   by  TGFβ   signalling,   but   not   by GDF9. Downregulation of 
Tmepai expression was associated with a reduction in follicle size, which implies that normally, 
the expression of Tmepai in follicles is important for follicle growth, rather than atresia. Further 
studies are required to assess the direct effect of Tmepai modulation on follicle development 
using different protocols such as siRNA, immuneneutralisation or exogenous protein 
supplementation. Since Tmepai functions to inhibit the Smad2/3 pathway and activate the non-
Smad pathway, Tmepai might be a key factor implicated in the activation state of early growing 
follicles.  
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Chapter 6 
Expression and localisation of latent  TGFβ  binding 
proteins (Ltbp) in the mouse ovary 
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6.1. Introduction 
Extracellular matrix (ECM) is a complex three-dimensional structure composed of different 
large molecules including glycoproteins, elastic and collagen fibres found adjacent to cells that 
have generated it (Hirai et al., 2007; Tsang et al., 2010). The main functions of ECM included 
supporting, establishing cells into tissues, and regulating cell functions by stimulating 
intracellular  signalling  pathways,  such  as  TGFβ,  that  have  an  essential  role  in  cell  growth  or  
apoptosis (Nagase et al., 2006; Olivieri et al., 2010). Attachment to the ECM is a principle 
process for the majority of cells to provide regular cell development and maintenance, while, 
disassociation from ECM or attachment to inadequately structured ECM leads to initiation of 
cellular death (Marastoni et al., 2008). Recently, it has been suggested that progression of 
pathological disorders in tissues with a damaged ECM is associated with dysregulated growth 
factor  signalling,  such  as  TGFβ/  Smad  signalling,  but not due to the destructed ECM (Bourd-
Boittin et al., 2011; Robinson et al., 2006). 
To this point, most of the studies presented in this thesis have focussed on the intracellular 
regulators  of  TGFβ   signalling.  However,   as  outlined   in  Chapter  1,  TGFβ   signalling   can  be  
regulated at many levels, including at the level of ligand processing and extracellular 
availability. In the mouse ovary, little information is available on the extracellular effectors of 
the  TGFβ/  Smad  signalling  represented  by  latent  TGFβ  binding  proteins  (Ltbp). Ltbp1-4 are 
extracellular matrix proteins with high molecular weight (150-220 kDa) belongs to the Ltbp/ 
fibrillin superfamily (Unsold et al., 2001). Each Ltbp member contains multiple epidermal 
growth factors (EGF) repeats, which can bind with calcium (Ca+2) to support the Ltbp structure 
by reducing the effect of proteases (Jovanovic et al., 2008). The other part is the cysteine-rich 
repeat, called 8-Cysteine,   or   TGFβ   binding   protein-like repeats, which are a unique 
characteristic of Ltbp/fibrillin family (Hyytiainen et al., 2004). All Ltbp members include four 
cysteine-rich repeats and a repeat that locates on the N-terminal domain called the hybrid repeat 
as it contains sequences similar to that in both cysteines rich and EGF-like repeats (Hyytiainen 
et al., 2004; Saharinen et al., 1996). The third cysteine-rich repeat of Ltbp1, 3 and 4 is the site 
of disulphide binding  to  the  small  latent  TGFβ  complex (SLC). The functional impact of the 
other two cysteine-rich repeats has not indicated, yet. The N-terminal and C-terminal regions 
of Ltbp members contain the non-calcium binding EGF-like repeats, which are essential for 
association with other ECM proteins (Unsold et al., 2001). The N-terminal (amino terminus) 
of the Ltbp molecule contain a protease-sensitive region (Hinge-region) enriched with proline 
or glycine and targeted by proteolytic enzymes during dissociation of Ltbp from the ECM at 
the  process  of  TGFβ  activation  (Ge and Greenspan, 2006) (Figure 6.1). 
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Figure 6.1. Structural  differences  of  latent  TGFβ  binding  proteins  members.  The N-terminal is a site 
for the association with the ECM. The N-terminal of all Ltbp members include two (Ltbp1, 3, and 4) or 
three (Ltbp2) EGF-like repeats (green/blue blocks), one 8-Cys repeat (red block), and a hybrid repeat 
(black block) that share sequences of both the 8-cysteine repeat and EGF-like repeats, but contains 
seven cysteines. A protease sensitive region (Hinge region) locates close to the N-terminal domain 
where dissociation from ECM occurs. While a protease-resistant region is the long central region 
composed of 8-13 EGF-like repeats. The C-terminal of Ltbp contains the 8-Cys repeat (red block) where 
the  small  latent  TGFβ  complex is associated to Ltbp1, 3 and 4 by disulphide bonds; while in Ltbp2 it 
provides sites for ECM binding, adapted from (Koli et al., 2001; Todorovic et al., 2005).  
The  small   latent  TGFβ  complex  SLC  (includes   latency-associated peptide LAP and mature 
TGFβ;;  see  Figures 1.7-8) binds to a Ltbp to  form  a  large  latent  TGFβ  complex  LLC  (Annes et 
al., 2003).  Binding  of  small  latent  TGFβ  complex  to  Ltbp  is  an  important  step  to  enhance  their  
secretion, accumulation in a particular region in the extracellular matrix, and plays an essential 
role  in  the  activation  of  latent  TGFβ  (Annes et al., 2004; Koli et al., 2001). Ltbp1 was initially 
identified in human platelets (Miyazono et al., 1988). Later, Ltbp2 and Ltbp3 were 
characterised according to their sequence similarity to Ltbp1 (Moren et al., 1994; Yin et al., 
1995); while Ltbp4 was initially identified in  the human heart, aorta, uterus, and small intestine 
(Saharinen et al., 1998). In addition to their tissue specificity, each Ltbp members interacts 
with  a  particular  TGFβ  member.  For  example,  Ltbp1  and  Ltbp3  have   the  potential   to   form  
complexes  with  TGFβ1-3,  while  Ltbp4  can  only  associate  with  TGFβ1  (Penttinen et al., 2002; 
Saharinen and Keski-Oja, 2000). 
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Unlike other Ltbp members, Ltbp2 is unable to bind to the LAP part of SLC because its third 
8-Cys repeat does not include two amino acids between the cysteines 6 and 7 (Saharinen and 
Keski-Oja, 2000).  In  order  to  enable  the  initiation  of  TGFβ  signalling,  it  is  essential that the 
mature  TGFβ  becomes  dissociated  from  LAP  (Koli et al., 2001; Rifkin, 2005). The different 
mechanisms for dissociation are reviewed in section 1.7.3. 
Studies using conditional gene targeting in mice revealed the importance of Ltbp members in 
different tissues; for example, mice lacking Ltbp1 exhibit congenital cardiac disorders 
(Todorovic et al., 2007) and disorders in facial tissue formation (Drews et al., 2008). Deletion 
of Ltbp2 leads to early embryonic death (Shipley et al., 2000), while mice lacking Ltbp3 suffer 
from bone malformation, particularly affecting long and skull bones accompanied by a 
reduction in  TGFβ  signalling  (Dabovic et al., 2002). 
Animals with reduced Ltbp4 expression exhibit major lung dysfunction, cardiomyopathy and 
intestinal cancer due to impaired   TGFβ   activity   (Sterner-Kock et al., 2002). Furthermore, 
modification in the expression level of a particular Ltbp isoform has no impact on levels of 
other members (Kretschmer et al., 2011), which implies that each Ltbp isoform is regulated 
independently from the other members. However, another study suggested Ltbp4 can substitute 
for Ltbp1 in tissues deficient in the latter, as their C-terminal shares the same binding properties 
to fibrillin, an extracellular microfiber (Isogai et al., 2003). 
Since   the   bioavailability   of   the   TGFβ   superfamily   members   is   largely   dependent   on   Ltbp  
members (Annes et al., 2003; Su et al., 2015), given   the   proposed   requirement   for   TGFβ  
signalling in the ovary (Knight and Glister, 2003; Pangas, 2012) and association of fibrillin 
family with polycystic ovary syndrome (Hatzirodos et al., 2011), it is hypothesised that Ltbps 
will be detectable in the ovary. The aim of this chapter is to identify the expression levels of 
Ltbp1-4 mRNAs and to determine the staining pattern of Ltbp1 and 4 proteins in ovaries from 
immature and adult mice. 
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6.2. Materials 
6.2.1. Animals and tissues 
Ovaries from mice (d4, 8, 16, and adults) were dissected and manipulated as described in 2.1. 
Ovaries were used to determine the expression of Ltbps using both RT-PCR/qPCR and 
immuno-staining. In addition, oocytes were mechanically isolated from d16 ovaries using blunt 
acupuncture needles (AcuMedic) in drops of isolation media. Isolated oocytes (n=9; Figure 
6.2) were pooled in an Eppendorf tube, snap frozen in liquid nitrogen and stored at -80ºC to be 
used for total RNA extraction and the expression of Ltbp4 mRNA by RT-PCR.  
 
Figure 6.2. Isolated oocytes used for RNA extraction. Intact oocytes were collected with a curved glass 
pipette and snap frozen in liquid nitrogen. Oocytes were imaged with Olympus CKX41 with a Nikon 
camera DS-Fi1,  Scale  bar=50μm. 
6.2.2. RNA extraction, RT-PCR and qPCR 
Ovaries (n=6 each age group) and an oocyte sample (n=1) were used for total RNA extraction 
according  to  manufacturer’s  instructions  of  Qiagen  RNeasy  Micro  Kits  (QIAGEN,  Crawley,  
UK) (section 2.3). Extracted RNA samples were assessed for concentration and integrity using 
Agilent Bio-analyser and equivalent amounts of RNA (25ng/µl) were utilised for cDNA 
synthesis (section 2.4). Primers (Ltbp1-4; Table 6.1) were designed to detect mouse transcripts 
for each candidate gene as described in section 2.5. For gene qualification and quantification, 
primers were used at a concentration of 500nM for each primer set. The prepared cDNA 
samples from d4, 8, 16 and adult ovaries were initially checked for the expression of Gapdh.  
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Then, cDNA samples from all age groups were assayed for Ltbp1-4 by RT-PCR as described 
in section 2.6. RT-PCR was also used to determine whether Ltbp4 is detectable in the oocyte 
sample. In addition to a non-template negative control, cDNA from oocytes sample and adult 
ovary cDNA was used for the detection of Gdf9 as a positive control. 
To determine the expression levels of Ltbp1-4 mRNA in the utilised age groups, qPCR reaction 
mix  (20μl)  were  prepared,  two  technical  replicates  for  each  gene,  using  2X  SensiFAST SYBR 
Hi ROX Mix (Bioline). Control groups (non-template) were included for each reaction where 
nuclease-free water was added instead of cDNA. Thermal cycles included an initial 
denaturation for 2 minutes at 95°C, followed by cycles of 5 seconds at 95°C, annealing for10 
seconds at 59°C, and extension at 72°C for 12 seconds. qPCR data were analysed as fold 
changes relative to a housekeeping gene (Atp5b) using the equation 2-ΔΔCT (Livak and 
Schmittgen, 2001). 
Table 6.1. Oligonucleotide primer sequences used to amplify transcripts of Ltbp1-4  
Gene Primer Sequence 
Annealing 
Temperature 
Product size 
(bp)  
Ltbp1 F: TGAATGCCAAGACCCTAACA 
R: ACGAGAGGACGGCTACACA 
59.3 217 
Ltbp2 F: AGACCCTCCCTGACAAAGGT R: ACTTGCTCTTCTGCTGGACT 59.3 152 
Ltbp3 F: CCTGGATGGTGTGAGAACCT 
R: ACTGGAAAGAGCCTGGTGTG 
59.9 160 
Ltbp4 F: CTGGGCGTTGCGAGAATACA 
R: CGGGACACACACATAGGAA 
60.1 175 
Gdf9 F: TCACCTCTACAATACCGTCCGG 
R: AGCAAGTGTTCCATGGCAGTC 
59 139 
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6.2.3. Immunofluorescent staining 
After optimisation with various concentrations of antibodies, Rabbit anti-Ltbp1 and Rabbit 
anti-Ltbp4 antibodies (Table 6.2) were used for the localisation of Ltbp1 and Ltbp4 proteins in 
paraffin embedded sections of d4, d8, d16 and adult mouse ovaries. These two Ltbp members 
were selected for localisation as there is no information about their protein expression in 
immature ovaries. An equivalent amount of non-immune Rabbit IgG (Vector) was used as a 
negative control. The same staining protocol described in 2.9.3 was followed. Stained sections 
were imaged with confocal microscopy using Leica inverted SP5 confocal laser scanning 
microscope 
Table 6.2. Primary and secondary antibodies used for immunofluorescent staining 
Primary antibody Company Concentration Secondary antibodies 
Ltbp1 Santa Cruz sc-98275 0.25μg/ml 
Alexa fluor 555 
Donkey anti-Rabbit 
Ltbp4 Santa Cruz sc-33144 0.5μg/ml 
Alexa fluor 488 
Donkey anti-Rabbit 
 
6.2.4. Statistical analysis 
For statistical evaluation, qPCR data were statistically analysed using one-way ANOVA with 
Bonferroni post-hoc test comparisons test. Differences between age groups were considered 
significant at P<0.05. Statistical analyses were performed using Prism (v6.0d; Graphpad) and 
data were presented as mean ±standard error of the mean (SEM). 
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6.3. Results 
6.3.1. Expression of Ltbp1-4 mRNAs in immature and adult ovaries 
Gapdh was detected in all cDNA from immature (d4, d8, d16) and adult ovaries by RT-PCR. 
Ltbp1-4 mRNAs were also expressed in the same ovary ages. Ltbp1 bands were expressed with 
similar intensity in all age groups. Strong bands were detectable for Ltbp2 and Ltbp4 in d8 and 
d16 ovary samples, while a clear strong band was also seen for Ltbp3 in d8, d16 and adult 
ovaries (Figure 6.3). 
 
Figure 6.3. RT-PCR gel image showing the expression of Ltbp1-4 in mice ovary. In addition to Ltbp1-
4, both positive (Gapdh) and negative controls (non-template) were included in the RT-PCR reaction. 
Red line in Ltbp2 gel represents to a pasted ladder. 
To determine whether steady state transcript levels of Ltbp1-4 change with age, the expression 
levels were assessed in ovaries at d4, d8, and d16 by qPCR (n=6). By comparison with d4 
ovary, levels of Ltbp1-4 mRNA were relatively constant and did not vary statistically (P>0.05) 
(Figure 6.4). 
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Figure 6.4. Expression levels of Ltbp1-4 at different ages of immature ovaries. Data were normalised 
relative to the expression of the internal housekeeping gene, Atp5b, and expressed as fold changes 
relative to day4 ovary. Statistical analysis was assessed using one-way ANOVA with Bonferroni post-
hoc test. Data are presented as mean ± SEM (n=6 ovaries per age group).  
6.3.2. Localisation of Ltbp1 in immature and adult ovary. 
Ovary sections at d4, d8, d16 and from adult mice were used for immunofluorescent 
localisation of Ltbp1 protein. Results demonstrated that Ltbp1is localised throughout the ovary 
stroma with a higher intensity in the ovarian surface (Figure 6.5). High power microscopy 
demonstrated confirmed the positive staining of Ltbp1in epithelial cells and the intensity of 
staining reduced in stroma beneath the ovarian surface where primordial follicles are situated 
(Figure 6.6). In agreement with Ltbp1 gene expression, there was no visual difference in the 
intensity of staining pattern between the different ages of immature ovaries; however, staining 
was visually reduced in the adult ovary (Figure 6.7). Ltbp1 protein was undetectable in other 
ovary components such as follicles or blood vessels.  
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Figure 6.5. Localisation of Ltbp1 protein in immature ovaries. Confocal microscopy revealed that 
Ltbp1 protein (red) is generally detectable in the stroma cells and being stronger in epithelial cells 
located at the ovarian surface (OS). There are no visual differences in the staining pattern between the 
d4, 8, or 16 ovaries. Negative control ovary sections were hybridised with an equivalent concentration 
of non-immune Rabbit IgG. All ovary sections were incubated with Alexa Donkey anti-Rabbit 555 
secondary antibodies. Nuclei were counterstained with DAPI  (blue).  Scale  bar=  50μm. 
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Figure 6.6. High power confocal microscopy for Ltbp1 in immature ovaries. Images show that Ltbp1 
protein staining (Red) is evident in stroma and cells located at the ovarian surface (OS) where many 
primordial follicles (PFs) are present. A similar pattern and staining intensity were revealed in d4, d8 
and d16 ovaries. Negative control ovary section was hybridised with an equivalent concentration of 
non-immune Rabbit IgG and all sections were incubated with Alexa Donkey anti-Rabbit 555 secondary 
antibodies. Nuclei were counterstained with DAPI  (blue).  Scale  bar  =25μm. 
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Figure 6.7. Localisation of Ltbp1 protein in the adult ovary. Ltbp1 protein (red, upper row) was 
undetected in the ovarian surface. Non-specific red spots staining (white arrows) were identified. 
Negative control (lower row) was hybridised with an equivalent concentration of non-immune Rabbit 
IgG. All sections were incubated with Alexa Donkey anti-Rabbit 555 secondary antibodies. Nuclei were 
counterstained with DAPI  (blue).  Scale  bar  50μm.   
6.3.3. Localisation of Ltbp4 in immature and adult ovary. 
Ltbp4 protein was localised in ovary sections of d4, d8, d16 and adult in a different expression 
pattern compared to Ltbp1 protein expression. In all ovary ages, Ltbp4 protein was specifically 
detected in the blood vessels and also, but with reduced intensity in the stroma. In addition, in 
d4 and d8 and adult sections, Ltbp4 protein was observed with a high intensity of staining in 
the outer membrane of the oocytes; however, Ltbp4-positve oocyte staining was only detected 
in numerous oocytes of d16 ovary sections. In immature d4 ovaries, the majority of the Ltbp4-
positive oocytes were in growing follicles situated in the medulla (Figure 6.8). Stained sections 
demonstrated that Ltbp4 protein was visually reduced in d8 (Figure 6.9) and greatly decreased 
in the d16 ovary (Figure 6.10), where it localised in small distinct foci, compared with d4 ovary. 
However, the strongest staining pattern of Ltbp4 protein was revealed in the adult ovary (Figure 
6.11). 
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Figure 6.8. Confocal microscopy of Ltbp4 staining in the d4 ovary section. Ltbp4 (green) was not 
detectable in primordial follicles (PFs) located in the marginal region. In low power images, Staining 
was evident in large blood vessels (BV) and in oocytes (Oo) of growing follicles (GFs) located in the 
medulla. High power images demonstrated that Ltbp4 (green) was localised in blood vessels (A; BV) 
located among several primordial and small growing follicles. Ltbp4 was also detectable in oocytes 
(circled, Oo) of follicles, where intensity was more evident in the small growing follicles than non-
growing primordial follicles (A-B). Positive staining was also evident in extracellular matrix close to a 
primordial follicle (B) where blood vessels were absence. As red blood cells (RBC) naturally fluoresce, 
the red channel (middle images) were included to show to visualise RBCs and localise blood vessels.. 
Negative control was hybridised with an equivalent concentration of non-immune Rabbit IgG non-
immune Rabbit IgG. Nuclei were counterstained with DAPI (blue). Scale bar  =  25μm. 
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Figure 6.9. Expression of Ltbp4 in the d8 ovary. Ltbp4 (green) was detected in blood vessels (BVs) 
located close to primordial follicles (PFs, labelled 1) and also near to growing follicles (GF, labelled 2). 
Positive staining was also evident in oocytes (Oo) of the growing follicles, particularly those located in 
the medulla, but not in primordial follicles (PFs). Negative control was hybridised with an equivalent 
concentration of non-immune Rabbit IgG and all sections were incubated with Alexa 488 secondary 
antibodies.  Nuclei  were  counterstained  with  DAPI  (blue).  Scale  bar  =  25μm. 
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Figure 6.10. Expression of Ltbp4 in the day16 ovary. Ltbp4 protein staining (green) was noticeably 
reduced where localisation was limited to small regions (encircled) in the ovary section. High power 
images (1 and 2) showing Ltbp4 positive stain in blood vessels. Negative control was hybridised with 
an equivalent concentration of non-immune Rabbit IgG and all sections were incubated with Alexa 488 
secondary antibodies. Nuclei were counterstained with DAPI  (blue).  Scale  bar=  50μm. 
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Figure 6.11. Expression of Ltbp4 in adult ovary. The staining intensity of Ltbp4 protein (green) in adult 
ovary was considerably increased. High power images revealed localisation of Ltbp4 in blood vessels 
(BV, white arrows) where red blood cells (RBCs) are evident. Ltbp4 was also localised in the stroma 
(yellow arrows). Positive staining was evident in the oocytes of growing follicles (Oo) but not in 
granulosa cells (GCs). The red channels were included to determine the endogenous fluorescence and 
to visualise red blood cells. Negative control was hybridised with an equivalent concentration of non-
immune Rabbit IgG. Nuclei were counterstained with DAPI (blue). Scale  bar  50μm. 
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In contrast to the d16 ovary, several oocytes in d4, d8 and adult ovary sections demonstrated 
positive staining for Ltbp4 protein by immunofluorescence. RT-PCR was therefore performed 
in a sample of oocytes to identify whether Ltbp4 mRNA is expressed in these cells. An oocyte-
specific gene was expressed in a sample of pooled oocytes; however, Ltbp4 was not detected 
in the same sample (Figure 6.12).  
 
Figure 6.12. RT-PCR gel image presenting the expression of Ltbp4 in oocyte and adult ovary samples. 
Ltbp 4 (175bp) was not detected in oocytes sample (1), while it was expressed in the whole adult ovary 
(2). Gdf9 (139bp), an oocyte-specific factor, was detected with a strong band in the same oocyte sample, 
confirming the validity of the utilised oocyte sample (3). A non-template negative control is also shown 
(4). 
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6.4. Discussion 
Previous chapters aimed to investigate the expression and role of several intracellular factors 
that   have   potential   to   regulate  TGFβ   signalling   in   the  mouse   ovary.   In  many   tissues,   Ltbp  
members were identified as extracellular elements that regulate the bioavailability  of  TGFβ  
(Dabovic et al., 2002; Drews et al., 2008; Hyytiainen et al., 2004). Surprisingly, even though 
TGFβ  signalling  is  known  to  play  an  essential  role  in  follicle  development  (Kaivo-oja et al., 
2006; Pangas, 2012) expression of Ltbp members in the mouse ovary has not been reported. 
Thus, this part was designed as a small preliminarily study to determine the expression of 
Ltbp1-4 mRNA and proteins (Ltbp1 and 4) in mouse ovaries and to relate this with early follicle 
development. In the present study, transcripts of Ltbp1-4 were detectable by RT-PCR in 
immature ovaries at d4, d8, d16 and in adult ovary.  
Data from qPCR demonstrated no significant changes in the transcript levels of all Ltbp 
members between different prepubertal ages containing different proportions of non-growing 
and growing follicles. These results suggest that each individual Ltbp isoform is equally 
required in the developmental process of immature ovaries. It is possible that the stable 
expression reflects the activity of these proteins in the extrafollicular compartments, as 
previous studies indicated the essential role of Ltbp molecules in ECM formation (Rifkin, 
2005; Unsold et al., 2001). In addition, early follicle growth at the utilised ages is considered 
as a gonadotrophin-independent stage (Edson et al., 2009; Orisaka et al., 2009),  where  TGFβ  
signalling is essentially required either to enhance or inhibit the growth of small follicle 
including primordial follicles (Knight and Glister, 2006).  
In a previous study, expression of Ltbp1-4 did not differ throughout pregnancy in the human 
(1st- and 2nd-trimester) and bovine fetal ovaries; however, differences in the expression levels 
were evident by comparison with adult ovaries. For instance, Ltbp3 and Ltbp4 were higher in 
human ovaries while Ltbp1 and Ltbp2 were   higher   in   the   cow’s   ovaries   relative   to   their  
expression in fetal ovaries (Hatzirodos et al., 2011). This indicates that expression levels of 
Ltbp1-4 in the ovary are changeable according to the species and age. In addition, variation in 
the expression levels between immature and adult ovaries might be associated with the 
presence of different histological structures in these ovaries; for example, in the adult ovary, 
advanced stages of follicle growth, ovulated follicles and corpora lutea are evident compared 
to immature ovaries, which only contain primordial and small preantral follicles. 
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In the present work, Ltbp1 and Ltbp4 proteins were differentially localised in immature and 
adult ovary sections. In immature ovaries, Ltbp1 was mainly detected in the surface epithelium 
and with less intensity of staining in stroma, where primordial follicles are situated. However, 
Ltbp1 protein was undetectable in adult ovary sections. Reduced Ltbp1 protein in the adult 
ovary might be a consequence of increased steroid hormones. In monkeys, oral treatment with 
progesterone caused a reduction in the TGFβ1  expression   in   the  ovarian  surface  epithelium  
accompanied with increased apoptosis of these cells (Rodriguez et al., 2002). Thus, since Ltbp1 
is responsible for the bioavailability   of  TGFβ,   physiologically,   progesterone   secreted   from  
corpus luteum might have a relevance in downregulation of Ltbp1 expression in the surface 
epithelium of adult ovaries.  
Localisation of Ltbp1 protein in immature ovaries is consistent with data from qPCR, as no 
visual difference was observed in the Ltbp1 staining pattern between age groups. Previous 
studies on adult bovine ovary revealed that Ltbp1 protein is detectable in ovarian tunica 
albuginea with reduced staining in the stroma underneath the surface epithelium adjacent to 
primordial and preantral follicles (Hatzirodos et al., 2011; Prodoehl et al., 2009). Functionally, 
Ltbp1   has   the   potential   to   interact   with   TGFβ1-3, which have anti-proliferative effects on 
epithelial cells (Singha et al., 2014).   In   human   and   bovine   ovaries,   TGFβ1-3 and their 
respective  receptors  (TGFβRI  and  II)  are  detectable  in  the  surface  epithelium  (Henriksen et al., 
1995; Nilsson et al., 2001a). Previous studies indicated that reduction in Ltbp1 levels caused 
downregulation   in   the   bioavailability   of   extracellular   TGFβ1   leading   to   promotion   of   the  
carcinogenic process in epithelial cells (Eklov et al., 1993; Kretschmer et al., 2011). Thus, 
based on these data, the staining pattern of Ltbp1 in the immature ovary surface might indicate 
its  essential  role  in  secretion  and  storage  of  TGFβ1-3 in the ovary surface. This might play an 
important role in the maintenance and activation of primordial follicles in the marginal region 
of the immature ovaries.  
Ltbp4 protein was mainly localised in blood vessels located close to primordial and growing 
follicles. In addition, some staining was evident in stroma and the surface of small growing 
oocytes. In agreement with Ltbp4 protein staining, an oocyte sample from d16 ovary did not 
express Ltbp4 mRNA. However, it would be interesting to perform the same analysis on 
isolated oocytes from d4 and d8 ovaries, particularly if larger growing oocytes could be 
dissected. Even though there was no change in mRNA expression levels between age groups, 
the staining intensity of Ltbp4 was decreased in d8 and d16 ovaries relative to d4 ovary; in 
contrast, the detection of Ltbp4 protein in adult ovary was greatly increased.  
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The reduction in protein expression in d8 and d16 ovaries might reflect either the dynamic 
biological activity at these ages manifested by increased number of activated/growing follicles 
(Palma et al., 2012) or due to the delay in the process of gene translation into protein (Gedeon 
and Bokes, 2012). However, the increased Ltbp4 protein staining in adult ovary might be due 
to the presence of the large blood vessels relative to immature ovaries and to the increased 
demand   of   tissue   for   TGFβ   signalling,   which   induces   stromal   fibroblasts   proliferation   to  
produce structural collagens and tissue healing (Govinden and Bhoola, 2003).  
This chapter does not included the localisation of Ltbp2 and Ltbp3 proteins; therefore, it would 
be interesting to identify the expression pattern of these proteins. Isolated oocytes from d16 
ovary were used to confirm the expression of Ltbp4 in oocytes, it was reasonable to use oocytes 
from adult ovaries, as relative protein staining was more evident by comparison with d16.  
In conclusion, this is the first study that aimed to evaluate the expression and localisation of 
Ltbp members in immature and adult mouse ovaries. Transcripts of Ltbp1-4 are detectable and 
their expression levels are constant in the immature ovaries. Immunofluorescent staining 
indicated that each of Ltbp1 and Ltbp4 proteins has a unique expression site in the ovary.  
Ltbp1 appears to be strongly localised at the ovary surface epithelium, while Ltbp4 specifically 
localised in the blood vessels with evidence of discrete expression in the stroma and oocytes. 
In the adult ovary, Ltbp1 protein is not detectable while strong staining was detected for Ltbp4. 
These two different staining patterns suggest that Ltbp1 and 4 have different roles in the ovary 
development. Further studies are required to specify the localisation of Ltbp2 and Ltbp3 
proteins in the immature mouse ovary. Moreover, to identify the molecular role of Ltbp 
members  on  the  TGFβ  signalling and the consequent influence of these factors on early follicle 
development. 
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Chapter 7  
General Discussion 
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7.1. Introduction 
For decades, even though considerable progress has been made in understanding the mystery 
of ovarian follicle growth, more investigations are needed to understand the complex molecular 
mechanisms responsible for primordial follicle activation and early follicle development. The 
first chapter of this thesis, the literature review, focused on the process of ovarian 
folliculogenesis and the factors that regulate early follicle growth. Activation of the small 
quiescent primordial follicle is the initial step where these follicles exhibit an increase in oocyte 
size, morphological changes in the shape of granulosa cells from flattened to cuboidal, and an 
increased number of granulosa cells (Hirshfield, 1991). Complex  ‘gonadotropin-independent’  
interactions between autocrine and paracrine-secreted factors are responsible for the regulation 
of the early follicle growth (Kaivo-oja et al., 2006). In this study, particular attention was 
directed to different levels of the TGFβ  superfamily, their specific receptors, mediator elements 
(R-Smads) as well as the intracellular extracellular and regulators.  
In  many  tissues,  TGFβ/  Smad  signalling  is  implicated  in  the  regulation of cell proliferation, 
differentiation, migration, and survival (Rahimi and Leof, 2007).  TGFβ  signalling  is  initiated 
by   the   formation  of   a   complex  between   the  activated  TGFβ   ligand  and   the   transmembrane  
serine-threonine kinase type I and type II receptors. To  date,   seven  TGFβ   type   I receptors 
(ALK1-7)   and   five   TGFβ   type   II   receptors   (TGFβRII,   BMPRII,   AMHRII   ActRII, and 
ActRIIB) have been identified (Shi and Massague, 2003; ten Dijke and Hill, 2004). The 
activated receptors recruit R-Smads for activation by phosphorylation. Once activated, to 
enhance their nuclear translocation for gene regulation, R-Smads form a heteromeric complex 
by the associating with Smad4 (Schmierer and Hill, 2007; Shi and Massague, 2003).  
TGFβ  ligands  can  signal through either the Smad-dependent or Smad-independent pathways 
(Derynck and Zhang, 2003).  In  the  ovary,  several  TGFβ  members  are  expressed in the oocyte, 
granulosa cells or theca cells, including those that either signal through the Smad2/3 pathway 
(TGFβ,  GDF9,  Activin, and inhibin) or Smad1/5/8 (BMPs and AMH) (Drummond et al., 2002; 
Knight and Glister, 2006).  
Although  many  studies  have  highlighted  the  essential  role  of  the  TGFβ  pathway  in early follicle 
development (Ding et al., 2010; Pangas, 2012; Wang et al., 2014), numerous aspects require 
further investigation. For example, the   impact   of   attenuated   TGFβ   signalling   on   the   early  
follicle  development  is  not  clearly  understood.  In  other  TGFβ  responsive  tissues,  both  duration  
and   strength   of   TGFβ/   Smad   signalling   are negatively regulated at different cell levels by 
numerous intracellular inhibitors (Inoue and Imamura, 2008; Lonn et al., 2009). 
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 Thus, the present study was designed to investigate factors that have the potential to regulate 
TGFβ/  Smad  signalling  in  the  context  of  the  ovary  and  to  specifically  determine  their  impact  
on early follicle development. Although this thesis was sensibly designed, numerous 
limitations and shortages were apparent and were specified in each particular chapter. These 
were mainly a consequence of either technical issues or time limitation. These limitations were 
specified in each individual chapter. Even though the existence of some limitations, this work 
provides  valuable  knowledge  on  TGFβ/  Smad  regulators  in  relation  with  different  ovary  ages.   
7.2.  TGFβ  signalling  mediators  and  many  Smad  inhibitors  are  detectable  in  the  ovary 
Since  TGFβ  signalling  is  active  in  the  ovary  (Li et al., 2008b; Pangas, 2012), it was proposed 
that numerous candidate Smad inhibitors would also be detectable and their expression related 
to R-Smad expression. Thus, the aim of the first part of this thesis was to determine the 
expression pattern of R/Co-Smads during early follicle development and to identify candidate 
Smad inhibitors for further investigation. Immature mouse ovaries at d4, d8 and d16 (and 
adults) containing increasing density of more advanced stages of follicle growth were utilised. 
These ages were selected to track the molecular changes in both gene and protein expression 
during early follicle growth. Although the expression of R-Smads (Smad1, 2, 3, 5, 8) in the 
ovary has been previously described (Fenwick et al., 2013), the present study provides more 
evidence about the growth stage-specific expression of their mRNA and proteins in three 
different ages of immature ovaries. In addition, it has confirmed previous data from our lab 
(Fenwick et al., unpublished work) that the exclusion of Smad2/3 from the nuclei of granulosa 
cells might be an early sign of primordial follicle activation. As the present work was concerned 
with early follicle development, ten Smad2/3 inhibitors were selected from the literature, to be 
analysed for their expression in relation to Smad2/3. 
Transcripts of all candidate inhibitors were detected in immature and adult ovaries. Thus, it is 
interesting to note that in addition to Smad7, a commonly recognised inhibitor of Smad2/3, 
many other factors exist that could potentially negatively regulate this pathway in the ovary. In 
other tissues, inhibition of the Smad2/3 pathway by Smad7 can be enhanced by further 
interaction with other inhibitors such as Strap (Datta and Moses, 2000) or Smurf1/Smurf2 (Liu 
et al., 2002). The significant reduction in the expression of Smad3 in d16 ovary relative to d4 
might be the result of a cooperative process between Smad7 and some of these inhibitors. 
Differences in the transcript levels of some candidate genes relative to control (d4) were 
evident, which may indicate that some of these inhibitors are expressed in a follicle stage-
specific manner. 
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For example, transcripts levels of Smad7, Smurf1, Smurf2, Ski, and Strap were significantly 
decreased with age, while no statistical variation was determined in the expression of Ppm1a, 
Exportin4, SnoN or RanBP3 at the same age groups. Therefore, a range of isolated follicle 
samples (primordial to large antral follicles) were utilised to identify whether the expression of 
the above candidate Smad inhibitors are specifically associated with follicle growth. Strap, 
Ppm1a, and Ski were expressed in all follicle stages including primordial follicles. For further 
investigation, Strap and Ppm1a were then selected to relate their protein expression with 
Smad2/3 and follicle development. 
Although Ppm1a protein was previously localised in mature mouse oocytes (Chuderland et al., 
2012), the present study was unable to corroborate these findings or detect specific Ppm1a 
staining in any of the immature ovaries, which may be attributed to the specific antibody used, 
or the technique used to localise proteins in sections. In contrast, Strap protein was localised in 
all of the immature ovaries from a range of ages. In particular, the detection of Strap in 
granulosa cells of small follicles was found to overlap with the expression of cytoplasmic 
Smad2/3, suggesting a possible role of Strap in the regulation of Smad2/3 and consequently 
early follicle development. Thus, at this point, the study was directed to identify the functional 
role of Strap on early follicle growth. 
7.3. Consequences of Strap modification on early follicle development 
Strap acts as an inhibitor of the Smad2/3  pathway  by  stabilising  Smad7  to  the  activated  TGFβ  
receptors complex preventing activation of Smad2/3 (Datta et al., 1998; Datta and Moses, 
2000). Strap can also interact with activated Smad2/3 to block translocation to the nucleus 
(Halder et al., 2006). The general hypothesis of this part was to determine whether treatments 
that affect the expression or action of Strap have a consequence on primordial and preantral 
follicle development. To test the hypothesis, firstly, the study aimed to identify the effect of 
Strap downregulation by siRNA or Strap protein inhibition by anti-Strap antibodies on 
primordial and preantral follicles.  
Likewise, the effect of exogenous Strap was analysed using recombinant protein 
supplementation. Both d4 ovary fragments, which mainly contain primordial follicles, and 
isolated preantral follicle culture models were utilised in the present work. In the d4 ovary 
model, in order to determine the effect of treatments on follicle growth, a novel oocyte 
classification protocol was developed where oocytes were assigned as non-growing, 
transitional or growing according to their diameter and number of granulosa cell layers from 
histological sections stained with haematoxylin and eosin.  
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In the d4 ovary fragments model, downregulation of Strap expression by Strap siRNA or 
neutralisation of Strap protein by anti-Strap IgG treatments promoted a significant increase in 
the median oocyte diameters relative to controls. In both experiments, the proportion of non-
growing oocytes was significantly reduced alongside an increase in the proportion of growing 
oocytes relative to controls. Furthermore, cultured ovary fragments exhibited many Amh-
positive granulosa cells, suggesting the presence of more growing follicles in the treated 
groups. To some extent, it is difficult to explain these results as inhibition of Strap 
expression/function  would  be  expected  to  increase  the  duration  and  strength  of  TGFβ  signalling  
through the Smad2/3 pathway assuming  TGFβ  functions  as a growth suppressor in this context 
(Brown et al., 2007).  
In human cancer, one study suggested that modulation in the signalling pathway elements 
might  convert  the  growth  suppression  effect  of  the  TGFβ  to  a  proliferative  effect  (Elliott and 
Blobe, 2005). For example, exposure of cultured cortical human ovarian tissue to a low 
concentration of Activin caused inhibition of primordial follicle activation, while, treatment 
with a higher concentration caused an increase in primordial follicle activation  (Ding et al., 
2010). Thus, in  the  present  work,  prolonged  TGFβ  signalling  due  to  the  inhibition  of  a  Smad2/3  
inhibitor may enhance the activation process of primordial follicles relative to controls. The 
importance of R-Smads for follicle development has also been evaluated in knockout mice 
where deletion of Smad2 and Smad3 resulted in more primordial follicles with a decreased 
number of growing follicles (Li et al., 2008b; Tomic et al., 2004). Inhibition of a Smad2/3 
inhibitor might enhance signalling  of  other  TGFβ  superfamily  members  pathway  such  as  Gdf9  
and activin signalling, both of which have a positive impact on primordial and preantral follicle 
growth in various species (Fenwick et al., 2013; Zhao et al., 2001).  
By comparison exposure to Strap siRNA in cultured preantral follicles revealed no effect on 
follicle growth. This suggests that the role of Strap may be follicle stage specific. This 
assumption was further tested by the incubation of the d4 ovary fragments with a media 
enriched with rhStrap. After 7 days, a considerable increase in the proportions of transitional 
and growing oocytes was observed relative to controls. In addition, the median diameter of 
growing oocytes was greater than in controls supported by Amh staining in granulosa cells. 
Similarly, in the preantral follicle model, rhStrap promoted the rate of growth relative to 
controls. These results indicate that Strap has a dual role in the regulation of early follicle 
development; firstly, in the primordial follicle, it functions to reduce the activation rate and 
secondly it promotes the growth of the activated follicles.  
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The molecular mechanism may extend beyond Smad signalling (Reiner and Datta, 2011) since 
other studies have shown that Strap can activate pathways that function to enhance cell 
proliferation and survival such as ERK/MAPK (Halder et al., 2006) and PDK1 (Seong et al., 
2005). Activation of these pathways is associated with enhanced follicle growth (John et al., 
2008; Reddy et al., 2009; Reddy et al., 2008; Zheng et al., 2012). Thus, in addition to inhibiting 
the antiproliferative impact of the Smad2/3 pathway, Strap supplementation might enhance the 
growth of growing follicles by activation of non-Smad pathways. 
7.4.  Tmepai  is  detectable  in  the  mouse  ovary  and  regulated  by  TGFβ  signalling 
Next, another Smad inhibitory factor, Tmepai, was investigated in the context of the ovary 
since its expression is reported to be induced by androgens (Xu et al., 2000) and it was shown 
to  be  overexpressed  in  advanced  stages  of  cancer  where  TGFβ  signalling  was  found  to  further  
promote its expression (Singha et al., 2014; Watanabe et al., 2010). Tmepai acts to inhibit both 
androgen  and  TGFβ  signalling  in  a  negative  feedback  mechanism  by  blocking  their  signalling  
receptors (Bai et al., 2014; Li et al., 2008a). There is no available data on the expression, 
regulatory mechanisms or role of  Tmepai  in  the  ovary.  Thus,  given  the  importance  of  TGFβ  
signalling and androgens in the ovary, it was proposed that Tmepai might be detectable in the 
mouse ovary and be regulated  by  TGFβ  signalling.   
Tmepai mRNA was detected in immature and adult ovaries and its transcript levels were 
significantly increased in d16 ovaries, which contain many small preantral follicles. This 
suggested that the upregulation of Tmepai expression is associated with early stages of follicle 
growth. Indeed, Tmepai protein was detectable in granulosa cells of small preantral follicles 
found mainly in d8, d16 and adult ovaries. In contrast, Smad3 mRNA and Smad2/3 protein 
staining were reduced in d16 ovaries, indicating a possible molecular association between 
Tmepai and Smad2/3. 
Another interesting finding was that Tmepai positive follicles were located in the medulla of 
the d4 and d8 ovaries, while in the d16 ovaries these follicles were situated in the cortex. This 
unique pattern of staining provides strong evidence that Tmepai is associated with the stage of 
follicle development. In the d16 ovary, follicles that had developed more than three layers of 
granulosa cells were located in the medulla and were negative for Tmepai and for Smad2/3. 
This might be attributed to the nature of primordial follicle recruitment waves, as in the pre-
pubertal period follicles located in the medulla are activated to grow shortly after birth and 
most of these follicles rapidly degenerate; while, primordial follicles located in the cortical 
region are activated to grow later (Mork et al., 2012).  
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High power images revealed that strong staining was obvious in cuboidal granulosa cells that 
have excluded Smad2/3 from their nuclei. However, at this point, it is unknown whether the 
expression of Tmepai is associated with enhanced or inhibited follicle growth.  
A recent study indicated that Tmepai has the potential to inhibit Smad2/3, a growth suppressor, 
and can activate the Smad-independent pathways such as PI3K and AKT, which enhances cell 
proliferation and survival, by inhibition of PTEN (Singha et al., 2014). Thus, in the ovary, 
expression of Tmepai might be involved with early preantral follicle growth by regulating 
various  pathways.  To  determine  the  effect  of  the  TGFβ  signalling  on  Tmepai expression and 
the subsequent impact on the preantral follicle growth, preantral follicles were exposed to a 
TGFβ  receptor  inhibitor,  a  TGFβ  ligand  (Gdf9)  or  a  mixture  of  both.  After  24h  of  exposure,  
receptor inhibition, with or without Gdf9 treatment caused a significant reduction in Tmepai 
expression relative to untreated control. By excluding the possibility of follicle atresia, these 
results indicate that expression of Tmepai depends  on  the  TGFβ  ligands   that  signal   through  
TGFβRI/Alk5 receptor. The reduced Tmepai mRNA levels  in  response  to  inhibition  of  TGFβRI  
might be relevant since these follicles were also decreased in size. Based on the fact that 
Tmepai has a role in the activation of Smad-independent pathways that promote cell 
proliferation (Azami et al., 2015; Vo Nguyen et al., 2014), it can therefore be assumed that 
Tmepai is important for promoting or maintaining early follicle growth.  
Preantral follicles exposed to rmGdf9 treatment demonstrated a significant increase in size 
relative to control. Similar observations have been reported previously (Fenwick et al., 2013; 
Vitt et al., 2000). Despite this effect on follicle size, Gdf9 did not affect the expression of 
Tmepai transcript levels. These results indicate that Tmepai expression is not regulated by Gdf9 
signalling. Although, it is possible that an inappropriate concentration of Gdf9 was used or the 
time at which the follicles were assayed was inappropriate. In breast cancer and cell line 
cultures, previous studies indicated that expression of Tmepai is   regulated   through   TGFβ  
signalling in both time and dose-specific manner (Singha et al., 2014; Watanabe et al., 2010).  
In the present study, since Tmepai levels were significantly reduced by the inhibition of the 
TGFβRI  receptor,  it  is  possible  that  other  TGFβ  ligands  that  signal  through  these  receptors such 
as  TGFβ1-3 and Activin could regulate its expression (Watanabe et al., 2010). Despite the 
reduction in Tmepai expression levels, there were no statistical changes in the Smad3 levels 
relative to control. This might reflect the influence of other Smad3 inhibitors in the follicle, 
where many Smad2/3 inhibitors were identified in the present study.  
172 
 
This section provides new information about the expression and regulation of Tmepai in mouse 
ovaries. Further work is ongoing to uncover other regulatory factors of Tmepai expression and 
to determine the impact of Tmepai modification on follicle development. 
7.5. Ltbp members are detectable in the mouse ovaries  
TGFβ   superfamily   members   are   secreted   into   the   ECM   as   small   or   large   latent   TGFβ  
complexes where their localisation and activation are largely dependent on Ltbp1, 3 and 4 
(Hyytiainen et al., 2004; Koli et al., 2004; Su et al., 2015). Deletion of any of these extracellular 
molecules in mice is associated with varied pathologies from embryonic death to minor 
morphological mutations mainly caused   by   a   disruption   in   the   bioavailability   of   TGFβ  
(Dabovic et al., 2002; Koli et al., 2004; Shipley et al., 2000; Todorovic et al., 2007). Therefore, 
as  the  ovary  is  a  TGFβ  responsive  tissue,  it  was  proposed  that  Ltbp1-4 would be detectable in 
the mouse ovary. This study aimed to determine the expression pattern of their mRNA (Ltbp 
1-4) and protein (Ltbp1 and-4) in immature and adult ovaries.  
Transcripts of all Ltbp genes were detectable in immature and adult ovaries; however, there 
were no significant differences in the mRNA expression levels of all Ltbp genes between age 
groups and control. These data suggest a role for all Ltbp members throughout the pre-pubertal 
period in the mouse ovaries; however, the relationship with follicle development was less clear. 
In the present study, Ltbp1 and Ltbp4 proteins were localised in varied regions of the mouse 
ovaries but were not directly associated with follicle (granulosa and theca) cells. In immature 
ovary sections, Ltbp1 protein was localised with a higher intensity in the ovary surface 
epithelium and with less staining intensity in the stroma. Ltbp4 was strongly localised in blood 
vessels and was less evident in the stroma.  
The variation in staining pattern suggests that each Ltbp isoform has a specific function in the 
ovary. For instance, Ltbp1 can regulate the  bioavailability  of  TGFβ1-3, which are known to 
influence the growth of the epithelial cells, while Ltbp4 might control the growth of endothelial 
cells,  particularly  by  the  regulation  of  TGFβ1  (Saharinen and Keski-Oja, 2000). In immature 
ovaries, the majority of primordial follicles are situated in the ovary cortex, thus, the 
localisation of Ltbp1 in this region might be relevant in terms of regulating signalling in these 
follicles. Similar observations were reported in bovine ovaries as Ltbp1 was localised in the 
surface epithelium of adult ovaries, but it was undetectable in fetal ovaries (Hatzirodos et al., 
2011; Prodoehl et al., 2009), indicating that expression of Ltbp1 is varied according to the age 
and animal species.  
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In the present study, it is interesting to note that Ltbp4 is detectable in blood vessels and stroma 
close to primordial and growing follicles, proposing a functional role in follicle development. 
Unlike Ltbp1 protein, the strongest staining of Ltbp4 was observed in adult ovary relative to 
other age groups, which could be attributed to the increased demand for Ltbp4 due to the 
presence of larger blood vessels in the adult ovary relative to immature ovaries. 
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7.6. Impact of the study 
It is a fact that females are born with a limited number of primordial follicles resulting in 
restricted  reproductive  lifespan.  To  date,  in  the  human  ovary,  understanding  the  role  of  TGFβ  
signalling is incomplete, particularly in the process of early follicle growth. Although some 
variation exists in the regulatory mechanisms responsible for follicle development between 
humans and mice, many genes associated with follicle activation and growth were initially 
characterised in the mouse. Therefore, development of a mouse model with modified 
expression of TGFβ inhibitory factors may provide essential knowledge on the functional role 
of these factors in both physiological and pathological disorders. Understanding the factors that 
regulate the ovarian reserve could allow the potential to extend reproductive lifespan and 
therefore influence disorders such as premature ovarian failure, polycystic ovary syndrome, 
age-related infertility or toxicant-induced ovarian failure. For example, increasing the 
activation of primordial follicles by inhibition of a PI3K pathway inhibitor (PTEN) was 
employed (Reddy et al., 2008) to obtain a sufficient number of growing follicles from ovaries 
obtained from women with premature ovarian failure (Kawamura et al., 2013). However, using 
these approaches, the entire reserve will be activated by the treatment. Thus, results in the 
present study have identified a potential candidate Smad inhibitor that can regulate early 
follicle growth without global activation of the reserve. In the current study, inhibition of either 
Strap expression or function caused a significant increase in the recruitment of quiescent 
follicles to initiate growth. This function of Strap can be employed in vitro to increase the 
number of activated follicles used for maturation techniques and potential fertilisation. These 
findings might challenge results indicated by other studies of using PTEN inhibitors, as Strap 
supplementation did not cause massive activation of primordial follicles in treated group; thus, 
Strap treatment maintained the normal molecular interactions between non-growing and 
growing follicles. Another study indicated that although bpV(HOpic), a synthetic inhibitor of 
PTEN, caused substantial promotion in primordial follicle activation; however, the growth of 
treated preantral follicles was accompanied with an increased rate of follicle atresia 
(McLaughlin et al., 2014). Strap is a natural protein, not synthetic, and therefore may provide 
a safer alternative to current synthetic compounds. Taken together, Strap, and other candidates 
identified in this thesis (e.g. Tmepai) may be clinically important as regulators of maintenance 
and early follicle growth. 
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7.7. Future work 
Our future work will be also directed to fill the specified gaps, so that, our framework will be 
approximately completed. 
1. In the present study many Smad2/3 inhibitors were detected, thus, further investigations 
could be conducted to determine their protein localisation and to assess the relative 
functional role on early follicle development, in vitro. 
2. Supplementation of Strap promoted an increase in the size of preantral follicles. Therefore, 
future experiments could focus on evaluating expression levels of numerous genes, which 
are associated with follicle growth and steroidogeneses such as Fshr or Amh, Cyp11a1 or 
Cyp19a. 
3. Further studies are required to assess the direct effects of Tmepai modulation on follicle 
development using culture models described here along with the different protocols such 
as siRNA, immunoneutralisation or exogenous protein supplementation.  
4. The effect  of  TGFβ  ligands,  other  than Gdf9,  such  as  TGFβ1-3, ActivinA, and ActivinB 
could be assessed for their association with Tmepai expression and to be assessed in 
relation to follicle growth. Ongoing experiments were designed by our lab group to 
determine the effect of different concentrations of Androgen (dihydrotestosterone DHT) 
treatments on Tmepai expression and preantral follicle growth. 
5. Further studies are required to localise Ltbp2 and Ltbp3 proteins in the immature mouse 
ovary. Moreover, it would be interesting to investigate the effect of molecular modulation 
of  each  Ltbp  member  on  TGFβ  signalling  and  the  subsequent  influence  on  early  follicle  
development. 
6. From the literature, in addition to Smad inhibition, both Strap and Tmepai can activate 
non-Smad pathway, thus, additional work could also focus on linking these two functions 
with early follicle growth.  
  
176 
 
7.8. Conclusions 
Overall, the present study provides further evidence that R-Smads are expressed and function 
in a follicle stage-specific manner. The exclusion of Smad2/3 from the nucleus of granulosa 
cells was considered as an initial indicator of follicle growth. The detection of a number of 
Smad2/3 inhibitors in immature and adult ovaries raised the possibility that these factors could 
regulate   early   follicle   development   through   regulation   of   duration   and   strength   of   TGFβ  
signalling (chapter 3). Indeed, modification of Strap expression and function in different 
culture models provided evidence that Strap can influence early follicle development in a stage-
and dose dependent specific manner (chapter 4).  
Tmepai is also detectable in immature and adult mouse ovaries in a follicle stage-specific 
manner. However, unlike Strap, Tmepai expression was limited to follicles that had just 
initiated growth suggesting a specific role for this protein in follicle growth and its expression 
is  modulated  by  the  functional  state  of  the  TGFβR1  receptor (chapter 5).  
The  extracellular  TGFβ-processing Ltbps were also detectable in ovaries, where Ltbp1 protein 
is more evident in the surface epithelium and stroma, which may represent an important 
regulator  of  TGFβ/Smad  signalling  in  nearby  primordial  and small growing follicles, which 
are known to present nuclear Smad2/3. Ltbp4 was mainly detectable in the blood vessels, 
suggests a role in the regulation of endothelial cell development (chapter 6).  
To sum up, this study identified the expression of many Smad2/3 inhibitors in immature mouse 
ovaries. In particular, for the first time, Strap is detected in immature mice ovary and 
demonstrated a role in the regulation of early follicle growth in a stage-specific manner. 
Similarly, the detection of Tmepai in small preantral follicles where its expression found to be 
regulated  by  TGFβ  signalling,  this  might  indicate a relevance role of Tmepai in follicle growth. 
Ltbp members are detectable in various ovarian compartments. Such studies are essential to 
understanding molecular factors that regulating early follicle development and might 
contribute to resolving some physiological and pathological disorders that affecting the 
mammalian ovary such as early ovarian failure or cancer.  
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Appendices 
I. TGFβ  signalling through Smad pathway 
 
I.1. At the cell surface,  TGFβ  ligand  stimulates  type  II  receptor,  which  in  turns stimulates type 
I receptors by phosphorylation. In Smad2/3 pathway, but not Smad1/5/8 pathway, the 
phosphorylated Type I receptor recruits R-Smad which directing by SARA protein to the 
activated receptor, where the association between Smad2/3 and SARA is enhanced  by  a  TGFβ  
induced cytoplasmic protein (PML). Then, heteromeric complex forms via the interaction of 
R-Smad with Smad4. Through nuclear import, this complex interact to the Smad-binding 
elements (SBE) of the targeting gene. The regulation of gene transcription occurs by interaction 
with transcriptional co-activators or co-repressors. TGFβ/Smad2/3  signalling  is  terminating  by  
Smad7, while Smad1/5/8 pathway can  antagonise by both Smad6 and Smad7. 
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II. Equipment 
Equipment Company 
96-well plate  Nunclon 
acupuncture needles  AcuMedic 
Centrifuge- accuspin 3R Fisher Scientific 
Agilent 2100 Bioanalyser  Agilent G2938B 
Culture plates of 24-wells  Corning Costar- Sigma-Aldrich 
Edge pen Vector Laboratories 
Electrophoresis  (Power  Pac™  HC) Bio Rad- Singapore 
Flow hood with a dissecting microscope Leica 
inverted Widefield fluorescence microscope  Leica 
DMI4000B Leica 
Leica inverted SP5 confocal laser scanning 
microscope  
Leica Microsystems, Wetzlar, 
Germany 
Manual processing microtome Reichert-Jung 
Olympus CKX41 with a Nikon camera DS-Fi1 Olympus 
Olympus IX73 inverted microscope Olympus 
Superfrost Plus Microscope Slides Thermo scientific 
Stage micrometre Graticules PYSER-SGI 
Thermal cycler  Geneflow 
Ultraviolet transilluminator  Geneflow 
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III. Chemicals and reagents 
Chemical agents Company 
10X TAE Buffer Gibco 
2X SensiFAST SYBR Hi ROX Mix Bioline 
384- well plate Applied Biosystems Inc 
Agarose gel Bioline/ Bioproducts, AGD1 
Applied Biosystems 7900HT Fast instrument  Applied Biosystems Inc 
Aqueous eosin 1%  Diagnostics 
Bovine serum albumen Vector Laboratories 
CAS-Block Invitrogen 
Citrate Buffer Sigma- Aldrich 
DNase I Qiagen; West Sussex, UK 
DPX (Xylene, Dibutylphtalate) Merck 
Ethanol Fisher Scientific, UK 
Fetal bovine serum FBS  ThermoFisher 
GelRed TM Nucleic Acid Gel Stain Biotium 
Hematoxylin gills II stain  Surgipath 
Histochoice Clearing agent Sigma- Aldrich 
Hyper Ladder  Bioline 
Insulin-Transferrin-Selenium (ITS) Sigma 
KAPA SYBR Green KAPA Biosystems, KK4602 
Leibovitz’s    L-15 medium 1x Gibco Life Technologies 
Leibovitz’s  media  L15   Gibco 
L-Glutathione reduced 99%   Sigma- Aldrich 
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Low gelling temperature agarose  Sigma 
MyTagTM Red Mix Bioline 
Neutral Buffered Formalin Solution 10x  Sigma- Aldrich 
Non-immune mouse IgG or Rabbit IgG  Vector 
Nuclear fast red stain Sigma 
Optical adhesive  cover  Applied Biosystems Inc 
Penicillin  Sigma PENK 
Prolong Gold antifade reagent with Dapi  Invitrogen 
Qiagen RNeasy Micro Kits QIAGEN, Crawley, UK 
RNase/DNase free water (10ml) Qiagen 
ROX dye KAPA Biosystems 
Sodium phosphate dibasic  Sigma- Aldrich 
Sodium phosphate monobasic  Sigma- Aldrich 
Streptomycin sulphate Sigma 
Superscript III First strand synthesis system Invitrogen 
Tris (Hydroxymethyle) aminomethane (mw 121.14)  BDH Prolabo 
Triton  Sigma 
Vectashield ABC Kit PK- 6100 Vector Laboratories 
β- Mercaptoethanol 98% Sigma- Aldrich 
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IV. Buffer and solution recipes 
Buffer\ Solution Preparation and composition 
100ml of 1X TAE  buffer,  10ml of 10X TAE was added to 90ml of dH2O 
2% agarose gel solution Two grams of agarose powder added to 100ml TAE 1X 
70% ethanol 
80% ethanol 
95% ethanol 
30 ml of ddH2O added to 70 ml of ethanol (96–100%). 
20 ml of ddH2O added to 80ml of ethanol (96–100%). 
5 ml of ddH2O added to 95 ml of ethanol (96–100%). 
Bovine serum albumin  
BSA 4% 
0.2 grams of BSA powder in 5 ml PBS 
Citrate Buffer (0.01M Citric 
Acid 
Citric acid (anhydrous)  ------- 1.92 g 
Distilled water ------------------ 1000 ml 
Mixed to dissolve, and pH was adjusted to 6.0.  
DNase I stock solution 
Lyophilized DNase I dissolved in 550μl  of  RNase/  DNase  
free water, stored at –20°C. 
L-Glutathione –Tris solution 
Tris 50mM (0.605g) dissolved in 70ml of H2O, pH was 
adjusted to 8.0 by concentrated HCL before the addition of 
glutathione 10mM (0.307g), and a final volume of 10 ml 
was completed by water. 
Phosphate Buffered Saline        
(0.1 M) 
Sodium  phosphate  dibasic  Na2HPO4……...  10.9  g 
Sodium  phosphate  monobasic  NaH2PO4…..  3.2 g 
NaCl  ………………………………………...  90  g 
Mixed to dissolve and brought to a final volume of 1000 ml 
with distilled water. Adjusted to pH 7.4. Stored at room 
temperature, for working solution, diluted at 1:10. 
Working solution of DNase I 
10μl  DNase  I  stock  solution  added  to  70μl  buffer  RDD  to  
make a final  volume  of  80μl  per  a  sample,  stored  at  -20°C. 
working solution of poly A 
RNA  (4ng/μl) 
5  μl  of  poly  A RNA stock solution (310ng /ml) added to 
34μl  RLT  buffer.  Then,  12μl  of  the  previous  solution  added  
to 108μl  buffer  RLT. 
Working solution of RPE 
buffer 
44ml of ethanol (96–100%) added to RPE Buffer volume 
(11 ml). 
β- Mercaptoethanol  (β-ME) - 
RLT buffer 
10μl  β-ME added to 1ml RLT buffer 
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V. Immunofluorescence staining and troubleshooting  
1. Antibodies   used   in   this   study  were   selected   from   supplier’s  web   sites   stated that the 
desired antibody is suitable for immunohistochemistry staining. In addition, most of these 
suppliers provided publications in which antibodies have been used and/or images of 
staining were included. This provided essential detail on the concentration used, specific 
localisation of their target proteins within the tissue or cell compartments.  
2. To ensure consistency for all staining, solutions including Histochoice and ethanol were 
periodically refreshed.  
3. Other antigen retrieval buffer was used such as Tris (MW 121.14 BDH PROLABO) and 
urea (BDH ANALAR 5%). Tris-urea buffer was prepared as following: 
 800 ml H2O  
 12.11 grams Tris. 
 50 grams urea. 
 Adjust PH to 10.0. 
 Add 200 ml of H2O to prepare 1liter 
4. Alternative blocking approach was used such as bovine serum albumin block (BSA 4% 
in PBS) for 20 minutes rather than CAS block for 10 minutes.  
5. To optimise dilutions used for primary antibodies where optimum dilutions were not 
included in their data sheath, a wide range of serial dilution were used (1:100, 1:200, 
1:400, 1:800, 1:1600).  
6. Slides stained with primary antibodies were differentially incubated either at room 
temperature for 1hours or overnight at 4°C. 
7. To ensure consistency of staining, freshly embedded and sectioned ovary sections (d4, 
d8, d16 and adults) were used. 
8. Ovary sections from mice of other ages including d21 and d26 were used as controls. 
9. In addition to use a positive control of a well-known working antibody (Ddx4), sections of 
heart, kidney and uterus tissues (where Ppm1a is highly expressed) were used along with 
ovary sections stained for Ppm1a.  
10. For colocalisation of two antibodies (double staining), two protocols were tested to 
determine whether primary antibodies to be added individually or together:  
 Ovary sections were incubated overnight at 4°C with the first primary antibody, while 
the second primary antibody was added next day for 1hour at room temperature and 
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vice versa. At the end of incubation, secondary antibodies were added either 
individually or both together for 45 minutes. 
 Both primary antibodies were added together on the section followed by incubation 
with secondary antibodies for both primary antibodies.  
11. To troubleshoot an extensive unspecific background staining of primary/secondary 
antibodies:   
 Slides were incubated with CAS for a longer period (20 minutes). 
 Prolong time of washing with PBS to 15 minutes x3. 
 Washing with 0.5% Tween solution of with PBS. 
 Less concentrated solutions of primary antibodies were used. 
 Reduce the incubation time of secondary antibodies to 30 minutes. 
12. For each particular experiment, to eliminate technical errors, stained sections and controls 
(positive and negative) were imaged using same exposure and gain.  
13. Before being used for staining, paraffin embedded ovary sections were visualised with 
fluorescent microscope using all channels to ensure that no auto-fluorescence background 
signal are produced.  
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VI. Immunofluorescent localisation of Smad2/3 and Smad1/5/8 in the preantral follicle 
 
VI.1. Preantral follicle sections used to assess immunofluorescent staining protocol. Smad2/3 (2-3, red; 
0.25μg/ml,  Santa  Cruz  sc-133098) was lightly localised in the granulosa cells; while, Smad1/5/8 (2-3, 
green;;  0.5μg/ml,  Santa  Cruz  sc-6031-R) were detected with high intensity of staining in granulosa cells. 
Negative controls were treated with non-immune mouse IgG (4, above row) or Rabbit IgG (4, down 
row). Slides were incubated with Alexa Donkey anti-Mouse 555 or Donkey anti-Rabbit 588 antibodies, 
respectively. Nuclei (blue) were contrastained with DAPI (1). Images were taken with Olympus IX73 
inverted microscope. Scale  bar  =  100μm.  
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VII. Protocol used for oocyte measurement in ovary section 
 ImageJ was used for calculation of oocyte diameters in ovary sections stained by haematoxylin 
and Eosin stain. Ovary sections from d4 (n=5), d8 (n=8), d13 (n=5), d16 (n=7) were used to 
provide a model for oocytes classification to be utilised for evaluation the effect of different 
treatment on follicle development. The morphology represented by a number of granulosa cells 
layers surrounding the oocyte was to identify the growing state of follicles. A single oocyte 
that surrounded by a monolayer of undeveloped flat cells was considered non-growing follicle. 
Follicles containing one layer of granulosa cells that included both cuboidal and flat cells 
accounted as a transitional oocyte. Large oocyte with at least one complete layer of cuboidal 
granulosa cells classified as growing oocyte. Only clearly presented oocytes were included in 
measurements. 
 
VII.1. An example of oocyte measurement in a day 16 ovary section stained by haematoxylin and eosin 
stain.  
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VIII. Isolated oocyte and follicle samples used for RNA extraction 
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IX. Illustrate RT-PCR results for the expression of control genes in various follicles stages. Symbol: - 
not expressed; + weak band; ++ moderate band; and +++ strong band. 
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Gabpdh + ++ ++ +++ +++ +++ ++ + - 
Amh + +++ +++ +++ + - + - - 
Amhr2 + ++ ++ ++ + - - - - 
Gdf9 ++ +++ +++ +++ - - ++ +++ - 
Fshr - ++ ++ ++ ++ - ++ - - 
Cyp17a - - - ++ +++ ++ - - - 
Kl1 - ++ ++ ++ ++ ++ - - - 
Kl2 - ++ ++ +++ ++ ++ - - - 
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X. Illustrate RT-PCR results for the expression of Smad inhibitors in various follicles stages. Symbol - 
not expressed; + weak band; ++ moderate band; and +++ strong band. 
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Gapdh + + + ++ ++ ++ + + - 
Strap + + ++ ++ ++ +++ ++ +++ - 
Ppm1a + + ++ ++ ++ ++ + + - 
Ski - + + ++ ++ ++ + - - 
SnoN - + + + + + - - - 
Ranbp3 - + + + + + - + - 
Exportin4 - -­ + + + + - + - 
Smad7 - - ++ ++ ++ + + + - 
Smurf1 - -­ - + + + + - - 
Smurf2 - - + + + + - - - 
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XI. Optimising culture media for Strap siRNA treatment 
The aim of this experiment was to determine whether to use the Accell delivery media for the 
experiment of Strap siRNA with or without supplements. Preantral follicles were isolated from 
d16 mouse ovaries, as described in 2.2.2. The experiment was designed to include three 
treatment groups, where each group included 21 preantral follicles. For each 96 wells plate 
(n=3) three lines of treatments were  prepared (each line included 7 follicles). Follicles in the 
first group were cultured in 100µl MEM-α   (Gibco)  with  supplements,   the  second  and   third  
groups included Accell media with or without supplements, respectively, Figure XI-1.  
 
Figure XI.1. An example of 96 wells plates for culture optimisation. Three plates were prepared to 
identify the effect of adding growth supplements to Accell delivery media on follicle growth. Follicles 
were cultured in three rows where each row consists of seven follicles (a single follicle in each well). 
Treatment groups included MEM-α  medium  with  supplements (1), accell delivery with and without 
supplements (2, 3 respectively). Plates were incubated for three days at 37°C in the presence of 5% 
CO2.  
The  supplement  consists  of  0.1%  (w/v)  BSA  (Sigma),  75μg/ml  penicillin  (Sigma),  100μg/ml  
streptomycin sulphate (Sigma) and insulin-transferrin-sodium  selenite   ITS  (5μg/ml,  5μg/ml,  
5ng/ml, respectively; Sigma). All plates were cultured at 37°C in the presence of 5% CO2. Half 
of the culture medium was replaced after 48 hours of incubation. Follicles were regularly 
imaged at time points of 0, 24, 48 and 72 hours using light microscopy (Olympus CKX41 with 
a Nikon camera DS-Fi1). Images were obtained for the measurement of follicle diameter by 
ImageJ software. Two measurements were taken from the basal lamina of the follicle, 
excluding theca cells layer. The two measurements were averaged and were presented as mean 
follicle diameter, see 2.10.1. 
  
215 
 
After 72h in culture, even though the mean follicles in Accell delivery with supplements group 
was greater than other groups, there was no significant difference in follicle size between 
groups (Figure XI-2). Thus, a decision was made that growth supplements to be added to the 
Accell delivery for Strap siRNA experiment. 
 
Figure XI-2. Effect of different culture media on preantral follicle growth. The aim of this experiment 
was to optimise Accell delivery media to be used for Strap knockdown either with or without 
supplements at different time points. Even though follicle diameter revealed no significant difference 
in follicle growth between groups. The mean diameter of follicles cultured in Accell delivery media 
with supplements was  greater  (165.3μm)  than  those  cultured  in  Accell  delivery  without  supplements  
(162.3μm)  or  in  MEM-α  medium  with  supplements  (160.3μm).  Follicle  diameters  were  presented  as  
mean ± SEM (n=21 follicles for each group), data were statistically analysed using Kruskal-Wallis and 
Dunn’s  multiple  comparisons  test  P<0.05. 
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XII. Agilent Bioanalyser and expression of Gdf9 in cultured preantral follicle samples by RT-
PCR. 
All of the tested RNA samples (5 samples for each group where each sample included 5 
follicles) were considered as good quality and valid for further gene analysis. Treatment groups 
included C: control; G: Gdf9; SD: SD208 and S+G: a mixture of SD208 and Gdf9 groups. 
 
XII.1. Evaluation of extracted RNA using Agilent Bioanalyser and expression of Gdf9 in cultured 
preantral follicle samples by RT-PCR.  
 
 
